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ABSTRACT 
Jacob Peter Matson: Regulation of MCM helicase loading during early differentiation and cell 
cycle re-entry 
(Under the direction of Jeanette G. Cook) 
 
 Cells initiate DNA replication at thousands of DNA replication origins every cell cycle. 
Minichromosome maintenance complexes (MCM) unwind DNA to initiate replication in S phase. 
MCM loading onto DNA, called “origin licensing”, occurs in G1 phase. Multiple mechanisms 
restrict origin licensing to G1 phase to prevent aberrant MCM loading and genotoxic re-
replication in S phase. For this reason, cells load 5-10 fold excess MCM in G1 as dormant 
origins to protect against replication stress in S phase. The origin licensing checkpoint ensures 
sufficient MCM loading before S phase entry. MCM loading occurs in G1, yet cells have a 
variety of G1 lengths. Stem cells have short G1s while differentiated cells have long G1 phases. 
Additionally, cells may exit the cell cycle to quiescence, a state without division. Cells re-
entering the cell cycle from quiescence have longer G1s than actively proliferating cells. How 
cells accomplish the same MCM loading under these different G1 lengths is poorly understood.  
 We used quantitative single cell flow cytometry and live cell imaging to measure MCM 
loading across varying G1 lengths. We found that stem cells with short G1s load MCM 
significantly faster than differentiated cells with long G1s. MCM loading rate decreases and G1 
length increases during stem cell differentiation to all germ layers. The rapid licensing is due to 
increased Cdt1 protein in stem cells. Rapid origin licensing is intrinsic to pluripotency, as 
slowing MCM loading in stem cells promotes their differentiation. Cells re-entering into long G1 
phases from quiescence are underlicensed with less loaded MCM at S phase entry than 
proliferating cells. The underlicensing causes replication stress sensitivity in S phase, and 
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repeated rounds of quiescence and re-entry increase the replication stress sensitivity. A 
defective origin licensing checkpoint combined with a slow MCM loading rate causes the 
underlicensing during cell cycle re-entry, and extending the first G1 phase rescues the 
underlicensing. Thus, cell cycle re-entry is a higher risk cell cycle than active proliferation. 
Proper regulation of the rate and amount of MCM loading is critical across different G1 types to 
control differentiation, proliferation and genome stability.  
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CHAPTER 1: INTRODUCTION 
Cell cycle structures 
The eukaryotic cell cycle consists of four phases: G1, S, G2, and M phase. However, all 
cells do not have the exact same cell cycle structure, with some cells having large variations in 
G1 lengths. Additionally, some cell cycles are missing phases altogether such as 
endoreduplication cycles which lack M phase (Edgar and Orr-Weaver, 2001). My research has 
focused on events in G1 and S phase. My overall goal is to understand how cells with different 
cell cycle structures progress through the same molecular pathways in G1 phase and enter into 
S phase. G1 length varies between cell cycles during development, where stem cells have rapid 
cell cycles with short G1 lengths and differentiated cells have slow cell cycles with long G1 
lengths (VanOudenhove et al., 2016). I compared these two cell cycles to understand how a 
change in G1 length changes regulation of G1 events and regulates development. Cells in G1 
phase may leave the cell cycle and exit to quiescence, a state outside the cell cycle without cell 
division. Quiescent cells can re-enter the cell cycle in G1 phase to begin dividing again. I 
compared cells transitioning from quiescence back into G1 phase and actively proliferating cells 
to understand how active cell cycle regulation differs from cell cycle re-entry from quiescence. I 
found that G1 regulation is critical for maintaining pluripotency in stem cells and that abnormal 
G1 regulation during cell cycle re-entry makes the first cell cycle a high risk cycle compared to 
proliferating cell cycles. Thus, understanding unique cell cycle structures will provide insight into 
how their structure influences cell fate decisions and the lifecycle of a cell. 
  Stem cells have an abbreviated G1 phase to maintain their pluripotency. Stem cell 
pluripotency is the ability of a stem cell to differentiate into multiple specialized cell types 
comprising all three germ layers, endoderm, ectoderm, and mesoderm (Soufi and Dalton, 
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2016). The cell cycle is linked to the probability of a stem cell to become a differentiated cell. 
Studies show that stem cells treated with a differentiation stimulus tend to differentiate 
asynchronously, suggesting that stem cells only respond to a stimulus at certain times. Pauklin 
and Vallier showed that pluripotent cells respond to differentiation cues only in G1 phase and 
that cells in early G1 phase respond to endoderm and mesoderm cues and cells in late G1 
phase respond to ectoderm cues (Pauklin and Vallier, 2013). Further studies revealed that key 
cell cycle regulators in S, G2, and M phase including Checkpoint kinase 2 and Cyclin B are 
refractory to differentiation cues, restricting the stem cell responses to differentiation cues to G1 
phase (Gonzales et al., 2015). Taken together, these studies demonstrate the reason stem cells 
differentiate asynchronously is because their cell cycles are asynchronous and some cells must 
progress through the cycle into G1 before responding to a stimulus. Thus, a short G1 phase 
balances self-renewal and differentiation by limiting the time for differentiation. 
 Pluripotent stem cells maintain their short G1 phase by overriding several of the normal 
G1 regulatory mechanisms that increase G1 length. (For a detailed discussion on G1 regulation 
and cell cycle commitment see Chapter 2). Differentiated cells have a period of low Cyclin 
Dependent Kinase (CDK) activity in early G1 phase that gradually increases as cells move 
through G1. Eventually CDK2 activity hyperphosphorylates the Retinoblastoma protein (Rb) and 
other substrates to promote S phase entry. Pluripotent stem cells eliminate much of early G1 by 
maintaining near constitutive high CDK2 activity (Neganova et al., 2009). The high CDK2 
activity results in a shortened G1 phase that is molecularly similar to the time when Rb is 
hyperphosphorylated in G1 phase of differentiated cells. Stem cells also have low levels of the 
CDK2 inhibitor proteins p27 and p21, which promotes high CDK2 activity (Neganova and Lako, 
2008; Soufi and Dalton, 2016). Another major regulator of early G1 phase is the Anaphase 
Promoting Complex (APC), which regulates key proteins that drive S phase entry by targeting 
them for destruction in early G1 phase (Siddiqui et al., 2013). Inactivation of APCCdh1 in mid to 
late G1 phase allows S phase entry and is proposed to mark the point of no return for 
3 
commitment to S phase (Cappell et al., 2016). APCCdh1 activity is attenuated and almost 
completely inactive in pluripotent stem cells due to inhibitory phosphorylation by CDK2, high 
levels of the APC inhibitor Emi1, and high levels of Skp2 (which targets APC subunits for 
degradation) (Ballabeni et al., 2011; Bar-On et al., 2010). All of these deregulations of G1 
control in pluripotent stem cells drive an abbreviated G1 phase of only 2-3 hours. Once stem 
cells begin differentiation, they regain a long G1 phase by increasing CDK inhibitor proteins, 
increasing APC activity, and decreasing CDK2 activity (VanOudenhove et al., 2016; Boward et 
al., 2016). Thus, pluripotent cells maintain a short G1 phase by deregulation of G1 cell cycle 
control and gain a longer G1 phase upon differentiation. 
 Another instance of a unique cell cycle structure are quiescent cells re-entering the cell 
cycle with a longer G1 phase than actively proliferating cells. Quiescence is a state outside the 
cell cycle where cells do not divide (quiescence is also known as G0). However, it is distinct 
from a G1 arrest, and characterized by repression of cell cycle genes and activation of genes to 
maintain the quiescent state including upregulation of anti-differentiation, anti-apoptotic and anti-
senescent genes (Sang et al., 2008; Legesse-Miller et al., 2012; Imai et al., 2014; Coller et al., 
2006). Quiescence is a broad category that encompasses several kinds of cell cycle exit, all 
unified as  a reversible cell cycle exit instead of a permanent cell cycle exit. Multiple signals 
induce exit to quiescence, including mitogen withdrawal, contact inhibition and loss of adhesion, 
and each signal invokes unique changes in gene expression as well as a core expression 
program common to all forms of quiescence (Coller et al., 2006). Additionally, quiescence varies 
by the length of time a cell is quiescent. Longer term quiescence is associated with greater gene 
repression and chromatin compaction than short term quiescence (Coller et al., 2006; Evertts et 
al., 2013). The longer a cell remains in quiescence, the longer it takes to re-enter the cell cycle 
(Kwon et al., 2017). Thus, quiescence exists as a spectrum of states with different inputs and 
degrees of quiescence, yet all are unified by the ability to re-enter the cell cycle into a long G1 
phase. 
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 Quiescent cells re-entering the cell cycle into G1 phase must first reset all the restrictive 
regulations that maintain quiescence and prevent proliferation. One key hurdle to re-enter the 
cycle is Rb hyperphosphorylation, which activates E2F transcription as part of the restriction 
point. The deeper the quiescence, the longer it takes to activate E2F gene expression, making 
the first G1 phase during cell cycle re-entry longer than G1 of proliferating cells (Kwon et al., 
2017). Cells must alter regulatory pathways upstream and downstream of Rb to fully re-enter 
G1 phase. In proliferating cells, Rb is monophosphorylated in G1 phase, but in quiescent cells 
Rb is unphosphorylated requiring the extra step of CDK4/Cyclin D phosphorylation of Rb during 
cell cycle re-entry (Narasimha et al., 2014). Next, CDK2 would hyperphosphorylate Rb to 
activate E2F gene expression but that also has additional steps. CDK2 is cytoplasmic in 
quiescent cells and must translocate to the nucleus (Dietrich et al., 1997; Nevis et al., 2009). 
Additionally, the CDK2 inhibitor p27 is upregulated in quiescence and must be degraded by 
specialized ubiquitin ligases during the transition from G0 to G1 (Kamura et al., 2004; Susaki et 
al., 2007). The program of cell cycle gene repression in G0 is mediated by the DREAM 
complex, which includes the Rb related protein p130 and requires the Dyrk1a kinase activity for 
DREAM complex assembly (Litovchick et al., 2007, 2011). To re-enter the cell cycle, G0 cells 
must disassemble the DREAM complex and decrease Dyrk1a kinase activity, presumably 
through protein degradation (Liu et al., 2016; Chen et al., 2013; Bhattacharya et al., 2003). 
Taken together, all of these hurdles cause G1 during cell cycle re-entry to be longer than G1 in 
proliferating cells. 
Minichromosome Maintenance Complexes and origin licensing 
 A major purpose of G1 phase is to prepare cells for DNA replication in S phase. In S 
phase, helicases begin DNA replication by unwinding DNA at DNA replication origins. A DNA 
replication origin is a region of the genome where DNA replication first begins. The central 
component of the replicative helicase is the Minichromosome maintenance complex (MCM) 
(Deegan and Diffley, 2016). Cells load MCMs onto DNA replication origins in G1 phase, and the 
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MCM loading is also referred to as “origin licensing” (DePamphilis et al., 2006). Once cells enter 
S phase, replication origins “fire” when MCM (along with other proteins) unwinds DNA to begin 
replication (Remus and Diffley, 2009). MCM travels with replication forks to unwind DNA ahead 
of the DNA polymerase that replicates DNA. MCMs are unloaded off DNA once replication forks 
terminate (Moreno et al., 2014; Maric et al., 2014). Thus, MCM regulation is divided into two 
phases – origin licensing occurs in G1 phase and origin firing occurs in S phase. 
 Origin licensing begins as early as the telophase preceding G1 in some cell types, or in 
G1 phase (Dimitrova et al., 2002). The exact timing of when MCMs load onto DNA is not clear, 
but it certainly happens over time as cells progress through G1 (that is, all MCMs are not loaded 
onto origins simultaneously). An origin is licensed for replication once it has two DNA loaded 
MCM hexamers loaded head to head (called double hexamers). However, MCMs cannot load 
onto DNA on their own; other proteins facilitate MCM loading onto DNA. First, the Origin 
Recognition Complex (ORC) binds to origin DNA. ORC recruits Cell Division Cycle 6 (CDC6) 
and CDC6 binds ORC directly. CDC6 is required to recruit MCMs to origins, and has an ATPase 
function with the additional role of quality control, ejecting incorrectly bound MCMs. Next, Cdc10 
dependent transcript 1 (CDT1) binds to MCM to facilitate loading onto DNA. MCM is a 
hexameric ring with a gate between MCM2 and MCM5 that opens and closes to encircle DNA 
(Samel et al., 2014). CDT1 alters MCM conformation to hold the gate open and allow loading 
onto DNA (Frigola et al., 2017). The CDT1-MCM complex interacts with ORC-CDC6 to induce 
conformational changes that facilitate MCM loading onto DNA and MCM ring closing (Sun et al., 
2013). The MCM loading reaction occurs twice to result in two head to head MCMs forming a 
double hexamer on DNA (Evrin et al., 2009; Remus et al., 2009). It is currently controversial if 
one ORC loads both MCM hexamers or two adjacent ORCs each load one MCM, but the end 
result is that CDT1, CDC6 and ORC all dissociate, leaving behind the DNA loaded MCM double 
hexamer, a fully licensed origin (Ticau et al., 2015; Coster and Diffley, 2017). 
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DNA Replication Origins 
 Origin licensing occurs at discrete genomic loci, in the context of other DNA based 
processes including transcription, chromatin, and DNA sequence.  
Budding yeast have origin consensus sequences to specify origin locations, but higher 
eukaryotes do not have an origin consensus sequence (Leonard and Méchali, 2013). Instead, 
metazoan origins are associated with euchromatin, G-quadraplexes, promoters and termination 
sites (Prioleau and Macalpine, 2016). Loaded MCM double hexamers can slide along DNA, 
pushed by RNA polymerase to locations other than the origin where MCM was first loaded 
(Gros et al., 2015). Therefore, actively transcribed genes may sweep MCM out of the 
transcribed region, localizing MCM to the beginning or end of transcribed genes (Powell et al., 
2015; Chen et al., 2019). This repositioning of MCM is important, as intragenic origins in actively 
transcribed genes cause transcription-replication conflict in S phase (Macheret and Halazonetis, 
2018). Thus, locations of origins in higher eukaryotic are influenced by many factors. 
Chromatin environment shapes origin location and may require additional proteins 
facilitate MCM loading. The ORC associated protein (ORCA) localizes to heterochromatin and 
recruits ORC to DNA during G1 phase. Cells without ORCA cannot recruit ORC to 
heterochromatin (Shen et al., 2010). ORCA also recruits histone modifying enzymes to 
heterochromatic regions to promote their replication in late S phase (Giri et al., 2015). CDT1 
recruits the H4-histone acetyltransferase HBO1 (Human acetylase binding to ORC1) to origins 
to acetylate nearby histones, which is required for MCM loading (Miotto and Struhl, 2008, 2010). 
Finally, the lysine methyltransferase Set8 monomethylates histone H4K20 to promote origin 
licensing (Tardat et al., 2010). The monomethyl is converted to dimethyl and is present on about 
80% of histones across the genome (Kuo et al., 2012). ORC1 contains a bromo adjacent 
homology domain that binds to H4K20me2 (which requires H4k20me1 first) and promotes 
recruitment of ORC to origins, thus promoting MCM loading (Kuo et al., 2012). These data 
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suggest that origin licensing depends on the chromatin environment, and that origins at genomic 
loci with different chromatin structure may require specialized MCM loading reactions.  
MCMs in S phase 
Licensed origins require several co-factors to convert the loaded MCM double hexamer 
to active helicases in S phase. The fully active helicase is called CMG and consists of Cdc45, 
MCM2-7 and GINS (Psf1, Psf2, Psf3 and Sld5) (Costa et al., 2011). S phase kinase activity of 
CDK2 and the Dbf4-dependent kinase (DDK) phosphorylate various components of CMG to 
activate them and fire the origin (Labib, 2010). DDK exclusively phosphorylates double 
hexamers and not free MCM by binding MCM2 and MCM4 across both hexamers, one from 
each adjacent MCM in the double hexamer (Sun et al., 2014). Origins fire throughout S phase in 
a generalized order called the replication timing program (Aparicio, 2013). Origins are classified 
as early or late depending on when they fire in S phase and is regulated by many factors 
including chromatin modifications, higher order nuclear structure and stress such as a DNA 
damage response (Fragkos et al., 2015). New origin licensing is strictly prohibited in S phase by 
mechanisms targeting all the MCM loading proteins. CDC6 is phosphorylated by CDK2/Cyclin A 
and exported to the cytoplasm (Yim et al., 2013; Petersen et al., 1999a). ORC1 is 
phosphorylated by CDK2/Cyclin A and targeted for destruction by the E3 ubiquitin ligase 
SCFSkp2 (DePamphilis, 2003; Méndez et al., 2002). CDT1 is targeted for degradation by 
CRL4Cdt2 and SCFSkp2 as well as directly inhibited by Geminin protein binding and CDK1/Cyclin 
A phosphorylation (Arias and Walter, 2005; Sugimoto et al., 2004; Nishitani et al., 2004; 
McGarry and Kirschner, 1998; Zhou et al., 2018). The methyltransferase Set8 is also degraded 
by CRL4Cdt2 to prevent re-replication (Tardat et al., 2010). If any licensing occurs in S phase, 
cells may re-replicate their DNA, causing double strand breaks, aneuploidy and genome 
instability (Truong and Wu, 2011; Neelsen et al., 2013). Therefore, MCM loading and firing must 
be strictly segregated to ensure proper genome replication. 
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 Cells must load all the MCM required for replication in the preceding G1 phase, but in 
times of replication stress cells need more MCM to ensure complete replication. For that reason, 
cells typically load 5-10 times extra MCM than normally required to complete S phase as 
“dormant origins” (Woodward et al., 2006; Ge et al., 2007; Ibarra et al., 2008). When a 
replication fork encounters replication stress it will stall and stop replicating. Cells then fire a 
nearby dormant origin to start a new replication fork and rescue the stalled fork (Yekezare et al., 
2013). Cells may continue to proliferate with decreased origin licensing, but fewer dormant 
origins makes them hypersensitive to replication stress. Mice with diminished dormant origins 
have defects in proliferative tissues such as the hematopoietic system, increased genome 
stability, and cancer (Pruitt et al., 2007; Kunnev et al., 2010; Shima et al., 2007). Ensuring 
sufficient loaded MCM at S phase entry is critical to maintain genome stability. 
The Origin Licensing Checkpoint 
 Cells ensure sufficient loaded MCM through the origin licensing checkpoint. The 
licensing checkpoint is p53-dependent pathway that decreases CDK2 activity to block S phase 
entry until there is a sufficient amount of loaded MCM (Nevis et al., 2009; McIntosh and Blow, 
2012). The licensing checkpoint seems to inhibit CDK2 by multiple mechanisms, but the exact 
pathway is unknown. CDK2 requires phosphorylation of T160 for kinase activity, this 
phosphorylation is decreased when MCM loading is decreased, suggesting the origin licensing 
checkpoint regulates CDK2 T160 phosphorylation (Nevis et al., 2009). Another licensing 
checkpoint target upstream of CDK2 is Cyclin D expression, which is diminished during 
decreased origin licensing (Liu et al., 2009). Cancer cells tend to have lost p53 and Rb pathway 
expression or function, and subsequently they also have a defective origin licensing checkpoint 
(Nevis et al., 2009). The lack of a licensing checkpoint makes cells sensitive to treatments that 
decrease origin licensing. Cancer cell lines, but not untransformed cells, prematurely enter S 
phase with few dormant origins during treatments that reduce origin licensing (Shreeram et al., 
2002; Nevis et al., 2009; Zimmerman et al., 2013). These cells that lack the origin licensing 
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checkpoint and enter S phase prematurely are hypersensitive to replication stress and treatment 
with replication inhibitors causes apoptosis (Feng et al., 2003; Shreeram et al., 2002; 
Zimmerman et al., 2013). The specific sensitivity of cancer cells but not normal cells to 
decreased MCM loading makes origin licensing a potential target in cancer therapy, and 
preliminary drug screens for licensing inhibitors shows promise targeting cancer cells (Gardner 
et al., 2017).  
How does CDK activity affect MCM loading? 
 The cell cycle is broadly divided into a period of low CDK activity in G1 phase and a 
period of high CDK activity in S/G2/M phases. MCM loading and DNA replication are restricted 
to G1 and S phase, respectively. Presumably low CDK activity is permissive for origin licensing 
and high Cdk activity is inhibitory for origin licensing and permissive for origin firing (Siddiqui et 
al., 2013). One group claims that CDK2/Cyclin E activity inhibits MCM loading, while another 
that it is CDK2/Cyclin A activity that inhibits MCM loading (Ekholm-Reed et al., 2004; Wheeler et 
al., 2008). However, CDK2/Cyclin E is also required to stabilize Cdc6 for MCM loading (Mailand 
and Diffley, 2005). How can Cdk2 activity both be activating and inhibiting MCM loading at the 
same time? Is there a clear role for CDK2 in MCM loading? I address this question in Chapter 3 
by overproducing Cyclin E and measuring MCM loading rate, finding that Cyclin E does not 
inhibit MCM loading, rather it only shortens G1 so cells have less time to load MCM. 
What are the MCM loading dynamics in G1? 
 We know that MCM complexes are loaded onto DNA in G1 phase, but the exact details 
of when in G1 or how fast MCM are loaded are unknown. It could be that MCM load onto DNA 
at a linear rate, a certain amount per minute. Then G1 length would be the major contributor to 
the total amount of loaded MCM with longer G1 phases resulting in more loaded MCM. It is 
unclear when MCM loading begins in G1, and it could be determined by the availability of Cdc6, 
which is degraded in early G1 by APCCdh1 (Mailand and Diffley, 2005; Petersen et al., 2000). If 
MCM loading is linear and starts in late G1, then cells with different G1 lengths could still load 
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the same amount of MCM, because most G1 variation occurs in the early G1 phase (Foster et 
al., 2010). Another model is that MCM loading increases exponentially as cells move through 
G1 phase. In this case, no matter if MCM loading begins in early G1 or late G1, the bulk of MCM 
loading would be in late G1.  Some data support a model where most MCM loading occurs in 
late G1. Symeonidou et al. used Fluorescence Recovery After Photobleaching to measure the 
immobile (DNA-loaded) fraction of MCM in G1 phase. They found a transient association 
between MCM in DNA in telophase and early G1 phase, and then a gradual increase in the 
stable (loaded) fraction throughout G1. However, about 50% of MCM total immobile fraction 
became immobile in the very late G1 phase, suggesting some factor rapidly promoted loading in 
late G1. Perhaps there is enough MCM loaded to relieve the licensing checkpoint, increasing 
Cdk2 activity to stabilize Cdc6? Then Cdc6 could help load more MCM, further increasing Cdk2 
activity, which would start a positive feedback loop by stabilizing even more Cdc6. Whichever 
type of loading is correct, linear or exponential, the length of G1 will also be a factor in the 
amount of loaded MCM at the start of S phase. 
 How do cells with different G1 lengths load MCM onto DNA? Do they load at the same 
rate so cells with short G1s enter S phase with less MCM loaded? Or can the MCM loading rate 
change between cell types? MCM loading rate has not been measured in cells, however. The 
only measurements of MCM loading rate were done with in vitro reactions using purified yeast 
proteins to load MCM complexes onto plasmids (Remus et al., 2009; Evrin et al., 2009). It is 
plausible the MCM complex loading rate could be different between cells because cell express 
different amounts of licensing proteins (Lau et al., 2007). Cells with high levels of licensing 
proteins would load faster than cells with low levels of licensing proteins, regardless of the G1 
length. This manipulation of MCM loading rate could be important for cancer cells, which 
overexpress licensing proteins and also likely lack the licensing checkpoint. The cancers cells 
would need a rapid MCM loading rate to ensure sufficient MCM loading because they would be 
unable to extend G1 phase as they have a defective licensing checkpoint (Lau et al., 2007). I 
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address this question in Chapter 3 by measuring average loading rate in stem cells and 
differentiated cells with short and long G1 lengths. I found that high amounts of Cdt1 promotes a 
fast MCM loading rate in stem cells with a short G1 phase. However, in Chapter 4 I find that the 
long G1 during cell cycle re-entry is underlicensed due to slow MCM loading and a defective 
origin licensing checkpoint.  
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CHAPTER 2: CELL CYCLE PROLIFERATION DECISIONS: THE IMPACT OF SINGLE CELL 
ANALYSES1 
Introduction 
The cell cycle is a series of tightly-regulated molecular events controlling DNA replication 
and mitosis, producing two new daughter cells from a single parent cell. Every cell cycle, 
individual metazoan cells have the opportunity to adopt one of two mutually-exclusive 
proliferation-related fates: continued cell cycle progression or cell cycle exit. Cell cycle exit 
encompasses multiple distinct states including permanent arrests associated with terminal 
differentiation or senescence and reversible arrest known as quiescence (G0). Settings where 
the importance of cell cycle entry is particularly apparent include hematopoiesis, replenishing 
the epithelial lining of the digestive tract, replacing shed skin cells, activation of adaptive 
immune responses, and wound healing. Tight control over cell cycle entry and exit is also critical 
for tumor prevention since most transformed cells do not appropriately respond to cues that 
trigger quiescence. It is thus important to understand the processes that determine cell cycle 
entry, cell cycle progression, and exit to quiescence. In this review, we highlight advances in 
understanding such proliferation decisions in mammalian cells and particularly the impact of 
recent improvements in single cell analysis methods.  
Much of our understanding of the molecular determinants of cell cycle progression 
comes from analyses of cell populations. There are well-documented substantial changes in 
gene expression, protein abundance, protein post-translational modifications, and DNA 
synthesis as a population of cells moves from one cell cycle phase to the next,  or when a 
                                                            
1Modified from: Matson, J. P. and Cook, J. G. (2017) ‘Cell cycle proliferation decisions: the 
impact of single cell analyses’, FEBS Journal, 284(3), pp. 362–375. doi: 10.1111/febs.13898. 
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population becomes quiescent. Commonly-used methods to monitor these changes include  
immunoblotting and quantitative real-time PCR for individual proteins or messenger RNAs or 
proteomics and transcriptomics for global analyses. The limits of detection for these methods 
have, until very recently, required pooled material from many thousands or millions of cells. A 
culture of genetically identical cells grown together are presumed to behave very similar to one 
another in the interpretation of such ensemble techniques though this assumption is not 
necessarily valid. 
Even when two cells begin a cell cycle phase at the same time - such as immediately 
after cytokinesis -  marked variation among individual cells and heterogeneous responses to 
external and internal cell cycle cues lead to different rates of cell cycle progression (Chiorino et 
al., 2001). Cell cycle heterogeneity arises from intrinsic and extrinsic variability in gene 
expression resulting in heterogeneity in mRNA and protein levels among individual cells (Snijder 
and Pelkmans, 2011; Raj and van Oudenaarden, 2008; McAdams and Arkin, 1997). Additional 
cell cycle variation could be a consequence of cell division itself. Although DNA is actively 
distributed equally into daughter cells, RNA, proteins, metabolites, and organelles may be 
randomly and unequally distributed at every cell division (Dueck et al., 2015; Darzynkiewicz et 
al., 1982). For example, Czerniak et al. used antibody staining to examine the distribution of 
several individual proto-oncoproteins with the potential to profoundly impact cell cycle 
progression, including the Ras GTPase and the c-Myc transcription factor. These authors found 
intercellular variability particularly in G1 phase cells, and most notably, differences in antigen 
concentrations in newly-born sister cells (Czerniak et al., 1992). Once a cell acquires higher or 
lower concentrations of a key protein, the difference from the population average can remain for 
two or more cell cycles (Sigal et al., 2006). There may also be coexisting and interconverting 
subpopulations of cells with different molecular states that influence proliferative fate (Overton et 
al., 2014; Spencer et al., 2013; Sakaue-Sawano et al., 2008).  
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Each individual cell “decides” to proliferate or exit the cycle separately from the whole 
population, integrating numerous signals to time the transition from one phase of the cycle to 
the next (Spiller et al., 2010). The intercellular heterogeneity and generally asynchronous 
growth of proliferating cells creates challenges for precisely tracking their behavior. A popular  
method to overcome heterogeneity is artificially synchronizing cells with inhibitors in one cell 
cycle phase, releasing them from the block, and monitoring molecular markers over time. 
Although cell cycle synchronization creates generally homogenous populations, the further each 
time point is removed from the initial synchronizing block, the more heterogeneous the 
population becomes (Illustrated in Figure 2.1). Furthermore, the arrests themselves can induce 
unique stress signaling pathways that aren’t normally engaged (or are engaged at much lower 
intensity) in normal cell cycles (Murray et al., 2004; Lanni and Jacks, 1998; Kurose et al., 2006). 
For example, nocodazole synchronization in mitosis can create genome instability after mitotic 
exit (Minn et al., 1996). 
Moreover, a population of cells may harbor consistent or transiently interconverting 
distinct subpopulations with different proliferation dynamics. Methods that measure the 
aggregate concentration or activity in a population may mask subpopulations containing 
different levels of individual protein abundance or activity (Balazsi et al., 2011). If a culture 
contains two very distinct populations in significant numbers (such as a mixture of proliferating 
cells and quiescent or senescent cells, ensemble molecular detection methods will report an 
intermediate level of activity that may not be a true reflection of either state (Figure 2.1B). Only 
experiments measuring cell cycle parameters from single cells can identify distinct 
subpopulations that are hidden by methods that average the whole population.  
Methods to assess proliferation in individual cells.  
Single cell analysis is not itself new in the cell proliferation field. Counting the individual 
mitotic cells per field in a biopsy tissue sample has been a long-standing practice in clinical 
settings as one prognostic cancer indicator. Similarly, for decades patient samples have been 
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routinely probed with antibodies to proteins that are only expressed in proliferating cells, and the 
expression intensity and number of expressing cells provide valuable diagnostic information 
(Walker, 1954; Champy, 1922; Gerdes et al., 1983; Yu et al., 1992). With respect to 
understanding fundamental cell cycle regulation, early studies assessed DNA synthesis (using 
radioactive nucleotides or nucleotide analogs), protein abundance, localization, post-
translational modifications, and cell division in single cells grown under a variety of culture 
conditions. In this way, the eukaryotic cell cycle was divided into discrete phases (Taylor, 1960; 
Lajtha et al., 1954; Howard and Pelc, 1953).  
The development of microfluidic flow cytometry that measures the intensity of 
fluorescent DNA or antibody stains revolutionized the cell cycle field. One of the many 
advantages over the earlier methods is the routine and rapid quantification of thousands of cells 
per sample and the relatively unbiased comparisons among different samples (Darzynkiewicz et 
al., 2004). Moreover, multiple molecular parameters can be assessed simultaneously, and the 
number of distinct measurements is limited only by the spectral properties of the reagents and 
the fluorescence detectors. Since large numbers of cells are analyzed by flow cytometry 
simultaneously, researchers have opportunities to derive rates of cell cycle phase transitions 
and identify minor subpopulations of cells (Kafri et al., 2013; Roy et al., 2013). The opportunities 
for multiplex measurements have expanded significantly with the recent development of mass 
cytometry (Bendall et al., 2011).  
The advent of genetically-encoded fluorescent proteins expanded the capabilities of 
single cell analysis in many fields, including the cell cycle. An important recent contribution by 
Sakaue-Sawano et al. took advantage of existing knowledge about specific ubiquitin-mediated 
protein degradation events to create a pair of cell cycle biosensors they named FUCCI for 
“fluorescent ubiquitination-based cell cycle indicator.” (Sakaue-Sawano et al., 2008). They 
generated and co-expressed red and green fluorescent protein fusions that are degraded in S 




Figure 2.1. Advantages of single cell analysis 
(A)  Hypothetical molecular signal in individual cells of an artificially-synchronized population. 
Black dots represent cell divisions. Cells are synchronized in the first cell cycle, but within two to 
three cell cycles the population is completely asynchronous. (B, Left) Single cell analysis 
identifies and tracks a representative molecular signal in coexisting cell populations where 
different subpopulations take different cell cycle fates. (B, Right) Ensemble analysis of the same 
coexisting populations reports only the average signal that may not represent either 
subpopulation’s cell cycle fate.  
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cell imaging, these biosensors were utilized initially by Sakaue-Sawano and subsequently by 
many others in a variety of physiological, developmental, and pathological settings to visualize 
cell cycle phases (Zielke et al., 2014; Coronado et al., 2013; Sugiyama et al., 2009). New 
genome editing tools to efficiently incorporate fluorescent tags at endogenous genes will expand 
the proliferation reporters beyond the original FUCCI pair (Stewart-Ornstein and Lahav, 2016). 
The high time resolution of fluorescent live cell imaging using fluorescent reporters is 
particularly powerful for determining the relationships among two or more events, even when 
they are closely-spaced in time (Welch et al., 2011; Spiller et al., 2010). Live cell microscopy 
reveals when a stereotypical order of events characterizes a given cell cycle phase (Muzzey 
and van Oudenaarden, 2009). For example, live imaging studies in both budding yeast and 
human cells identified sequences of protein degradation events that characterize passage 
through the individual subphases of mitosis or at the onset of S phase (Lu et al., 2014; Izawa 
and Pines, 2011; Coleman et al., 2015). Furthermore, automated cell identification and tracking 
computer programs and scripts now make it possible to generate robust datasets of reporter 
signal intensities from many hundreds of cells without the potential biases of quantifying cells by 
hand (Jaqaman et al., 2008; Carpenter et al., 2006). While these software tools are rapidly 
advancing, each imaging data set usually requires a customized image analysis pipeline and 
parameter optimization.  
Cell cycle proliferation and the restriction point phenomenon 
Commitment to either cell cycle progression or quiescence is mutually exclusive. 
Moreover the collection of molecular states that differ between quiescent cells and cells 
committed to S phase entry is extensive and varied (Coller, 2011). It’s worth emphasizing here 
that quiescent cells are not characterized simply as the absence of proliferation-associated 
activities. Quiescence is actively maintained not only through continual transcriptional 
repression of genes required for DNA replication and mitosis, but also through active expression 
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of anti-apoptotic, anti-senescence, and anti-differentiation genes (Coller et al., 2006; Legesse-
Miller et al., 2012; Sang et al., 2008; Litovchick et al., 2007).  
The commitment to proliferation is a binary decision that is marked by the onset of DNA 
replication, an irreversible process.  For this reason the transition from G1 to S phase is under 
tight and multifaceted controls; disruption in those controls drive many aspects of cancer cell 
phenotypes. Moreover, partial replication of chromosomal DNA is particularly dangerous in 
actively proliferating cells, because the eventual dissolution of replication forks that do not 
ultimately meet one another during normal termination leads to double-stranded chromosome 
breaks (Zeman and Cimprich, 2014). Thus, cells that start replication must be fully prepared to 
finish replication in a time-frame compatible with the biochemical limitations of the replication 
program (number of initiation sites, replication fork stability and speed, etc.). 
To ensure adequate preparation before S phase onset and a robust start and finish for 
DNA replication, the G1/S transition is a “bistable switch.” Bistability is a steady state distribution 
of two populations which may interconvert in a rapid, switch-like manner. It characterizes many 
cell cycle transitions so that progression from one phase to the next is rapid, complete, and 
unidirectional (Tyson and Novak, 2008; Barr et al., 2016; Ferrell et al., 2011). In the case of the 
G1/S transition, bistability applies to the activation of the cyclin dependent kinase (Cdk) Cyclin 
E/Cdk2 which triggers replication initiation (Yuan et al., 2014). A series of molecular feedback 
and feedforward relationships ensure that very little Cdk2 is active during early-to-mid G1 but in 
late G1, Cdk2 activity is sharply upregulated and stably maintained until later in S phase. These 
include: Cyclin E synthesis, degradation of a Cdk2 inhibitor protein (p27KIP), Cdc6-dependent 
loading of the replicative DNA helicase to license replication origins, and Cyclin E/Cdk2 
activation. Cdk2 activation is abrupt, but not at the exact same time in different cells. At any time 
in a population there may be subpopulations of cells with different discrete Cdk2 activity levels. 
The experimental challenges posed by this intercellular variability in the timing of rapid, 
irreversible, transitions from one phase to the next are greatly alleviated by single cell analyses.  
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Cells commit to either quiescence (G0) or future S phase entry at the restriction point. 
The term “restriction point” or “R-point” was first proposed by Arthur Pardee in 1974 based on 
the timing of DNA synthesis in populations of hamster fibroblasts after a cell cycle block and 
release (Pardee, 1974). The restriction point was the cell cycle point past which cells were 
irreversibly committed to S phase entry, regardless of whether or not extracellular mitogens 
were removed (Zetterberg et al., 1995).  It is sometimes described as the “point of no return” in 
the cell cycle with respect to S phase entry. Mammalian cells in culture require external 
mitogens for proliferation, and since the DNA content of quiescent cells is the same as G1 cells, 
and mitogen stimulation leads to DNA synthesis before mitosis, it seems obvious that cells exit 
to quiescence from G1. What has not always been obvious is precisely when during the cell 
cycle mitogens are sensed to execute the commitment to quiescence versus proliferation nor 
what the precise molecular nature of the decision itself is (Hitomi and Stacey, 2001).  
Pardee noted the limitations of measuring a cell population for cell cycle commitment 
and acknowledged the possibility that intercellular heterogeneity or the presence of fast-
responding subpopulations would be missed in his study (Pardee, 1974). A subsequent single 
cell microscopy study in 1985 by Zetterberg and Larsson indicated that the only time mitogens 
are essential for the commitment to proliferation is in G1 phase (Zetterberg and Larsson, 1985). 
In these pioneering experiments, the authors conducted time lapse microscopy of proliferating 
mouse fibroblasts that were transiently deprived of mitogens. They found that the only cells that 
responded to mitogen withdrawal (by markedly delaying the next cell division) were very “young” 
cells in the first few hours after mitosis. They also noted intercellular variability in G1 length. 
Their observations have guided discussions of cell cycle commitment as an exclusively G1 
event for the past 30 years.  
Cell cycle commitment during re-entry to G1 from quiescence 
The mechanisms by which mitogens stimulate passage through the restriction point and 
cell cycle commitment initiate at the plasma membrane with mitogen receptors (Figure 2.2A). Of 
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central relevance, external mitogens activate signal transduction activities including the Ras 
GTPase (Massagué, 2004). Ras activation stimulates a pathway culminating in activated gene 
expression through transcription factors such as c-Myc, serum response factor, and others  
(Blagosklonny and Pardee, 2002; Shaulian and Karin, 2002; Zhang et al., 2016). Among the 
principle proliferation genes under control of these transcription factors are those encoding D-
type cyclins (hereafter Cyclin D). Cyclin D protein complexes with either of two redundant cyclin-
dependent protein kinases, Cdk4 or Cdk6, and cyclin binding activates Cdk4/6 to phosphorylate 
the Retinoblastoma (Rb) transcriptional repressor at one of many individual phosphorylation 
sites. Rb does not itself bind DNA but rather is recruited to specific genes through interaction 
with the family of DNA binding transcription factors known as the E2F family. E2F controls the 
expression of a suite of genes necessary for DNA replication, S phase progression, and mitosis. 
Rb binds E2F which results in active transcriptional repression of those E2F target genes. For 
many years, the prevailing paradigm – based largely on molecular assays of whole cell 
populations - has been that initial partial Rb phosphorylation by Cyclin D/Cdk4 (or Cyclin 
D/Cdk6) gradually releases E2F inhibition to activate transcription (Massagué, 2004; Giacinti 
and Giordano, 2006; Weinberg, 1995; Blagosklonny and Pardee, 2002; Johnson and Skotheim, 
2013). One of the E2F target genes that is induced is cyclin E, and the Cyclin E protein binds 
and activates the Cdk2 protein kinase which then participates in Rb phosphorylation in a 
positive feedback loop; this feedback loop is further reinforced by the fact that E2F1 is one of 
the E2F target genes. Full Rb hyperphosphorylation completely releases Rb from E2F relieving 
repression of E2F target genes and allowing for activated E2F-dependent transcriptional 
induction and S phase entry.  
Pardee proposed that cells exist in two states – either proliferating or quiescent – and 




Figure 2.2. The restriction point during re-entry to G1 from quiescence 
(A) The prevailing paradigm of the restriction point. Mitogens activate Ras signaling, 
downstream MAP Kinases, and ultimately Cyclin D transcription. Cyclin D complexes with CDK4 
and CDK6 to partially phosphorylate Rb, and this hypophosphorylation causes release from E2F 
and partially activates Cyclin E expression. Cyclin E complexes with CDK2 to 
hyperphosphorylate Rb, creating a positive feedback loop where progressively increasing Cyclin 
E levels increase Rb phosphorylation leading to increased Cyclin E transcription and S phase 
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commitment. (B) An alternate model for the restriction point. Cyclin D-CDK complexes only 
monophosphorylate Rb on 14 unique sites. The monophosphorylated Rb remains E2F-bound, 
but at least some aspects of Rb-mediated gene repression are relieved moving cells from G0 to 
G1. Multiple sustained mitogen-dependent inputs (p27 degradation, origin licensing, etc.) 
activate Cyclin E-CDK2 complexes which rapidly hyperphosphorylate Rb in a switch-like fashion 
to drive commitment to S phase. 
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emerged later as a popular marker of post-restriction point cells which have committed to 
division. The prevailing model of gradual and progressive Rb phosphorylation during G1 was 
not easily reconciled with an all-or-none proliferation decision however. Methods that measure 
entire populations of cells – such as DNA synthesis by general thymidine incorporation or 
immunoblotting cell lysates for Rb hyperphosphorylation, report only a global average of any 
subpopulations, making it difficult to precisely detect a switch between two states. To overcome 
this hurdle and focus specifically on E2F control, Yao et al. used single cell flow cytometry with 
fluorescent E2F or Cyclin D transcriptional reporters to correlate mitogen-induced gene 
expression with the switch triggering cell cycle commitment during re-entry from quiescence 
(G0) (Yao et al., 2008). They synchronized cells in G0 by mitogen withdrawal then re-stimulated 
with serum. Transcriptional activity displayed an all or none bistable response resulting in two 
distinct cell populations. That is, each individual cell either remained quiescent with no reporter 
transcription, or displayed maximally-active expression. Significantly, there were no intermediate 
states and no partial commitment to the cell cycle. Sustained mitogen stimulation shifted the 
probability that any individual cell committed to S phase entry. This shifting probability was 
detectable as changes in the distribution of the population between the two states. Single cell 
flow cytometry clearly distinguished and quantified the two subpopulations of maximal or 
minimal response.  
The study by Yao et al. was also the first demonstration of a bistable commitment point 
directly related to E2F activity. A feature of this bistability was that cell cycle commitment 
measured by reporter activation required sustained and strong E2F stimulation, but once 
activated, was largely irreversible. Low levels of mitogens were insufficient to pass the 
restriction point and activate E2F. On the other hand, withdrawing mitogens after a cell passed 
the restriction point with high E2F transcriptional activity neither reduced E2F reporter activity 
nor prevented S phase entry. Thus, quiescent cells require a threshold of E2F activity to re-
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enter the cell cycle, and committed cells retain their high E2F activity even if the environment 
favoring proliferation changes.  
One mechanism that maintains E2F activity once it crosses the commitment point is 
feedforward regulation of the E2F1 gene itself. E2F1 transcription is stimulated not only by E2F 
but also by the c-Myc transcription factor (Leung et al., 2008) which is stabilized by mitogen 
signaling (Sears et al., 2000). The dynamics of mitogen activated E2F1 expression were 
precisely monitored by Dong et al. with an updated fluorescent E2F1 transcriptional reporter for 
single cell live imaging to compare the contributions of Cyclin/Cdk and Myc to E2F dependent 
cell cycle commitment (Dong et al., 2014). Importantly, they tracked the behavior of individual 
cells over time, and correlated commitment to divide with each cell’s history of reporter activity. 
At any time before irreversible commitment to the cell cycle, the E2F transcriptional activity in a 
cell predicted the probability for commitment to cell division. Greater levels of transcription 
before the restriction point correlated with higher probability to re-enter the cell cycle, passing 
the restriction point.  
A recent study further challenges the notion that E2F is progressively activated by 
progressive Rb phosphorylation via Cyclin D in early-to-mid G1 and then via Cyclin E in late G1 
(Narasimha et al., 2014). A team of scientists from the Dowdy lab (Narasimha, Kaulich, Shaprio, 
et al.) used isoelectric focusing gels and a series of phospho-specific Rb antibodies to show that 
Rb is exclusively monophosphorylated by Cyclin D throughout most of G1 phase (Figure 2.2B). 
Fully un-phosphorylated Rb was restricted to non-transformed cells under conditions of 
profound quiescence induced by mitogen deprivation or after terminal differentiation. 
Surprisingly, Rb was monophosphorylated at any one of the 14 individual Cdk sites by Cyclin 
D/Cdk4 (or Cyclin D/Cdk6), and the sites seemed to be functionally equivalent, though potential 
differences in their effects at different E2F-regulated genes remain to be investigated. 
Importantly, no intermediate Rb phospho-isoforms appeared at any time during G1. Moreover, a 
sharp Cyclin E mRNA increase coincided with Cdk2 activation and abrupt switch-like Rb 
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hyperphosphorylation at ≥ 10 sites. Each of the 14 different Cyclin D-induced 
monophosphorylated Rb isoforms remained bound to E2F, suggesting that some degree of 
active repression at E2F-regulated genes may be maintained throughout G1 even after Cyclin 
D/Cdk4-mediated Rb phosphorylation  (Narasimha et al., 2014). The apparent requirement for 
Cyclin E/Cdk2 to rapidly convert monophosphorylated Rb to fully hyperphosphorylated Rb 
suggests a strict division of labor between Cyclin D- and Cyclin E-activated kinases under 
normal conditions. The model proposed is that Cyclin D-mediated Rb phosphorylation is not the 
sole late G1 event that marks passage through the restriction point. Cyclin D may instead 
promote entry from quiescence into early G1 while other events are likely required to drive cells 
through G1 past the restriction point.  
The prime candidate for the event needed for restriction point passage was long-held to 
be cyclin E transcription which is under Rb-E2F control. Cyclin E protein activates Cdk2 protein 
kinase which both hyperphosphorylates Rb and can trigger DNA replication initiation. Certainly, 
high Cdk2 activity corresponds with both Rb hyperphosphorylation and post-restriction point 
behavior (i.e. mitogen-independent cell cycle progression) (Narasimha et al., 2014). Multiple 
recent studies using time-lapse microscopy of single cells have found inconsistencies with the 
Cdk2 and Rb-centric model that have not yet been fully resolved. In one study pharmacological 
Cdk2 inhibition did not block fibroblast cell passage through the restriction point, and cyclin E 
accumulation appeared later than the calculated restriction point time of 3-4 hours post-mitosis 
(Ekholm et al., 2001). Similarly Rb phosphorylation was not elevated until several hours after 
cells had already committed to mitogen-independent proliferation (Martinsson et al., 2005). The 
Cdk2 inhibitor used in that study, roscovitine, inhibits enzymes in addition to Cdk2 however, 
though it is not yet clear how important the other kinases are for restriction point passage (Bach 
et al., 2005). Highly selective Cdk2 inhibition in untransformed epithelial cells using chemical 
genetics suggested a positive role for Cdk2 in restriction point passage (Merrick et al., 2011). 
Thus, although a sharp increase in Cdk2 activity is required for Rb hyperphosphorylation and for 
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origin firing in S phase (at least in cells passing through G1 from quiescence), it is not clear that 
Cyclin E/Cdk2 activity alone normally causes commitment to future S phase entry.  
Classic studies with overproduced Rb mutant forms that block G1 progression, 
overproduced cyclin that accelerates G1 progression, or genetic Cyclin and Cdk null alleles 
should be carefully interpreted in light of our current understanding about the redundancies 
among Rb and cyclin family members. The question remains if Rb hyperphosphorylation itself is 
the principal molecular determinant of restriction point passage or if it is a downstream 
consequence of restriction point passage or some combination of both models. Cell type and 
whether the cells are actively proliferating or first entering the cycle from quiescence may be 
important determinants of when and how the commitment is made (discussed below). 
Regardless of whether Cdk2 causes restriction point passage or is a subsequent 
reflection of that commitment, the correlation between an increase in Cdk2 activity and 
commitment to S phase entry is widely accepted. The molecular mechanisms that drive the 
increase in cyclin E/Cdk2 activity are all in feedforward relationships with Cdk2 to reinforce 
bistability (Figure 2.2B). One of these relationships is Cdc6-dependent DNA replication origin 
licensing, and Cdc6 is itself stabilized by Cdk2 phosphorylation in late G1 (Mailand and Diffley, 
2005; Machida et al., 2005; Shreeram et al., 2002; Nevis et al., 2009).  A second major Cdk2 
regulator is the p27KIP protein which is both a direct inhibitor of Cdk2 kinase activity and also a 
substrate of Cyclin E/Cdk2. p27 is abundant in quiescent cells but is partially degraded shortly 
after cell cycle re-entry from G0 in early G1 which reduces, but does not eliminate p27 (Rizzardi 
and Cook, 2012). In late G1, the remaining p27 is eliminated by Cyclin E/Cdk2-induced 
degradation (Rizzardi and Cook, 2012). In another example of single cell biosensor use to track 
cell proliferation decisions, Oki et al. followed both the initial p27 drop from G0 to G1 and the 
subsequent elimination at G1/S by time-lapse fluorescence microscopy and flow cytometry of 
cells expressing a fluorescent p27 fusion. Altogether, this collection of distinct mitogen-
dependent molecular events cooperate in late G1 to activate Cyclin E/Cdk2, and the 
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feedforward mechanisms serve to maintain high activity through the G1/S transition (Cappell et 
al., 2016).  
Cell cycle decisions in actively-proliferating populations. 
The proliferation decision committing cells to complete the cell cycle or exit to 
quiescence has until recently, been thought to occur only in G1 (Zetterberg et al., 1995). 
However, single cell studies suggest the cell proliferation decision can occur during a window of 
G2 in the previous cell cycle in actively proliferating cells. Hitomi and Stacy first demonstrated 
that mitogen-induced Ras activity is required in G2 to complete the next cell cycle (Hitomi and 
Stacey, 1999). Spencer et al. subsequently explored this G2 mitogen requirement by removing 
mitogens from proliferating cultures during time lapse fluorescence microscopy (Spencer et al., 
2013). They observed a large subpopulation of cell in mitosis or early G1 when the mitogens 
were withdrawn that were already committed to complete one more cell cycle.  
A key component of this study was the use of a fluorescent fusion protein that responds 
to changes in Cdk2 activity, a Cdk2 “biosensor”. At the start of G1 (i.e. just after mitosis), new 
cells were either already on a trajectory to increase biosensor activity or they started G1 with 
measurably lower activity that remained low for many hours. Cells born with the already 
increasing kinase activity contained hyperphosphorylated Rb and were apparently irreversibly 
committed to completing the next cell cycle, even if mitogens were withdrawn or mitogen 
signaling was inhibited in early G1. Mitogen withdrawal, mitogen pathway inhibition or high 
levels of a Cdk2 inhibitor during the preceding G2 phase reduced biosensor activity in the 
subsequently-born daughter cells and blocked progression into S phase in the following cell 
cycle (though cells completed the ongoing G2, M phase, and cytokinesis). Conversely, cells 
born with naturally low Cdk2 activity entered a prolonged G1/G0-like state and required 
sustained mitogen signaling through early G1 to commit to cell division (similar to the Zetterberg 
and Larsson restriction point study) before committing to G1 progression. Sister cells were born 
with the same biosensor activity and cell cycle commitment, supporting the idea of a decision 
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occurring in the previous cell cycle. The low activity cells were interpreted as transiently exiting 
to quiescence and then re-entering the cell cycle at G1 whereas the high activity cells were pre-
committed to finishing the next cell cycle. 
Tracking cells from G2 through division and monitoring subpopulations in the next G1 
was only possible by single cell analysis. Moreover live imaging of the fluorescent reporter in 
single cells revealed the two subpopulations of cells with different Cdk2 activity levels and 
subsequently different G1 phases. Interestingly, different cell lines had different relative 
amounts of the two subpopulations; transformed cell lines had more of the increasing Cdk2 cells 
and non-transformed more of the low Cdk2 activity cells. These differences generally correlated 
with the propensity of the different cells to exit the cell cycle, a characteristic that varies with cell 
cycle and especially transformation status. 
A second study by Naetar et al. supports the role for a Cdk2-driven G2 decision window 
committing cells to the next cell cycle (Naetar et al., 2014). These authors withdrew mitogens 
from cells that they had pre-synchronized in G2 and used flow cytometry to measure DNA 
synthesis in the following cell cycle to test commitment to the next cell cycle. Removing serum 
mitogens during G2 caused cell cycle exit in the following G1 as expected. However, 
simultaneously inhibiting protein phosphatase 2A (PP2A) during the G2 mitogen withdrawal 
prevented cell cycle exit in the following G1. The cells committed irreversibly to completing the 
next cell division even though they entered G1 without mitogens present. Specific Cdk2 
inhibition by chemical genetics or dominant-negative Ras expression coincident with PP2A 
inhibition during G2 mitogen withdrawal imposed the expected cell cycle exit in the following G1. 
It seems that G2 specific PP2A-dependent protein dephosphorylation of substrates 
phosphorylated by Cdk2 and Ras-dependent kinases is required to re-establish mitogen 
dependence in early G1 phase. The requirement for mitogen dependent Ras signaling in G2 for 
commitment to the next cycle is also consistent with the pioneering single cell studies by Hitomi 
and Stacy (Hitomi and Stacey, 1999). Thus, a cellular decision to proliferate or become 
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quiescent can occur during the previous cell cycle in a window of G2 receptive to mitogens. The 
notion that the events in the previous cell cycle control the outcome of the next cycle is a 
relatively new concept in the field.  
The notion that a G2 proliferation decision can produce distinct subpopulations of G1 
cells with different molecular characteristics likely includes molecular distinctions beyond the 
activity of Cdk2 and its regulators. One possibility for an additional molecular distinction is the 
chromatin loading of replicative DNA helicases, known as Minichromosome maintenance 
complexes (MCM), to license DNA replication origins (Skarstad and Katayama, 2013; Remus 
and Diffley, 2009).  MCM loading is restricted to G1 and thought to be largely irreversible in that 
the only mechanism known for MCM unloading occurs during replication completion itself. 
(Kuipers et al., 2011; Maric et al., 2014; Moreno et al., 2014). Therefore, differences in G2 
proliferation decisions may be reflected in the kinetics or patterns of G1 MCM loading. In 
support of this idea Håland et al., using an innovative flow cytometry technique to measure 
protein chromatin association in single cells, compared the timing of MCM loading to the timing 
of Rb chromatin release (i.e. Rb hyperphosphorylation) (Håland et al., 2015). Cells re-entering 
G1 from G0 only loaded MCM complexes after Rb chromatin release (MCM loading only after 
the restriction point). On the other hand, cells entering G1 from a preceding mitosis were 
distributed into two populations: cells with loaded MCM before Rb chromatin release and cells 
with loaded MCMs after Rb chromatin release (MCM loading both before and after the 
restriction point). The potential for cycling cells with two modes of MCM regulation in G1 is 
consistent with the idea of two populations after the G2 decision window. 
A second study suggesting distinct G1 subpopulations focused on the inactivation of the 
APCCdh1 ubiquitin ligase at the G1/S transition. Cappell et al. co-expressed the Cdk2 biosensor 
from Spencer et al. with a second biosensor derived from the FUCCI system (Cappell et al., 
2016). Cells with increasing kinase activity in G1 not only spent little time in G1 but they also 
rapidly inactivated APCCdh1. Conversely, the subpopulation of cells with low kinase activity and 
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an extended G1/G0 inactivated APCCdh1 with delayed and variable timing. Interestingly, the G1 
subpopulation of G2 committed cells could be further divided into multiple smaller populations 
with variable responses to DNA damage, oxidative and osmotic stresses. We expect future 
single cell live cell imaging studies will discover even more unique subpopulations in many cell 
cycle phases (Darzynkiewicz et al., 2004). 
Multiple proliferation decision points – multiple mechanisms?  
The suggestion that mitogen-dependent proliferation commitments can occur in G2 
rather than G1 raises new questions about the molecular mechanisms that drive proliferation 
decisions. Cell cycle commitments during both the G2 decision window and the G1 restriction 
point require mitogen signaling through the Ras GTPase pathway (Dobrowolski et al., 1994; 
Peeper et al., 1997; Mulcahy et al., 1985; Hitomi and Stacey, 1999), but what are the key 
molecular targets of this pathway in either setting? Is Cyclin D/Cdk4 activity important for cells to 
commit to proliferation in G2? While the details of the G2 decision window are incompletely 
understood, we suggest that: (1): The G1 restriction point and the G2 decision window operate 
by related but not identical molecular mechanisms. (2): The G1 restriction point is most 
important during the transition from G0 to cell cycle re-entry in G1, while the G2 decision 
window functions in continuously cycling cells. We also favor the idea that actively proliferating 
cells - especially non-transformed cells – can spontaneously and transiently divert to 
quiescence, and that their eventual progression through G0/G1 requires passage through the 
same G1 restriction point as mitogen-starved and re-stimulated cells (Figure 2.3). 
In cells re-entering G1 from quiescence, mitogen-dependent Cyclin D expression 
supports an Rb-E2F molecular state that is required, but not sufficient, for subsequent G1 
progression. Progression from this permissive state past the G1 restriction point requires 
sustained mitogen signaling and a collection of interconnected and reinforcing mechanisms that 
stimulate Cdk2 activation. E2F-stimulated Cyclin E expression is one of these mechanisms, but 
p27 degradation at the G0/G1 transition and again in late G1, and MCM loading (which supports 
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Cdk2 activity by an as-yet unknown mechanism) are also important contributors to Cdk2 
activation (McIntosh and Blow, 2012). In addition, Cdk2 is cytoplasmic in at least some 
quiescent cells which prevents it from acquiring an essential activating phosphorylation by a 
nuclear kinase (Nevis et al., 2009; Lunn et al., 2010). Mitogen-stimulated signaling causes Cdk2 
to translocate to the nucleus for activation, but Cdk2 is constitutively nuclear and 
phosphorylated in actively proliferating cells. Thus at least one additional requirement to activate 
Cdk2 in cells entering G1 from G0 is already met by cells entering G1 from the preceding cell 
cycle. 
The Myc transcription factor also has different roles at the G1 and G2 proliferation 
decisions. For passage through the G1 restriction point, Ras-driven Myc accumulation regulates 
and cooperates with E2F transcriptional activity to control a suite of proliferation-related genes  
(Dong et al., 2014; Leung et al., 2008; Hölzel et al., 2001). For commitments made during G2 
however, Myc is apparently important primarily for Cyclin E transcription, possibly to prime G2 
cells for high Cyclin E/Cdk2 activity after mitosis (Naetar et al., 2014). Neither Cyclin D nor other 
E2F target genes including PCNA, CCNA2 (Cyclin A), and E2F1 are transcribed in G2 under the 
same conditions (Naetar et al., 2014). This observation suggests the G2 decision window, 
unlike the G1 restriction point during cell cycle re-entry, does not heavily rely on Rb-E2F control 
as a primary mechanism. Moreover cells lacking all three Rb family members, “triple knockout” 
mouse embryonic fibroblasts, require mitogen signaling in G2, but not G1, for proliferation 
(Foijer et al., 2005, 2008). We suggest that E2F transcription is not required in G2 for 
commitment to the following cell cycle, but rather continues to promote cell cycle transcription in 
the following G1 in cells which are already committed to division.  
The G2 decision window ultimately leads to increasing and self-reinforcing Cdk activity 
as the switch that determines proliferation or quiescence in the next cell cycle. Of note, Cdk2 
activity itself peaks in S phase, but many Cdk2 functions can also be carried out by Cdk1, so the 




Figure 2.3 Multiple proliferation decisions in actively dividing cells 
Actively dividing cells have two distinct proliferation decision points. The first is a window during 
G2, in which cells with CDK activity above a critical threshold pre-commit to completing the next 
cell cycle with a short G1. A subpopulation of G2 cells with reduced mitogen signaling and/or 
low Cyclin-CDK activity do not commit to the next cell cycle. These cells have a long, variable 
length subsequent G1/G0-like phase and are presented with a second proliferation decision at 
the G1 restriction point. Sustained mitogen signaling promotes increased CDK activity above 
the commitment threshold which is self-sustaining through multiple feedback and feedforward 
relationships. In the absence of sustained signaling and increasing CDK activity, cells exit to G0. 
The probability of cells committing to the cell cycle or exiting to G0 is the cumulative probability 
of multiple molecular events. 
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(L’Italien et al., 2006). The precise downstream target(s) of Cdk mediating the G2 proliferation 
decision are not clear, but it does not appear to be E2F-stimulated transcription in G2 (Naetar et 
al., 2014). Spencer et al. provided evidence that an important determinant of high or low Cdk 
activity in G2 is the abundance of the CDK inhibitor, p21 (which is related to p27 but regulated 
by different mechanisms) (Spencer et al., 2013). Cells with high p21 and low Cdk activity in G2 
entered a variable, but prolonged G1/G0-like state in the following cell cycle, and cycling cells 
lacking p21 altogether proliferated with high Cdk2 activity (Perucca et al., 2009; Spencer et al., 
2013). The relative contributions of CDK inhibitors, kinase activity, and Rb-E2F-controlled 
transcription to the ultimate commitment to proliferation are likely influenced not only by the 
differences between mitogen signaling for cell cycle re-entry from quiescence and mitogen-
dependent cell cycle progression in proliferating cells by also by cell type and cell context.  
G2-committed cells consistently pass quickly through the subsequent short G1 phase 
(Naetar et al., 2014; Spencer et al., 2013). Interestingly, G1 length varies considerably between 
different human cell types in culture: human embryonic stem cells spend as little as 2-3 hours in 
G1 whereas many differentiated cell lines spend 12 hours or more in G1 (Kapinas et al., 2013). 
It is intriguing to speculate that in a population of cells with very short G1 lengths, all the cells 
make the proliferation commitment in the G2 decision window and never face the G1 restriction 
point. Both cancer cells with short G1 lengths and embryonic stem cells have high levels of CDK 
activity, which may guarantee consistent G2 commitment in nearly every cell cycle (Malumbres 
and Barbacid, 2001; Kapinas et al., 2013). Mutations that cause high CDK activity might dictate 
G2 commitment to the next cell cycle, and consequently a short G1 phase.  
Outlook 
Technological advances in microscopy, flow cytometry, and fluorescent reporters have 
made it increasingly clear that individual cells make different proliferative decisions, even when 
they are genetically identical to one another and are cultured together. These intercellular 
differences are likely to be more pronounced in tissues where variations in cellular 
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microenvironments affect local proliferation signals. For example, the intestinal epithelium 
comprises a broad range of proliferative stem cells and differentiated cells that respond to 
diverse spatial signaling cues (Simons and Clevers, 2011). Understanding the behavior of a cell 
population requires a nuanced appreciation that each cell responds to intrinsic or extrinsic cues 
by shifting its probability of entering or exiting the cell cycle. Thus, statistical models that take 
these probabilities into account will be particularly useful predictive tools (Klein and Simons, 
2011). Mathematical models of cell cycle transitions have been in development for several 
years, and the increasingly-sophisticated ability to acquire real-life parameters for molecular 
events using robust quantitative single cell approaches will both test and refine these models 
(Barr et al., 2016; Huard et al., 2012; Tyson and Novák, 2015; Weis et al., 2014).    
One long-term goal held by many in the field is deep mechanistic understanding of 
proliferation decisions and the factors that affect the probabilities of progressing from G1 to S 
phase or exiting from G1 to quiescence. An important contributor to the achievement of that 
goal will be combinations of assays that reveal the relationships among molecular events and 
cell behaviors.  For example, simultaneously tracking two or more biosensors in the same cell is 
the best way to determine the order of two events and if one is likely the cause of the other 
(Stewart-Ornstein and Lahav, 2016; Coleman et al., 2015; Cappell et al., 2016). Furthermore 
combining different types of single cell assays, such as live cell imaging of fluorescent 
biosensors with single-cell transcriptomics or genomics, ties the recent molecular behavior of 
one cell with its later fate (Skinner et al., 2016; Toledo et al., 2013; Zhang and Pellman, 2015; 
Zhang et al., 2015). We anticipate that ongoing technological and conceptual breakthroughs will 
ultimately yield practical benefits such as precision cancer diagnoses and treatments, 
interventions into degenerative diseases and aging, and cell-based therapies.  
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CHAPTER 3: RAPID DNA REPLICATION ORIGIN LICENSING PROTECTS STEM CELL 
PLURIPOTENCY2 
Introduction 
Metazoan DNA replication requires initiation at thousands of DNA replication origins 
during S phase of every cell cycle. Origins are genomic loci where DNA helicases first unwind 
DNA and DNA synthesis begins. Origins are made competent for replication during G1 phase of 
each cell cycle by the loading of Minichromosome Maintenance (MCM) complexes onto DNA. 
MCM is the core component of the replicative helicase, and the process of MCM loading is 
termed origin licensing. Total MCM levels remain constant throughout the cell cycle, but the 
levels of DNA-loaded MCM change as cells progress through the cell cycle. Cells can begin 
MCM loading as early as telophase, and loading continues throughout G1 until the G1/S 
transition, the point of maximum DNA-loaded MCM(Kimura et al., 1994; Todorov et al., 1995). 
Throughout S phase, individual MCM complexes are activated for DNA unwinding as origins 
“fire”. MCM complexes travel with replication forks and are progressively unloaded as replication 
forks terminate (Figure 3.1A)(Deegan and Diffley, 2016; Remus and Diffley, 2009; Siddiqui et 
al., 2013).  
The control of origin licensing is critical for genome stability. Origins must not be re-
licensed after S phase begins because such re-licensing can cause a genotoxic phenomenon 
known as re-replication which may result in double strand breaks, gene amplification, 
aneuploidy, and general genome instability(Arias and Walter, 2007; Truong and Wu, 2011). To 
                                                            
2Modified from: Matson, J. P., Dumitru, R., Coryell, P., Baxley, R. M., Chen, W., Twaroski, K., 
Webber, B. R., Tolar, J., Bielinsky, A.-K., Purvis, J. E. and Cook, J. G. (2017) ‘Rapid DNA 
replication origin licensing protects stem cell pluripotency’, eLife, 6, p. e30473. doi: 
10.7554/eLife.30473. 
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avoid re-replication, MCM loading is tightly restricted to G1 phase by multiple overlapping 
mechanisms that destroy or inactivate MCM loading proteins to prevent any new origin licensing  
On the other hand, cells typically load 5-10-fold more MCM complexes in G1 than they strictly 
require under ideal circumstances, and the additional MCM loading ensures timely and 
complete genome duplication even if replication hurdles are encountered in S phase (Ibarra et 
al., 2008; Woodward et al., 2006; Ge et al., 2007). It is possible for cells to proliferate with less 
than optimal MCM loading, but such cells are hypersensitive to DNA damage and replication 
stress(Blow et al., 2011; McIntosh and Blow, 2012).  
 MCM loading to license origins is restricted to G1, but G1 length varies widely among 
different cell types. For example, specialized developmental and immune cell cycles have 
minimal G1 lengths of mere minutes(O’Farrell et al., 2004; Kinjyo et al., 2015; Kermi et al., 
2017).  In cultured human embryonic stem cells, G1 is only 2-3 hours, and this short G1 is both 
a hallmark of and has been implicated in maintaining pluripotency(Soufi and Dalton, 2016; 
Kareta et al., 2015b). G1 lengthens early in differentiation, and in cultured somatic cells is often 
greater than 12 hours (Calder et al., 2013). Thus, different proliferating cells have drastically 
different amounts of time available to complete MCM loading before making the G1-to-S phase 
transition. In addition, pluripotent stem cells respond to differentiation stimuli specifically in G1 
phase, suggesting that the balance among cell cycle phases influences differentiation 
potential(Gonzales et al., 2015; Pauklin and Vallier, 2013). 
Given that MCM loading is restricted to G1 and the wide variation of G1 lengths, we 
postulated that the absolute amount of loaded MCM in S phase is a product of both the time 
spent in G1 and the rate of MCM loading. The combination of these two parameters has 
implications for genome stability because loading more or less MCM in G1 influences S phase 
length and how effectively S phase cells can accommodate both endogenous and exogenous 
sources of replication stress(Shima et al., 2007; Pruitt et al., 2007). These implications are 




Figure 3.1. Pluripotent stem cells load MCMs faster than differentiated cells. 
(a) DNA-loaded MCM levels increase in G1 and decrease in S phase whereas total MCM 
protein levels are constant throughout the cell cycle.  
(b) Flow cytometric analysis of DNA-loaded and total MCM in asynchronously proliferating 
RPE1-hTERT cells. Cell cycle phases are defined by DNA content and DNA synthesis. Left: 
Cells were labeled with EdU, extracted with nonionic detergent to remove unbound MCM, fixed, 
and stained with anti-MCM2 (a marker for the MCM2-7 complex), DAPI (total DNA), and for EdU 
incorporation (active DNA synthesis). Orange cells are S-phase with DNA-loaded MCM, blue 
cells are G1-phase with DNA-loaded MCM, and grey cells are G1/G2/M phase cells without 
DNA-loaded MCM. Right: Cells were treated as on the left except that they were fixed prior to 
extraction to detect total MCM2.  
(c) T98G cells were synchronized in G0 by contact inhibition and serum deprivation, then 
released into G1 for 10 or 12 hrs, or re-synchronized in early S with hydroxyurea (HU), and 
released into S for 6 or 8 hrs. MCM3 in chromatin-enriched fractions (Loaded) or whole cell 
lysates (Total) was detected by immunoblotting.  
(d) Chromatin flow cytometry of the indicated asynchronous cell lines measuring DNA content 
(DAPI), DNA synthesis (EdU incorporation), and loaded MCM (anti-MCM2). Blue Cells are G1-
MCMDNA-positive and EdU-negative, orange are S phase-MCMDNA-positive; grey are G1/G2/M-
MCMDNA-negative.  
(e) Stacked bar graph of cell cycle phase distribution from cells in (d); mean with error bars ± 
SD (n=3 biological replicates). The doubling times were calculated experimentally using 
regression analysis in GraphPad Prism. 
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after S phase begins(Remus and Diffley, 2009; Arias and Walter, 2007; Truong and Wu, 2011). 
since many cancer cell lines also have short G1 phases. The actual rate of MCM loading in 
human cells has not yet been quantified however, and little is known about how the amount, 
rate or timing of MCM loading varies between cells with different G1 lengths. Here we utilized 
single cell flow cytometry to measure MCM loading rates in asynchronous populations of 
pluripotent and differentiated cells. We discovered that rapid MCM loading is intrinsic to 
pluripotency, slows universally during differentiation, and rapid replication licensing suppresses 
differentiation. These findings demonstrate that the rate of MCM loading is subject to 
developmental regulation, and we suggest that rapid origin licensing is a new hallmark of 
pluripotency.   
Results 
Pluripotent cells load MCM significantly faster than differentiated cells. 
We considered two possibilities for how cells with varying G1 lengths load MCM onto 
DNA. One possibility is that cells with short G1 phases load MCM at the same rate as cells with 
long G1 phases resulting in less total loaded MCM. Alternatively, cells with short G1 phases 
could load MCM faster than cells with long G1 phases and reach similar levels of loaded MCM. 
To distinguish between these scenarios, we developed an assay to measure DNA-loaded MCM 
in individual cells of asynchronously proliferating populations by adapting a previously-reported 
flow cytometry method(Håland et al., 2015; Moreno et al., 2016). We extracted immortalized 
epithelial cells (RPE1-hTERT) with nonionic detergent to remove soluble MCM. We then fixed 
the remaining chromatin-bound proteins for immunofluorescence with anti-MCM2 antibody as a 
marker of the MCM2-7 complex, and for DNA content (DAPI) and DNA synthesis (EdU) to 
measure cell cycle phases (Figure 3.1B, left). We used a sample without primary antibody as a 
control (relevant flow cytometry gating schemes are shown in Figure 3.2).  For chromatin flow 
cytometry, MCM signal below the antibody threshold is colored grey (“G1/G2/M-MCMDNA neg”), 
whereas detectable MCM signal is colored either blue in G1 cells (“G1-MCMDNA pos”) or orange 
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in S phase cells (“S-MCMDNA pos”). As expected, total MCM protein levels do not substantially 
change during the cell cycle (Figure 3.1B, right)(Todorov et al., 1995). For comparison to 
commonly used cell fractionation methods to assess MCM dynamics, we also probed 
immunoblots of chromatin-enriched fractions, and noted a similar MCM expression, G1 loading, 
and S phase unloading pattern (Figure 3.1C)(Cook et al., 2002; Mendez and Stillman, 2000). 
Interestingly, individual G1 cells (blue stripe) have a very broad range of DNA-loaded MCM 
levels with a more than 100-fold difference between minimum and maximum (Figure 3.1B, left). 
MCMs are unloaded during S phase, ending in G2/M with undetectable MCM on DNA (Figure 
3.1B, left). Moreover loaded MCM is resistant to extraction in high salt buffer which removes 
peripherally-bound chromatin proteins (Figure 3.3F-H), similar to yeast MCM complexes loaded 
in vitro (Bowers et al., 2004; Randell et al., 2006). We validated MCM2 antibody specificity using 
quiescent G0 synchronized cells (MCM unloaded), and we also observed the same broad G1 
signal distribution using MCM3 antibody (Figure 3.3A-D).  
Loaded MCM complexes are extremely stable on DNA, both in vivo and in vitro(Cocker 
et al., 1996; Evrin et al., 2009; Remus et al., 2009; Bowers et al., 2004). In human cells, MCMs 
can persist on DNA for more than 24 hours during a cell cycle arrest and are typically only 
unloaded during S phase(Kuipers et al., 2011). These properties result in MCM loading that 
occurs unidirectionally throughout G1 phase(Symeonidou et al., 2013). The unidirectional nature 
of MCM loading means that G1 cells with low MCM levels are in early G1, and G1 cells with 
high MCM levels are in late G1. Since we observed a broad distribution of MCM loading 
throughout G1 including many cells with low levels of loaded MCM, we conclude that RPE1-
hTERT cells load MCM relatively slowly during their ~9 hr G1. 
We then used this method to analyze MCM loading in asynchronous cells with different G1 
lengths. H9 human embryonic stem cells (hESCs) have a short G1 phase and spend most of 




Figure 3.2. Flow Cytometry Gating 
(a) Example flow cytometry gating with chromatin extracted ARPE-19 (RPE) cells from Figure 
3.1d, measuring Loaded MCM (anti-MCM2), DNA Synthesis (EdU incorporation) and DNA 
content (DAPI). Gating to discriminate cells from debris was on FS-area vs SS-area, singlets 
(individual cells) from clumps of cells was on DAPI height vs DAPI area, cell cycle phases were 
determined on DAPI-area vs EdU-647. Non-specific background staining by the secondary 
antibody was accounted for by using a negative control sample stained without primary 
antibody, only secondary antibody to gate on cells positive for DNA-loaded MCM on DAPI-Area 
vs MCM2-488. 
(b) Example flow cytometry color gating with chromatin extracted ARPE-19 cells from Figure 1d. 
Left: Negative control to define background staining without EdU incubation or MCM2 primary 
antibody. Cells were stained with DAPI, subjected to EdU detection chemistry, and stained with 
secondary antibody. Cells with greater EdU or MCM values than the majority of this background 
stained sample were gated as positive cells for DNA-Loaded MCM or DNA synthesis (EdU). 
Right: Chromatin flow cytometry of ARPE-19 measuring DNA content (DAPI), DNA synthesis 
(EdU-647), and loaded MCM (anti-MCM2). Gates define color schemes for color dot plots.  





Figure 3.3. Validation of MCM antibodies for chromatin flow cytometry. 
(a) Chromatin flow cytometry of RPE1 cells stained for loaded MCM2 (anti-MCM2), loaded 
MCM3 (anti-MCM3), and DNA content (DAPI). All 3 plots are the same sample. Cells stained 
with monoclonal MCM2 antibody for loaded MCM2 co-stain equally well for a polyclonal MCM3 
antibody for loaded MCM3. 
(b) Chromatin flow cytometry of RPE1 cells treated with 100 nM siControl or a 100 nM pool of 
siMCM3 for 72 hrs, measuring DNA content (DAPI), DNA synthesis (EdU incorporation), and 
loaded MCM3 (anti-MCM3). Loaded MCM3 levels decrease with siMCM3 treatment, 
demonstrating antibody specificity. 
(c) Immunoblot of cells from (b). 
(d) RPE1 cells synchronized in G0 by contact inhibition. Left: Total protein flow cytometry of G0 
cells measuring total MCM (anti-MCM2), DNA synthesis (EdU incorporation) and DNA content 
(DAPI). Right: Chromatin flow cytometry of G0 cells measuring loaded MCM (anti-MCM2), DNA 
synthesis (EdU incorporation) and DNA content (DAPI). G0 cells lack loaded MCM, 
demonstrating antibody specificity. 
(e) Immunoblot of cells for (d) demonstrating G0 synchronization. 
(f). Immunoblots of cells fractionated into soluble protein and pellet (chromatin associated 
protein) using a normal salt CSK buffer (100mM NaCl) or high salt CSK buffer (300 mM NaCl). 
High salt 300 mM NaCl strips away weakly chromatin associated proteins, including Cdc6, but 
not loaded MCM. 
(g) Chromatin flow cytometry of cells lysed with normal 100 mM NaCl CSK or high salt 300 mM 
NaCl CSK. 
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(h) Histograms of only the G1-MCMDNA –positive cells from (g). The loaded MCM in G1 remains 
constant with high salt, demonstrating the chromatin flow cytometry measures DNA loaded 
MCM. Note the harsh 300 mM salt makes flow cytometry samples more difficult, therefore we 
use the 100 mM NaCl for all other flow cytometry experiments, which measures loaded MCM 
equally well.  
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G1 hESCs had high levels of loaded MCM; very few G1 cells had low levels of loaded MCM 
(blue cells, Figure 3.1D). This difference suggests that hESCs load MCM rapidly to achieve 
abundant DNA-loaded MCM in a short time. To test if MCM loading varies in differentiated cells, 
we differentiated hESCs into neural progenitor cells (NPCs) to generate an isogenic pair of 
pluripotent and differentiated cells. In contrast to hESCs, differentiated NPCs had a longer 
doubling time and a wide distribution of DNA-loaded MCM in G1 (blue cells, Figure 3.1D); they 
also spend approximately five time longer in G1 (Figure 3.1E; e.g. 15% of a 17 hr hESC cell 
cycle is 2.5 hrs in G1 vs to 45% of a 30 hr NPC cell cycle is 13.6 hrs in G1). Since the NPCs 
had many cells with low levels of DNA-loaded MCM, we conclude that these differentiated cells 
load MCM more slowly than hESCs. 
To generate another isogenic pair of pluripotent and differentiated cells we reprogramed 
ARPE-19 primary retinal pigmented epithelial cells (RPE) into induced pluripotent stem cells 
(iPSCs). The iPSCs had hallmark features of pluripotency as measured by microscopy, bisulfite 
sequencing, gene expression, and teratoma formation (Figure 3.4A-E), and their G1 phases 
were typically seven times shorter than their differentiated parents (Figure 3.1E). Like hESCs, 
the pluripotent iPSCs had predominantly high levels of DNA-loaded MCM in G1 (Figure 3.1D). 
Importantly, both of the pluripotent cell lines reached approximately equal levels of DNA-loaded 
MCM at the start of S phase as their differentiated counterparts did, but in in less time (the 
absolute MCM loading intensities are comparable when samples are processed and analyzed 
with identical instrument settings). Taken together, these data demonstrate that pluripotent cells 
load MCMs rapidly in G1, but differentiated cells load MCMs slowly.  
 We then quantified the relative MCM loading rates in pluripotent and differentiated cells 
using ergodic rate analysis, a mathematical method that can derive rates from fixed, steady 
state populations(Kafri et al., 2013). Ergodic analysis can measure any unidirectional rate 
parameter from a steady state distribution, and is not limited to the cell cycle (e.g. car traffic 




Figure 3.4. Characterization of pluripotent and differentiated cells. 
(a) Representative phase contrast images in greyscale of indicated cell lines from Figure 3.1d. 
Scale bar is 50 μm.  
(b) Immunofluorescence analysis of iPS cells visualizing TRA-1-60, TRA-1-81, SSEA or OCT4 
(in green) and Nanog, SSEA3 or SOX2 (in red). DAPI counterstaining for DNA indicates the 
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nuclei of individual cells in each colony. Live alkaline phosphatase (AP) staining was also 
performed as a positive indicator of stem cells.  
(c) Bisulfite sequencing analysis of the NANOG and OCT4-2 promoter regions in ARPE-19 and 
ARPE-19-iPS cells is indicated. Methylated CpGs are indicated with a closed circle, and 
unmethylated CpGs are indicated with an open circle. An ‘X’ indicates a mismatch or gap in the 
bisulfite sequence. The CpG position relative to the downstream transcription start site is shown 
above each row.  
(d) Quantitative RT-PCR analysis showing the relative gene expression of OCT4, SOX2, 
NANOG, KLF4, MYC, LIN28, REXO1, ABCG2 and DNMT3B in ARPE-19 and ARPE-19-iPS 
cells (normalized to GAPDH). Error bars indicate standard error.  
(e) Hematoxylin and eosin staining of teratoma sections from immunodeficient mice injected 
with ARPE-19-iPS cells show cartilage, as well as endoderm and ectoderm teratoma formed by 
ARPE-19-iPS.  
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within a steady state population with a constant doubling time and cell cycle distribution, the 
number of cells at any point in the cell cycle is inversely related to the rate they move through 
that point. For any measured parameter, the density of cells indicates rate: low cell density on a 
flow cytometry plot indicates a fast rate passing through that cell cycle state whereas high cell 
density indicates a slow rate. This phenomenon is analogous to a high density of slow-moving 
cars observed at a given point on a road in a traffic jam compared to a low density of fast-
moving cars on an open highway. We visualized MCM loading as histograms of the MCMDNA 
intensities in only the G1 cells for ergodic rate analysis (G1-MCMDNA, Figure 3.5A, B and Figure 
3.6).  
 To compute MCM loading rate per hour, we experimentally determined the cell cycle 
distributions and doubling times of each cell population (Figure 3.6). Pluripotent cells reached 
near equal levels of loaded MCM at the G1/S transition in less time than differentiated cells. To 
quantify the actual MCM loading rate difference, we subdivided the G1-MCMDNA population into 
10 equally-sized bins, calculated the MCM loading rate for each bin, then the overall average 
MCM loading rate for each G1 population. These calculations revealed that pluripotent hESCs 
loaded MCM 6.5 times faster per hour than differentiated NPCs and pluripotent iPSCs loaded 
MCM 3.9 times faster per hour than differentiated RPEs (Figure 3.5). Thus, pluripotent cells with 
short G1 phases load MCMs significantly faster than differentiated cells with long G1 phases. 
Differentiation, G1 length, and MCM loading rate are coupled. 
 We hypothesized that MCM loading is fundamentally linked to pluripotency because 
MCM loading rate decreased during differentiation and increased during reprogramming. This 
idea predicts that slowed MCM loading is a phenomenon common to differentiation towards all 
germ layers. To test that hypothesis, we initiated differentiation in hESCs towards the three 
embryonic germ layers (neuroectoderm, mesoderm and endoderm), collecting cells at 24 hour 
and 48 hours after inducing differentiation (Figure 3.8). We confirmed progress towards each 




Figure 3.5. Quantification of MCM loading rate by ergodic rate analysis. 
(a) Gating scheme for chromatin flow cytometry of iPSCs measuring DNA content (DAPI), DNA 
synthesis (EdU incorporation), and loaded MCM (anti-MCM2); this sample is from Fig 3.1d.  
(b) Histograms of only the G1-MCMDNA –positive cells from the four chromatin flow cytometry 
samples in Fig 3.1d.  
(c) Calculated mean MCM loading rate per hour by ergodic rate analysis; mean with error bars ± 
SD. (n=3 biological replicates), unpaired two tailed t-test. **p=0.0049. ***p=0.001. See Methods 




Figure 3.6. Ergodic Rate Analysis binning. 
(a) Histograms from G1-MCMDNA+ samples in Figure 2B, binned into 10 regions for ergodic rate 
analysis (see Methods).  
(b) Ergodic rate equation based on (Kafri et al., 2013). wn is the rate in each bin n, α is a 
constant accounting for doubling time, F is the fraction of cells in G1-MCMDNA+ out of all cells, fn 
is the fraction of cells in each bin n out of G1-MCMDNA+ (see Methods). 
(c) Value of F for 3 biological replicates for each cell line, used to calculate Figure 3.5c. (d) 




Figure 3.7. Differentiation universally decreases MCM loading rate. 
(a) Chromatin flow cytometry of hESCs induced to differentiate towards mesoderm (BMP4), 
neuroectoderm, mesoderm (GSK3βi), or endoderm for 24 or 48 hrs. Histograms show only G1-
MCMDNA cells as in Figure 2b. See methods for differentiation protocols. Cell counts for 24 hr 
and 48 hr were normalized relative to corresponding hESC samples.  
(b) Stacked bar graphs of cell cycle distribution for cells in (a).  
(c) Gene expression analysis of differentiation markers by quantitative PCR of the samples in 





Figure 3.8. Stem cell differentiation.  
(a) Immunoblots of neuroectoderm differentiation, as in Figure 3.7a. 
(b) Representative phase contrast images in greyscale during the indicated differentiation 
protocols from Figure 3.7a. Scale bar is 50 μm. 
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markers and modest reduction of pluripotency markers – even at these very early time points 
(Figure 3.7C). We assessed MCM loading rates during differentiation by flow cytometry as 
before. The MCM loading rate clearly decreased for all germ layers rapidly within the first 48 
hours of initiating differentiation (Figure 3.7A, compare the grey histograms for undifferentiated 
G1 cells to the green and blue histograms). The decrease in MCM loading rate also coincided 
with the increase in the proportion of G1 cells for each lineage. For example, within 24 hours of 
neuroectoderm differentiation, G1 had already lengthened and MCM loading had slowed, but 
during mesoderm (BMP4) differentiation both G1 lengthening and slowed MCM loading took 48 
hrs (Figure 3.7A and B). The closely-coordinated changes that we universally observed during 
differentiation suggest that MCM loading rate is coupled to G1 length. Importantly, these results 
demonstrate that the rate of origin licensing by MCM loading is developmentally regulated. 
 We next asked if G1 length and MCM loading rate are obligatorily coupled, or if the link 
can be short-circuited by artificially advancing the G1/S transition. To distinguish between these 
possibilities, we constructed an RPE1-hTERT derivative with a CYCLIN E1 cDNA under 
doxycycline-inducible control. Cyclin E1 overproduction reproducibly shortened G1 length, 
consistent with previous studies (Figure 3.9A, B)(Resnitzky et al., 1994; Ekholm-Reed et al., 
2004). Strikingly, cells overproducing Cyclin E1 (designated as “↑Cyclin E1”) not only spent less 
time in G1 but also began S phase with much lower amounts of loaded MCM compared to the 
control; this new subpopulation appeared in the central triangular region of the plots that is 
typically clear of S phase cells (Figure 3.9C, D orange S-MCMDNApos). Cyclin E1 overproduction 
dramatically increased the proportion of these MCM-low  early S phase cells by six-fold from 
9.9% of control S phase cells to 63.6% of ↑Cyclin E1, S phase cells (Figure 3.9C, D). We also 
conclude that the MCM loading rate did not increase to accommodate the shorter G1 because 
the MCM loading pattern in G1 remained constant and the ↑Cyclin E1 cells had on average at 




Figure 3.9. Cyclin E overproduction uncouples MCM loading and G1 length. 
(a) Immunoblots of a stable derivative of RPE1-hTert cells bearing an integrated doxycycline-
inducible cyclin E construct treated with 100 ng/mL doxycycline for 72 hrs to overproduce Cyclin 
E1 (↑Cyclin E1) or with vehicle control  
(b) Stacked bar graphs of cell cycle distribution measured by flow cytometry for cells shown in 
(a); mean with error bars ± SD (n=3 biological replicates).  
(c) Chromatin flow cytometry of control or cyclin E-overproducing cells measuring DNA content 
(DAPI), DNA synthesis (EdU incorporation), and loaded MCM (anti-MCM2).  
(d) S-MCMDNA+ cells from samples in (c) divided into populations that began S phase with high 
or low MCMDNA. Early S cells are S phase cells with G1 DNA content.  
(e) The percentage of MCM-low S phase cells relative to all S-MCMDNA+ cells from three 
biological replicates; mean with error bars ± SD, unpaired two tailed t-test. ***p=0.002. 
(f) Mean loaded MCM in early S phase, (S-MCMDNA+, G1 DNA content) from three biological 
replicates; mean with error bars ± SD, unpaired two tailed t-test. ***p=0.0004. 
(g) Histogram of G1-MCMDNA+ cells from samples shown in (c). Counts for ↑Cyclin E1 are 
normalized to the control. 
(h) Histogram of early S cells from samples shown in (d). Counts for ↑Cyclin E1 are normalized 
to the control. These data are one of the replicates quantified in (f). 
(i) EdU intensity from ↑Cyclin E1, MCM-high or MCM-low cells from (d) as a box-and-whiskers 
plot. Center line is median, outer box edges are 25th and 75th percentile, whiskers edges are 
1st and 99th percentile, individual data points are lowest and highest 1%, respectively. Median 
EdU incorporation of MCM-high ↑Cyclin E1 cells is 1.8 fold greater than MCM-low, mean EdU 
incorporation is 1.6 fold greater in MCM-high than MCM-low, average of 3 biological replicates. 
Samples compared by unpaired, two tailed t-test, **p=0.0027, **p=0.0033, respectively. 
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Furthermore, the ↑Cyclin E, MCM-low cells incorporated significantly less EdU per unit time than 
MCM-high cells did (1.6 fold lower mean, 1.8 fold lower median), indicating that low levels of 
loaded MCM are insufficient for normal S phase progression (Figure 3.9I). The early S phase 
cells with the least MCM loaded also had the least DNA synthesis by EdU intensity (data not 
shown). Thus, shortening G1 length without increasing MCM loading rate causes G1 cells to 
enter S phase prematurely without the full complement of DNA-loaded MCM. 
 Previous studies have shown that CDKs can inhibit MCM loading by directly inhibiting 
MCM loading factors, such as by stimulating Cdt1 degradation (Cdc10 dependent transcript 1), 
a protein essential for MCM loading (Ekholm-Reed et al., 2004; Sugimoto et al., 2004; Tanaka 
and Diffley, 2002). Cdt1 levels in lysates of asynchronous cells indeed decreased upon Cyclin 
E1 overproduction (Figure 3.10A). On the other hand, since Cdt1 is stable in G1 phase and 
degraded in S phase, the lower Cdt1 signal could have reflected less Cdt1 in the lysate due to 
the higher proportion of S phase cells; this indirect effect could apply to any cell cycle-regulated 
protein in cell populations with different cell cycle distributions. To test that idea, we measured 
total Cdt1 protein levels specifically in G1 by flow cytometry (Figure 3.10B). Cyclin E 
overproduction did not significantly reduce Cdt1 G1 levels relative to control (1.1 fold higher 
mean, 1.2 higher median, Figure 3.10C). We validated the Cdt1 antibody for 
immunofluorescence flow cytometry (Figure 3.10D-F). We conclude that Cyclin E/Cdk2 inhibits 
MCM loading indirectly, at least in part, by shortening G1 and decreasing the time available for 
MCM loading. 
Fast loading hESCs have more Cdt1 in G1. 
 Loading MCM complexes onto DNA requires the six subunit Origin Recognition Complex 
(ORC), Cdc6, and Cdt1. We hypothesized that fast MCM loading in pluripotent stem cells is 
achieved by increased levels of the loading proteins. To test this idea, we probed protein lysates 
of asynchronous cells to compare the amount of MCM loading proteins between isogenic cell 




Figure 3.10. G1 Cdt1 levels remain constant with Cyclin E overproduction. 
(a) Immunoblots of whole cell lysates from cells treated as in (Figure 3.9a).  
(b) Total Cdt1 detected by flow cytometry of cells treated as in (b) measuring DNA content 
(DAPI), DNA synthesis (EdU incorporation), and Cdt1 (anti-Cdt1). Green cells are G1 cells, 
Purple cells are S phase cells (EdU positive), Grey cells are G2/M and >4C DNA content.  
(c) Box-and-whiskers plots of G1 Cdt1 concentration per cell from (H). Center line is median, 
outer box edges are 25th and 75th percentile, whiskers edges are 1st and 99th percentile, 
individual data points are lowest and highest 1%, respectively. G1 Cdt1 intensity in controls is 
1.1-fold greater mean and 1.2-fold greater median than G1 ↑Cyclin E1. Samples were not 
significantly different, compared by two-tailed, unpaired t test, p=0.1907, p=0.3525, respectively; 
average of 3 biological replicates. 
(d) Immunoblot of whole cell lysate from RPE1-htert cells treated with or without 20 J/m2 of UV 
irradiation, collected 1 hr after irradiation. UV irradiation induces DNA repair coupled PCNA 
loading, subsequently targeting Cdt1 for degradation. 
(e) Flow cytometry of control and UV irradiated cells as in (a), measuring DNA content (DAPI), 
DNA synthesis (EdU incorporation), and Cdt1 (anti-Cdt1). Plots demonstrate decreased DNA 
synthesis after UV irradiation. 
(f) The same samples as in (e). Cdt1 is degraded upon UV induced DNA repair, demonstrating 




Figure 3.11. hESCs have high levels of Cdt1 in G1. 
(a) Immunoblots of whole cell lysates from the indicated asynchronous cell lines.  
(b) Expected changes in total protein levels of Cdt1 and Cdc6 during the human cell cycle.  
(c) Total Cdt1 detected in asynchronous cells by flow cytometry measuring DNA content (DAPI), 
DNA synthesis (EdU incorporation), and Cdt1 (anti-Cdt1). Green cells are G1, purple cells are S 
phase (EdU positive), grey cells are G2/M and >4C DNA content. Lower plots are G1 cells only 
(green).  
(d) Box-and-whiskers plots of G1 Cdt1 concentration per cell from (C). Center line is median, 
outer box edges are 25th and 75th percentile, whiskers edges are 1st and 99th percentile, 
individual data points are lowest and highest 1%, respectively. Median G1 Cdt1 in hESCs is 2.9 
fold greater, mean is 2.2 fold greater than G1 Cdt1 in NPCs, mean p=0.0504 median p=0.0243, 
average of 3 biological replicates. 
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loading factors normally change in their abundance during the cell cycle due to regulated 
proteolysis. Cdc6 protein levels are low in G1 and high in S phase (Figure 3.11B). Conversely, 
Cdt1 protein levels are high in G1 and low in S phase (Figure 3.11B)(Mailand and Diffley, 2005; 
Pozo and Cook, 2016). Since an asynchronous population of pluripotent cells spends 
significantly more time in S phase than differentiated cells do, we expected Cdc6 levels to be 
higher in asynchronous pluripotent cells compared to their isogenic counterparts. Cdc6 was 
indeed higher in pluripotent cells, as was Geminin, a protein regulated in a similar manner as 
Cdc6 (Figure 3.11A)(McGarry and Kirschner, 1998). To our surprise, even though the majority 
of asynchronous pluripotent cells were in S phase, a time when Cdt1 is degraded, Cdt1 levels 
were higher in asynchronous pluripotent cells than in isogenic differentiated cells (Figure 3.11A). 
A similar observation was reported for mouse embryonic stem cells(Ballabeni et al., 2011). 
These data imply that Cdt1 levels are higher in G1 phase of pluripotent cells than G1 of 
differentiated cells, providing a potential explanation for fast MCM loading in pluripotent cells. 
 To directly measure Cdt1 levels specifically in G1, we collected asynchronous hESCs 
and NPCs then fixed and stained them for Cdt1, EdU and DAPI. S phase Cdt1 degradation in 
hESCs is similar to differentiated cells with very low levels in S phase (purple, Figure 3.11C). In 
contrast, the hESCs had a large population of cells with high Cdt1 levels in G1 (green cells) and 
significant amounts of Cdt1 in G2/M phase (grey cells), whereas the NPCs had a broad and 
overall lower Cdt1 distribution in G1 and very little Cdt1 in G2/M (Figure 3.11D). The G1 hESCs 
consistently harbored significantly more Cdt1 than G1 NPCs did (2.9 fold higher median, 2.2 
fold higher mean, 3 replicates (Figure 3.11D)). We note that CDT1 mRNA is modestly but 
consistently higher in asynchronous hESCs compared to differentiated derivatives, and that 
Cdt1 protein levels decrease during early differentiation coincident with the slowdown in 
licensing rate, but before loss of Oct4 (Figure 3.7C and Figure 3.8). We postulate that the higher 
amount of this essential MCM loading protein specifically in G1 contributes to the fast MCM 
loading rate in hESCs. 
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Manipulating MCM loading factors alters MCM loading rates. 
 Cdt1 is essential for MCM loading(Pozo and Cook, 2016); therefore reducing Cdt1 levels 
should slow MCM loading. If MCM loading rate is linked to G1 length, then slowing MCM 
loading by reducing Cdt1 levels could also lengthen G1. To test this prediction, we used siRNA 
to reduce Cdt1 in hESCs and measured changes in both MCM loading rate and G1 length 
(Figure 3.12A, B). As expected, Cdt1 depletion reduced MCM loading rate in hESCs (Figure 
3.12C). Strikingly, G1 length increased coincidentally with the decrease in MCM loading rate 
(Figure 3.12D). These data corroborate the close link between MCM loading rate and G1 length 
in hESCs.  
 As a complement to slowing MCM loading in hESCs with a short G1, we also attempted 
to accelerate origin licensing in cells with a long G1 by overproducing essential licensing 
proteins. We first constructed an RPE_hTERT derivative with ~two-fold inducible Cdt1 
overproduction, but this manipulation was insufficient to accelerate MCM loading (Figure 3.13B).  
We also tested ectopic myc-tagged Cdc6 expressed constitutively in RPE cells (Figure 3.13E); 
this addition also had only minimal effects on MCM loading rate (Figure 3.13G, compare the 
grey and green histograms).  We considered however, that human Cdc6 is unstable throughout 
much of G1 phase because it is targeted for degradation by APCCdh1 (Petersen et al., 2000; 
Mailand and Diffley, 2005).  We therefore expressed a previously-described Cdc6 mutant that is 
resistant to APCCDH1 mediated destruction both alone and combination with inducible Cdt1 
(Figure 3.12E and Figure 3.13A)(Petersen et al., 2000; Mailand and Diffley, 2005). We have 
previously demonstrated that tagged Cdc6 and Cdt1 are functional(Cook et al., 2002; Coleman 
et al., 2015; Chandrasekaran et al., 2011). Expression of the stable Cdc6-mut was sufficient to 
increase MCM loading rates (Figure 3.12G, compare the blue histogram to the grey and green 
histograms); Cdt1 overproduction had little additive effect on MCM loading rate in RPE cells 




Figure 3.12. Fast MCM loading rate promotes short G1 length in hESCs. 
(a) Immunoblot of total protein for hESCs treated with 25 nM siCdt1 or 100 nM siControl for 24 
hr and labeled with EdU for 30 min prior to harvest.  
(b) Chromatin flow cytometry of cells from (a) as in Figure 3.1d.  
(c) Histograms of loaded MCM in G1-MCMDNA cells. Counts for siCdt1 are normalized to the 
corresponding siControl sample.  
(d) Stacked bar graph of cell cycle distributions for samples in (a); representative of 2 biological 
replicates.  
(e) Immunoblots of RPE1 cells with combinations of: constitutive production of 5Myc-Cdc6-wt or 
5myc-Cdc6-mut (which is not targeted for degradation by APCCDH1, R56A, L59A, K81A, E82A, 
N83A) and an integrated doxycycline-inducible Cdt1-HA construct treated with 100 ng/mL 
doxycycline for 48 hrs to overproduce Cdt1-HA. 
(f) Stacked bar graphs of cell cycle distribution measured by flow cytometry for cells shown in 
(e); mean with error bars ± SD (n=3 biological replicates).  
(g) Histogram of loaded MCM in G1-MCMDNA cells in RPE1 cells from (e). Counts of Cdc6-wt 




Figure 3.13. Manipulating MCM loading factors alters MCM loading rates. 
(a) Validation of the 5myc-Cdc6-mut. Immunoblots of total cell lysates of RPE, RPE +5myc-
Cdc6-wt or RPE +5myc-Cdc6-mut. Cells were synchronized in G0 by contact inhibition. 
Asynchronous cells were treated with 10 ug/mL cycloheximide for 4 or 8 hr. Cdc6-mut is more 
stable in cycloheximde and is resistant to APCCDH1-induced degradation in G0 cells.  
(b) Histogram of loaded MCM in G1-MCMDNA positive cells in RPE cells expressing ectopic 
Cdt1 compared to control. There is little increase in MCM loading rate. Counts of Cdt1-
expressing cells (blue,+Cdt1) are normalized to parent RPE controls (grey).  
(c) Histogram of loaded MCM in G1-MCMDNA-positive cells in RPE cells from (Figure 3.12e) 
with the indicated combinations of Cdc6 and Cdt1 expression. Counts in experimental samples 
(green and blue) are normalized to their respective controls (grey).  
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RPEs (Figure 3.12F), further demonstrating that the length of G1 phase and the rate of MCM 
loading to license origins can be uncoupled. Slow MCM loading may delay S phase entry 
through the licensing checkpoint (Teer et al., 2006; Shreeram et al., 2002; Nevis et al., 2009; Ge 
and Blow, 2009), but rapid MCM loading itself is not sufficient to trigger S phase entry, other 
restriction point phenomenon are required. 
Rapid MCM loading protects hESC pluripotency 
 Our demonstration that slower MCM loading occurs universally during early 
differentiation suggested a functional link between the rate of MCM loading and pluripotency 
maintenance. We considered that slowing MCM loading might promote differentiation. To 
explore this idea, we prematurely slowed MCM loading in hESCs by Cdt1 depletion prior to 
inducing their differentiation (Figure 3.14E). After Cdt1 depletion, we stimulated differentiation 
towards mesoderm with BMP4(Bernardo et al., 2011). After 48 hours, we quantified Oct4 and 
Cdx2 by immunostaining. (Figure 3.14A, Figure 3.15). The pluripotency transcription factor Oct4 
and the homeobox transcription factor Cdx2 reciprocally repress one another’s expression, 
creating a clear distinction between Oct4 positive-Cdx2 negative pluripotent cells and Oct4 
negative-Cdx2 positive differentiating cells(Niwa et al., 2005). We quantified mean fluorescence 
intensity of both Oct4 and Cdx2 in >18,000 cells per condition with a customized, automated 
CellProfiler pipeline, plotting the signal intensities for each cell in a density scatter plot (Figure 
3.14B, C). Stimulating control hESCs with 10 ng/mL of BMP4 slightly shifted the population 
towards differentiation, but most cells remained pluripotent with high Oct4 levels at this time 
point. Strikingly, hESCs pretreated with Cdt1 siRNA to prematurely slow MCM loading gained a 
substantial population of Oct4 negative-Cdx2 positive differentiating cells relative to controls that 
were treated similarly. To quantify the extent of differentiation, we divided the Cdx2 intensity of 
each cell by its Oct4 intensity, creating a single differentiation score (Figure 3.14D). After 10 
ng/ml BMP4 treatment, Cdt1-depleted hESCs had significantly higher scores, indicating that 




Figure 3.14. Slow MCM loading promotes differentiation. 
(a) Immunofluorescence microscopy of hESCs treated with 100 nM of siControl or 100 nM of 
siCdt1 for 20 hr and then treated with BMP4 as indicated. Cells were fixed and stained with 
DAPI (blue), Cdx2 antibody (green), and Oct4 antibody (red). Images are one region of 18 
fields-of-view per condition; scale bar is 100 μm (see Methods).  
(b) Density scatterplots of mean fluorescence intensity (arbitrary units) of Oct4 and Cdx2 
staining for each cell in each condition, >18,000 cells were quantified per condition.  
(c) Diagram of the relationship between Oct4 and Cdx2 in pluripotent and differentiated cells as 
plotted in (b); color bar for scatterplots in (b).  
(d) Histogram of mean fluorescence intensity ratio Cdx2/Oct4 for all cells in siControl and siCdt1 
treated with 10 ng/mL BMP4 for 48 hrs. Rightmost histogram bin contains all values greater 
than 3.5. The inset is a box-and-whiskers plot of the same data, center line is median, outer box 
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edges are 25th and 75th percentile, whiskers edges are 1st and 99th percentile, individual data 
points are lowest and highest 1%, respectively. Medians are 0.3722, 0.9319, and means are 
0.4285, 1.194 for siControl and siCdt1, respectively. Samples compared by two tailed Mann-
Whitney test, ****p<0.0001.  
(e) Immunoblot for Cdt1 in whole cell lysates at 20 hr of siRNA treatment, prior to BMP4 
treatment.  




Figure 3.15. Complete microscopy dataset and endoderm differentiation. 
(a) Complete immunofluorescence microscopy data for Figure 7. White boxes mark the areas 
shown in Figure 7b; scale bars are 100 μM.  
(b) Immunoblots for Cdt1 in whole cell lysates of hESCs treated with 100 nM siControl or siCdt1 
for 24 hr prior to initiating differentiation toward endoderm, two biological replicates. Bar graph 




test). Both control cells and Cdt1-depleted cells differentiated more fully at a higher 
concentration of 50 ng/mL BMP4, but the Cdt1-depleted cells still differentiated further than the 
controls (p<0.0001, two-tailed Mann-Whitney test, Figure 3.14B and Figure 3.17A). Other 
combinations of BMP4 concentrations or treatment times also resulted in a consistent, 
significant increase in differentiation in cells pretreated to slow MCM loading (p<0.0001, two-
tailed Mann-Whitney test, data not shown). Importantly, the phenotype was conserved across 
multiple differentiation lineages, as prematurely slowing MCM loading prior to endoderm 
differentiation also increased the number of cells positive for the endoderm transcription factor 
Sox17 relative to controls at the same time point (Figure 3.15B). To test if the pluripotency 
maintenance was due to Cdt1’s role in origin licensing and not its mitotic or other 
functions(Varma et al., 2012), we slowed licensing by depleting the orthogonal MCM loading 
protein, Cdc6 (Figure 3.16A-D). A more modest Cdc6 knockdown correlated with a weaker, but 
detectable effect on MCM loading. Interestingly, this degree of licensing inhibition had no effect 
on G1 length. Despite the short G1 length, slowing MCM loading by depleting Cdc6 significantly 
promoted differentiation (Figure 3.17B-F, p<0.0001, two-tailed Mann-Whitney test. Thus, we 
conclude that slow MCM loading generally promoted differentiation and by extension, that rapid 
MCM loading preserves pluripotency.  
Discussion 
 In this study we demonstrate that rapid MCM loading to license replication origins is an 
intrinsic property of pluripotent cells. Human embryonic stem cells have a remarkably fast MCM 
loading rate, and reprogramming to create induced pluripotent stem cells increases MCM 
loading rate. Moreover, MCM loading slows concurrently with the G1 lengthening and extensive 
cell cycle remodeling that accompany the early stages of differentiation (Figure 3.14F). To our 
knowledge this is the first demonstration that the rate of MCM loading is developmentally 




Figure 3.16. Slow MCM loading promotes differentiation. 
(a) Histogram of mean fluorescence intensity ratio Cdx2/Oct4 for all cells in siControl and siCdt1 
treated with 50 ng/mL BMP4 for 36 or 48 hrs. Rightmost histogram bin contains all values 
greater than 3.0 or 4.0 respectively. The inset is a box-and-whiskers plot of the same data, 
center line is median, outer box edges are 25th and 75th percentile, whiskers edges are 1st and 
99th percentile, individual data points are lowest and highest 1%, respectively. Medians for 50 
ng/mL 36 hrs are 0. 0.5418, 0.9465, and means are 0. 0.5993, 1.05 for siControl and siCdt1, 
respectively. Medians for 50 ng/mL 48 hrs are 0.916, 1.368, and means are 1.055, 1.387 for 
siControl and siCdt1, respectively. Samples compared by two tailed Mann-Whitney test, 
****p<0.0001. 
(b) Immunofluorescence microscopy of hESCs treated with 100 nM of siControl or 100 nM of 
siCdc6 for 32 hr and then treated with BMP4 as indicated. Cells were fixed and stained with 
DAPI (blue), Cdx2 antibody (green), and Oct4 antibody (red). Images are one region of 27 fields 
of view per condition; scale bar is 100 μm. (see methods).  
(c) Density scatterplots of mean fluorescence intensity (arbitrary units) of Oct4 and Cdx2 
staining for each cell in each condition, >7,900 cells were quantified per condition.  
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(d) Diagram of the relationship between Oct4 and Cdx2 in pluripotent and differentiated cells as 
plotted in (b); color bar for scatterplots in (b).  
(e) Histogram of the mean fluorescence intensity ratio Cdx2/Oct4 for all cells in siControl and 
siCdc6 treated with 100 ng/mL BMP4 for 36 hrs. Rightmost histogram bin contains all values 
greater than 5.0. the inset is a box-and-whiskers plot of the same data, center line is median, 
outer box edges are 25th and 75th percentile, whiskers edges are 1st and 99th percentile, 
individual data points are lowest and highest 1%, respectively. Medians are 1.296, 1.58, and 
means are 1.433, 1.728 for siControl and siCdc6, respectively. Samples compared by two tailed 
Mann-Whitney test, ****p<0.0001.  
(e) Immunoblot for Cdc6 in whole cell lysates at 32 hr of siRNA treatment, prior to BMP4 




Figure 3.17. Reducing MCM loading rate by an alternative siRNA. 
(a) Immunoblot of total protein for hESCs treated with 100 nM siControl for 32 hr or 100 nM 
siCdc6 pool for 32 hr and pulse-labeled with EdU for 30 min prior to harvest.  
(b) Chromatin flow cytometry of cells from (a) stained with DAPI and anti-MCM2 and subjected 
to EdU detection.  
(c) Histogram MCMDNA intensity in G1 cells. Counts for siCdc6 are normalized to the 
corresponding siControl sample. 




showing higher levels of total Cdt1 in asynchronous mouse ESCs than in differentiated 
cells(Ballabeni et al., 2011). The regulated decrease in MCM loading rate is critical during 
differentiation, as rapid MCM loading protects pluripotency, and prematurely slowing MCM 
loading promotes differentiation.  
Pluripotent stem cells load MCM complexes rapidly to reach similar total amounts of 
loaded MCM at the G1/S transition in less time than their isogenic differentiated counterparts. 
Although we did not detect substantial MCM loading in telophase, as suggested 
previously(Dimitrova et al., 2002), it is clear that telophase loading is an option in some cells 
and a requirement in cells with no detectable G1 such as S. pombe and in the first nuclear 
divisions in D. melanogaster(Nishitani et al., 2000; Farrell and O’Farrell, 2014). Stem cells 
achieve faster MCM loading, at least in part, by particularly high Cdt1 levels in G1. These high 
levels are achieved not only by a modest difference in CDT1 mRNA (Figure 3.7C) but also post-
transcriptionally by specific re-accumulation of Cdt1 protein in the preceding G2 phase (Figure 
3.11C). Cdt1 stability in G2 phase has been attributed to geminin-mediated protection from the 
SCFSkp2 E3 ubiquitin ligase in non-stem cells(Tsunematsu et al., 2013; Ballabeni et al., 2004; 
Clijsters et al., 2013). It is not clear however that geminin levels are particularly high in stem 
cells relative to differentiated cells (aside from differences expected from cell cycle distribution 
changes (Figure 3.11A)(Ballabeni et al., 2011)), so it seems unlikely that geminin drives higher 
Cdt1 levels in stem cells. Skp2 levels also do not change in the earliest stages of stem cell 
differentiation(Egozi et al., 2007). Cdt1 is protected in late S phase and G2 by cyclin A/Cdk1 
activity(Rizzardi et al., 2015), and we thus consider it likely that the documented high CDK 
activity in stem cells contributes to Cdt1 stabilization in G2(Sela et al., 2012; Neganova et al., 
2009). The anticipatory Cdt1 accumulation to promote MCM loading in G1 was originally 
proposed from experiments in cancer-derived cell lines(Clijsters et al., 2013; Ballabeni et al., 
2004). Our observations in stem cells suggest this strategy is employed by non-transformed 
cells during developmental stages that require short G1.  
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Other factors besides Cdt1 accumulation may also accelerate MCM loading. The hESCs 
we assayed have 2-3 fold greater Cdt1 protein levels in G1 relative to NPCs yet load MCM 6.5 
times faster per hour than NPCs. One Cdt1 molecule can (in vitro) load multiple MCM 
complexes since Cdt1 is released into the soluble phase immediately after completing a loading 
reaction(Ticau et al., 2015). Stem cells may experience less Cdc6 degradation in early G1 due 
to nearly constitutive Cyclin E/Cdk2 activity and/or attenuated APCCdh1 activity, corroborated by 
our observation that a Cdc6 mutant that is not targeted by APCCdh1 increases MCM loading rate 
in cells with long G1 phases (Figure 3.12G)(Ballabeni et al., 2011; Neganova et al., 2009; 
Filipczyk et al., 2007). Additionally, stem cells are enriched for euchromatin, an environment that 
may be particularly permissive for rapid MCM loading(Chen and Dent, 2013).  
 Rapid MCM loading may itself contribute to mechanisms that maintain short G1 phases 
in pluripotent cells. The origin licensing checkpoint links the amount of loaded MCM to G1 
length by controlling Cdk2 activity. In that regard, overproducing Cyclin E “short-circuited” the 
licensing checkpoint in slow loading differentiated cells. This checkpoint has thus far only been 
demonstrated in p53-proficient differentiated mammalian cells(Ge and Blow, 2009), but the G1 
lengthening of hESCs after Cdt1 depletion suggests that pluripotent stem cells also have a 
functioning licensing checkpoint. Cells with fast MCM loading could satisfy this checkpoint 
quickly, activate Cyclin E/Cdk2, and thus spend less time in G1. Mechanisms that support short 
G1 length preserve pluripotency in hESCs (and promote reprogramming to iPSCs) since cells 
are most sensitive to differentiation cues in G1; in that regard, extending G1 phase in hESCs 
can increase differentiation propensity(Pauklin and Vallier, 2013; Filipczyk et al., 2007; 
Coronado et al., 2013; Soufi and Dalton, 2016). Recent work with quintuple knockout mice 
lacking all D and E type cyclins also reported that Cyclin E/Cdk2 further contributes to 
maintaining pluripotency by stabilizing the Oct4, Sox2, and Nanog transcription factors(Liu et al., 
2017). Fast MCM loading may have evolved as an intrinsic property of pluripotent cells to 
maintain high Cdk2 activity and keep G1 phase short.  
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Cyclin/Cdk activity is not the sole connection between the cell cycle and pluripotency. 
Non-CDK cell cycle-associated proteins regulate expression of key pluripotency genes including 
SOX2 and NANOG(Pauklin et al., 2016; Gonzales et al., 2015; Li et al., 2012). Pluripotency 
transcription factors themselves regulate expression of cell cycle genes including those 
encoding cyclins, CDK inhibitors, and E2F3a(Lee et al., 2010; Kanai et al., 2015; Choi et al., 
2012). On the other hand, pluripotency and cell cycle functions can be genetically uncoupled in 
experiments where manipulating the cell cycle didn’t alter pluripotency and vice 
versa(Scognamiglio et al., 2016; Kareta et al., 2015a). We observe that licensing inhibition can 
accelerate differentiation even without greatly lengthening G1 (Figure 3.16, 3.17) which may 
point to an additional direct and cell cycle-independent link between MCM loading rate and 
differentiation.  
 We note that early differentiation is not the only setting in which rapid MCM loading 
during a short G1 may be relevant. Like hESCs, activated T cells have very fast cell cycles with 
short G1 phases(Kinjyo et al., 2015). Oncogenic transformation is also frequently associated 
with G1 shortening. It may be that the pathways linking differentiation to MCM loading rate are 
also coopted in some cancers to induce rapid licensing. On the other hand, a subset of cancers 
may proliferate in a perpetually underlicensed state that contributes to the genome instability 
characteristic of transformed cells. Future investigations will elucidate the molecular 
relationships among developmental signaling pathways, MCM loading rate, and cell cycle 
remodeling.  
Materials and Methods 
Cell Culture 
Cell lines were authenticated by STR profiling (ATCC) and confirmed to be mycoplasma 
negative. T98G, HEK293T, and RPE1-hTERT were cultured in Dulbecco's Modified Eagle 
Medium (DMEM) supplemented with 2 mM L-glutamine and 10% fetal bovine serum (FBS) and 
incubated in 5% CO2 at 37 °C. ARPE-19 (male) were cultured in 1:1 DMEM:F12 supplemented 
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with 2 mM L-glutamine and 10% fetal bovine serum and incubated in 5% CO2 at 37 °C. T98G, 
HEK293T, RPE1-hTERT, and ARPE-19 cells were from the ATCC and were passaged with 
trypsin and not allowed to reach confluency. WA09 (H9 hESCs) were cultured in mTeSR1 
(StemCell Technologies) with media changes every 24 hours on Matrigel (Corning) coated 
dishes and incubated in 5% CO2 at 37 °C. H9s had normal diploid karyotype at passage 32 and 
were used from passage 32-42. ARPE-iPSCs were cultured in Essential 8 (Life Technologies) 
with media changes every 24 hours on Matrigel (Corning) coated dishes and incubated in 5% 
CO2 at 37 °C. iPSCs were used from passage 20-25 and had normal karyotype. Both hESCs 
and iPSCs were routinely passaged every 4 days as aggregates using ReLeSR, according to 
manufacturer’s instructions (StemCell Technologies). The hESCs and iPSCs were only 
passaged as single cells in 10 μM Y-27632 2HCl (Selleck Chemicals) for experiments, as 
described previously (Watanabe et al., 2007). NPCs were cultured in Neural Progenitor Medium 
(StemCell Technologies) with media changes every 24 hours on poly-L-ornithine/Laminin 
(Sigma Aldrich) coated dishes and incubated in 5% CO2 at 37 °C. NPCs were passaged with 
StemPro Accutase (Gibco) weekly. 
Total lysate and chromatin fractionation 
Cells were collected via trypsinization. For total protein lysates, cells were lysed on ice 
for 20 minutes in CSK buffer (300 mM sucrose, 100 mM NaCl, 3 mM MgCl2, 10 mM PIPES pH 
7.0) with 0.5% triton x-100 and protease and phosphatase inhibitors (0.1 mM AEBSF, 1 µg/ mL 
pepstatin A, 1 µg/ mL leupeptin, 1 µg/ mL aprotinin, 10 µg/ ml phosvitin, 1 mM β-glycerol 
phosphate, 1 mM Na- orthovanadate). Cells were centrifuged at 13,000 xg at 4 °C for 5 minutes, 
then the supernatants were transferred to a new tube for a Bradford Assay (Biorad) using a BSA 
standard curve. Chromatin fractionation for immunoblotting was performed as described 
previously(Cook et al., 2002; Mendez and Stillman, 2000), using CSK buffer with 1 mM ATP, 5 
mM CaCl2, 0.5% triton x-100 and protease and phosphatase inhibitors to isolate insoluble 
proteins and S7 nuclease (Roche) to release DNA bound proteins.  A Bradford Assay (Biorad) 
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was performed for equal loading. For 100 mM or 300 mM NaCl soluble/pellet fractionation, cells 
were lysed in standard CSK (100 mM NaCl) or high salt CSK (300 mM NaCl) with 0.5% triton X-
100 with protease and phosphatase inhibitors for 5 minutes on ice. Then cells were centrifuged 
at 2000 xg for 3 minutes, supernatants transferred to a new tube as the soluble fraction. The 
remaining pellet was suspended in 2x SDS loading buffer (2% SDS, 5% 2-mercaptoethanol, 
0.1% bromophenol blue, 50 mM Tris pH 6.8, 10% glycerol) as the pellet fraction. Bradford assay 
was performed on the soluble fraction for equal loading. 
Immunoblotting 
Samples were diluted with SDS loading buffer (final: 1% SDS, 2.5% 2-mercaptoethanol, 
0.1% bromophenol blue, 50 mM Tris pH 6.8, 10% glycerol) and boiled. Samples were run on 
SDS-PAGE gels, then the proteins transferred onto polyvinylidene difluoride membranes 
(Thermo Fisher) or nitrocellulose (GE Healthcare). Membranes were blocked at room 
temperature for 1 hour in either 5% milk or 5% BSA in Tris-Buffered-Saline-0.1%-tween-20 
(TBST). After blocking, membranes were incubated in primary antibody overnight at 4 °C in 
either 1.25% milk or 5% BSA in TBST with 0.01% sodium azide. Blots were washed with TBST 
then incubated in HRP-conjugated secondary antibody in either 2.5% milk or 5% BSA in TBST 
for 1 hour, washed with TBST, and then membranes were incubated with ECL Prime 
(Amersham) and exposed to autoradiography film (Denville). Equal protein loading was verified 
by Ponceau S staining (Sigma Aldrich). Antibodies used for immunoblotting were: Mcm2, (BD 
Biosciences, Cat#610700), Mcm3, (Bethyl Laboratories, Cat#A300-192A), Cdt1, (Cell Signaling 
Technologies, Cat#8064S), Cdc6, (Santa Cruz Biotechnology, Cat#sc-9964), Oct4, (Abcam, 
Cat#ab19857),Cyclin E1, (Santa Cruz Biotechnology, Cat#sc-198), Orc1, (Bethyl Laboratories, 
Cat#A301-892A), Orc6, (Santa Cruz Biotechnology, Cat#sc-32735), geminin, (Santa Cruz 
Biotechnology, Cat#sc-13015), Histone H3, (Cell Signaling Technologies, Cat#4499S), TRA-1-
60, (Invitrogen, Cat#41-1000), nestin, (Abcam, Cat#ab22035), p27 (Santa Cruz Biotechnology, 
Cat#sc-528), α-tubulin (Sigma Aldrich, Cat#9026). 
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Flow Cytometry 
For EdU labeled samples, cells were incubated with 10 uM EdU (Santa Cruz 
Biotechnology) for 30 minutes prior to collection. For total protein flow cytometry, cells were 
collected with trypsin and resuspended as single cells, washed with PBS, and fixed with 4% 
paraformaldehyde (Electron Microscopy Sciences) in PBS for 15 minutes at room temperature, 
then 1% BSA-PBS was added, mixed and cells were centrifuged at 1000 xg for 7 minutes (and 
for all following centrifuge steps) then washed with 1% BSA-PBS and centrifuged. Fixed cells 
were permeabalized with 0.5% triton x-100 in 1% BSA-PBS at room temperature for 15 minutes, 
centrifuged, then washed once with 1% BSA, PBS and centrifuged again before labeling. For 
chromatin flow cytometry, cells were collected with trypsin and resuspended as single cells, 
washed with PBS, and then lysed on ice for 5 minutes in CSK buffer with 0.5% triton x-100 with 
protease and phosphatase inhibitors. Next, 1% BSA-PBS was added and mixed, then cells 
were centrifuged for 3 minutes at 1000 xg, then fixed in 4% paraformaldehyde in PBS for 15 
minutes at room temperature. For 100 mM NaCl vs 300 mM NaCl CSK, cells were processed as 
in chromatin flow cytometry above, except CSK containing 300 mM NaCl was used instead of 
the normal 100 mM NaCl. Next, 1% BSA-PBS was added, mixed and cells were centrifuged 
then washed again before labeling. The labeling methods for total protein samples and 
chromatin samples were identical. For DNA synthesis (EdU), samples were centrifuged and 
incubated in PBS with 1 mM CuSO4, 1 μM fluorophore-azide, and 100 mM ascorbic acid (fresh) 
for 30 minutes at room temperature in the dark. 1% BSA-PBS + 0.1% NP-40 was added, mixed 
and centrifuged. Samples were resuspended in primary antibody in 1% BSA-PBS + 0.1% NP-40 
and incubated at 37 °C for 1 hour in the dark. Next, 1% BSA-PBS + 0.1% NP-40 was added, 
mixed and centrifuged. Samples were resuspended in secondary antibody in 1% BSA-PBS + 
0.1% NP-40 and incubated at 37 °C for 1 hour in the dark. Next, 1% BSA-PBS + 0.1% NP-40 
was added, mixed and centrifuged. Finally, cells were resuspended in 1% BSA-PBS + 0.1% 
NP-40 with 1 μg/mL DAPI (Life Technologies) and 100 μg/mL RNAse A (Sigma Aldrich) and 
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incubated overnight at 4 °C in the dark. Samples were run on a CyAn ADP flow cytometer 
(Beckman Coulter) and analyzed with FCS Express 6 software (De Novo). The following 
antibody/fluorophore combinations were used: (1): Alexa 647-azide (Life Technologies), 
primary: Mcm2 (BD Biosciences, Cat#610700), secondary: Donkey anti-mouse-Alexa 488 
(Jackson ImmunoResearch), DAPI. (2): Alexa 488-azide (Life Technologies), primary: Cdt1 
(Abcam, Cat#610700), secondary: Donkey anti-rabbit-Alexa 647 (Jackson ImmunoResearch), 
DAPI. (3): Alexa 647-azide (Life Technologies), primary: Mcm3 (Bethyl Cat#A300-192A), 
secondary: Donkey anti-rabbit-Alexa 488 (Jackson ImmunoResearch), DAPI. (4): primary: 
Mcm3 (Bethyl Cat#A300-192A), Mcm2 (BD Biosciences, Cat#610700), secondary: Donkey anti-
mouse-Alexa 488, Donkey anti-rabbit-Alexa 647 (Jackson ImmunoResearch), DAPI.   Cells 
were gated on FS-area vs SS-area. Singlets were gated on DAPI area vs DAPI height. The 
positive/negative gates for EdU and MCM were gated on a negative control sample, which was 
treated with neither EdU nor primary antibody, but incubated with 647-azide and the secondary 
antibody Donkey anti-mouse-Alex 488 and DAPI to account for background staining (Figure 
3.2). 
Doubling Time 
Doubling time was calculated by plating equal number of cells as described above and 
counting cell number over time using a Luna II automated cell counter (Logos Biosystems) at 
24, 48, and 72 hours after plating. Three or four wells were counted as technical replicates at 
each timepoint. GraphPad Prism’s regression analysis was used to compute doubling time, and 
multiple biological replicates were averaged for a final mean doubling time. ARPE-19s were 
counted 4 times, hESCs and NPCs 3 times, and iPSCs 2 times. 
Cell Synchronization and treatments 
To synchronize cells in G1, T98G cells were grown to 100% confluency, washed with 
PBS, and incubated for 72 hr in 0.1% FBS, DMEM, L-glutamine. After serum-starvation, cells 
were re-stimulated by passaging 1:3 with trypsin to new dishes in 20% FBS, DMEM, L-
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glutamine, collecting cells 10 hr and 12 hr post-stimulation. To synchronize T98G cells in early S 
phase, cells were treated as for G1, except 1 mM Hydroxyurea (Alfa Aesar) was added to the 
media upon re-stimulating and cells were collected 18 hr post-stimulation. To synchronize cells 
in mid-late S, cells were treated as in early S, then at 18 hr post-stimulation cells were washed 
with PBS and released into 10% FBS, DMEM, L-Glutamine, collecting 6 hr, 8 hr post release. 
To synchronize RPE1-hTERT cells in G0, cells were grown to 100% confluency, then incubated 
for 48 hr in 10% FBS, DMEM, L-glutamine. For RPE1 in G1/S, G0 cells were trypsinized and 
passaged 1:6 with trypsin to new dishes in 10% FBS, DMEM, L-glutamine, and collected with 
trypsin 22 hrs later. For cycloheximide (Sigma) treatment, asynchronous RPE cells were treated 
with 10 ug/mL for 4 hr or 8 hr as indicated. For UV irradiation, asynchronous RPE cells were 
treated with 20 J/m2 of UV with a Stratalinker (Stratagene) and collected 1 hr later. 
Cloning 
The pInducer20-Cyclin E plasmid was constructed using the Gateway cloning method 
(Invitrogen). The attB sites were added to Cyclin E1 cDNA by PCR using Rc/CMV cyclin E 
plasmid as a template and BP-cycE-F (5' 
GGGGACAAGTTTGTACAAAAAAGCAGGCTACCATGAAGGAGGACGGCGGC) and BP-cycE-
R primers (5' GGGGACCACTTTGTACAAGAAAGCTGGGTTCACGCCATTTCCGGCCCGCT) 
(Hinds et al., 1992). The PCR product was recombined with pDONR221 plasmid using BP 
clonase (Invitrogen) according to the manufacturer’s instructions and transformed into DH5α to 
create pENTR221-Cyclin E1. Then the LR reaction was performed between pInducer20 and 
pENTR221-Cyclin E1 using LR Clonase (Invitrogen) according to manufacturer’s instructions 
and transformed into DH5α to create pInducer20-Cyclin E1. The pInducer20 plasmid was 
converted to blasticidin resistance (pInducer20-blast2) by Gibson Assembly (New England 
Biolabs) following manufacturer’s protocol. pInducer20 was cut with AgeI and assembled with 
PCR products with the following primers: 
AgeI-rta3-F: 5- GCTCGGATCTCCACCCCGTACCGGTCCTGCAGTCGAATTCAC 
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AgeI-IRES-blast-R: 5- ACAAAGGCTTGGCCATGGTT TAAGCTTATCATCGTGTTTTTCA 
Blast-F:5- TGAAAAACACGATGATAAGCTTAAACCATGGCCAAGCCTTTGT 
Blast-AgeI-Ind-R: 5- GTTCAATCATGGTGGACCGG CTATTAGCCCTCCCACACATAACCA 
The pLenti CMV blast plasmid was a template for the blasticidin resistance gene. A 
tagged Cdt1-HA was cloned into pInducer20-blast using Gateway cloning as described above. 
The Cdc6 mutant unable to bind APCCDH1 (5myc-Cdc6-mut) was described previously: R56A, 
L59A, K81A, E82A, N83A(Petersen et al., 2000). pCLXSN-5myc-Cdc6-wt was cloned to 5myc-










Cell Line construction and inducible protein production 
To package retrovirus, pCLXSN 5myc-Cdc6 wt or mut were co-transfected with pCI-GPZ 
and VSVG plasmids into HEK293T using 50 μg/mL Polyethylenimine-Max (Aldrich 
Chemistry).To package lentivirus, pInducer20-Cyclin E1 or pInducer20-blast2-Cdt1-HA were co-
transfected with ∆NRF and VSVG plasmids into HEK293T using 50 μg/mL Polyethylenimine-
Max (Aldrich Chemistry). Viral supernatant was transduced with 8 ug/mL Polybrene (Millipore) 
onto RPE1-hTERT cells overnight. Cells were selected with 500 ug/mL neomycin (Gibco) or 5 
ug/mL blasticidin (Research Products International) for 1 week. To overproduce Cyclin E1, cells 
were treated with 100 ng/mL doxycycline (CalBiochem) for 72 hr in 10% FBS, DMEM, L-
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glutamine. Control cells were the Inducer20-Cyclin E1 without doxycycline. To overproduce 
Cdt1, cells were treated with 100 ng/mL doxycycline for 48 hr in 10% FBS, DMEM, L-glutamine, 
control cells were without doxycycline. 
siRNA transfections 
For siRNA treatment, Dharmafect 1 (Dharmacon) was mixed in mTeSR1 with the 
appropriate siRNA according to the manufacturer’s instructions, then diluted with mTeSR1 and 
added to cells after aspirating old media. The final siRNA concentrations were: 100 nM siControl 
(Luciferase), 25 or 100 nM siCdt1, or a mixture of two siCdc6 (2144 and 2534 at 50 nM each). 
The Cdt1 siRNA mix was incubated on cells for either 20 or 24 hours, then changed to new 
mTeSR1 without siRNA. The Cdc6 siRNA mix was incubated on cells for 24 hours, then 
changed to new mTeSR1 without siRNA for 8 hours (32 total hours). The Cdt1, Cdc6 and 
Luciferase siRNA were described previously (Coleman et al., 2015; Nevis et al., 2009). For 
siRNA treatment of RPE cells, Dharmafect 1 (Dharmacon) was mixed in Optimem (Gibco) with 
the appropriate siRNA according to manufacturer’s instructions, then diluted with DMEM, 10% 
FBS, L-glutamine and added to cells after aspirating old media. The next day the siRNA mix 
was aspirated and replaced with fresh DMEM, 10% FBS, L-glutamine, collecting samples 72 hrs 
after the start of siRNA treatment. The siRNA were siControl (Luciferase) at 100 nM or a mixture 
of two MCM3 siRNA (2859 and 2936 at 50 nM each). 
siMCM3-2859 5’- augacuauugcaucuucauugdTdT 
siMCM3-2936 5’- aacauaugacuucugaguacudTdT 
Differentiation 
Mesoderm (BMP4): hESCs were passaged as single cells at 7x103 /cm2 in mTeSR1 with 
10 μM Y-27632 2HCl onto Matrigel-coated plates. 24 hours later, the media was changed to 
start differentiation with fresh mTeSR1 with 100 ng/mL BMP4 (R&D Systems), and 24 hours 
later the media was changed to fresh mTeSR1 with 100 ng/mL BMP4 for 48 total hours of 
differentiation. 
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Neuroectoderm: hESCs were differentiated using a monolayer-based protocol in Neural 
Induction Medium: hESCs were passaged as single cells at 5.2x104 /cm2 in STEMdiff™ Neural 
Induction Medium (StemCell Technologies) with 10 μM Y-27632 2HCl onto Matrigel coated 
plates, and plating started the differentiation. 24 hours later, the media was changed to fresh 
Neural Induction Medium for another 24 hours for 48 hours total differentiation. To derive NPCs, 
hESCs were differentiated in Neural Induction medium (StemCell Technologies) using the 
Embryoid Body Neural Induction protocol according to manufacturer’s instructions, similar to 
previous reports (Robinson et al., 2016). Once generated, NPCs were maintained in Neural 
Progenitor Medium (StemCell Technologies). 
Mesoderm (GSK3βi): hESCs were passaged as single cells at 3x104 /cm2 in mTeSR1 
with 10 μM Y-27632 2HCl onto Matrigel coated plates. 24 hours later, the media was changed 
to start differentiation. Cells were washed with Advanced RPMI 1640 (Gibco), then incubated in 
Advanced RPMI 1640 with B27 minus insulin (Gibco), 2 mM L-glutamine, and 8 μM CHIR-
99021 (Selleck Chemicals). At 24 hours after changing the media, cells were washed with 
Advanced RPMI 1640 then incubated in Advanced RPMI 1640 with B27 minus insulin (Gibco), 2 
mM L-glutamine, without CHIR-99021 for 24 hours for a total of 48 hours of differentiation. 
Endoderm: hESCs were passaged as single cells at 4x103 /cm2 in mTeSR1 with 10 μM Y-27632 
2HCl onto Matrigel-coated plates. The next day the media was changed to fresh mTeSR1 
without Y-27632 2HCl. 24 hours later, the media was changed to start differentiation. The cells 
were washed with Advanced RPMI 1640 (Gibco), then incubated in Advanced RPMI 1640 with 
0.2% FBS, 2 mM L-glutamine, 100 ng/mL Activin A (R&D Systems) and 2.5 μM CHIR-99021. At 
24 hours after changing the media, cells were washed with Advanced RPMI 1640 then 
incubated in Advanced RPMI 1640 with 0.2% FBS, 2 mM L-glutamine, 100 ng/mL Activin A, 




Phase contrast microscopy 
Phase contrast images were acquired with an Axiovert 40 CFL inverted microscope, 20x 
objective. 
Immunofluorescence Microscopy 
For immunofluorescence microscopy, hESCs were plated as single cells in mTeSR1 
with 10 μM Y-27632 2HCl in Matrigel-coated, 24 well, #1.5 glass bottom plates (Cellvis) at 7x103 
/cm2 for siCdt1, Mesoderm (BMP4), at 5x103 for siCdc6, Mesoderm (BMP4), and at 4x103 /cm2 
for siCdt1, Endoderm. Cells were incubated with siCdt1 for 20 hours (Mesoderm (BMP4)), 24 
hours (Endoderm) or siCdc6 for 32 hours (Mesoderm (BMP4)) all in parallel with siControl as 
described above (siRNA transfections). After siRNA treatment, cells were differentiated as 
described above (Differentiation) with the following modifications: For Mesoderm (BMP4), 
multiple BMP4 concentrations and treatment times were used as indicated (Figure 3.15). For 
treatment less than 48 hours, cells were incubated in mTeSR1 after siRNA treatment until 
starting differentiation. (Example: 12 hours of mTeSR1 then 36 hours of BMP4, for a total of 48 
hours). For endoderm, the first RPMI/Activin/CHIR-99021 was immediately after siRNA, without 
a day of incubation in mTeSR1. After differentiation, cells were fixed in 4% paraformaldehyde in 
PBS for 15 minutes at room temperature, washed with PBS, and permeabalized with 5% BSA, 
PBS, 0.3% triton x-100 at 4 °C overnight. Next, cells were incubated in primary antibody in 5% 
BSA, PBS, 0.3% triton x-100 at 4 °C overnight. Cells were washed with PBS at room 
temperature, then incubated in secondary antibody in 5% BSA, PBS, 0.3% triton x-100 at room 
temperature for 1 hour. Cells were washed with PBS, then incubated in 1 μg/mL DAPI in PBS 
for 10 minutes at room temperature, then washed with PBS. For Mesoderm (BMP4)the primary 
antibodies were Oct4 (Millipore, Cat#MABD76) and Cdx2 rabbit (Abcam, Cat#ab76541), the 
secondary antibodies were goat anti-mouse-Alexa 594, donkey anti-rabbit-Alexa 488. For 
endoderm the primary antibody was Sox17 (R&D Systems, Cat#AF1924), the secondary 
antibody was donkey anti-goat-Alexa 594 (Jackson ImmunoResearch). Cells were imaged in 
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PBS on a Nikon Ti Eclipse inverted microscope with an Andor Zyla 4.2 sCMOS detector. 
Images were taken as 3x3 scan of 20x fields with a 0.75 NA objective, stitched with 15% 
overlap between fields using NIS-Elements Advanced Research Software (Nikon). Shading 
correction was applied within the NIS-Elements software before acquiring images. Raw images 
were quantified using a custom CellProfiler pipeline. 
qPCR (Figure 3.7) 
RNA lysates were prepared using Norgen Biotek’s Total RNA Purification Kit (Cat. 
37500). Lysates were first treated with Promega RQ1 RNase-Free DNase (Promega), and then 
converted to cDNA using Applied Biosystem’s High-Capacity RNA-to-cDNA Kit (Cat. 4387406). 
Quantitative real-time PCR (qPCR) with SYBR Green (Bio-Rad; SsoAdvanced Universal SYBR 
Green Supermix, Cat. 1725271) was carried out to assess gene expression. All results were 
normalized to ACTB. Primers for qPCR were ordered from Eton Bioscience. Primers: 
POU5F1-F: 5'-CCTGAAGCAGAAGAGGATCACC,  
POU5F1-R 5'-AAAGCGGCAGATGGTCGTTTGG,  
CDX2-F 5'-ACAGTCGCTACATCACCATCCG,  
CDX2-R 5'-CCTCTCCTTTGCTCTGCGGTTC,  
T-F 5'-CTTCAGCAAAGTCAAGCTCACC,  
T-R 5'-TGAACTGGGTCTCAGGGAAGCA,  
SOX17-F 5'-ACGCTTTCATGGTGTGGGCTAAG,  
SOX17-R 5'-GTCAGCGCCTTCCACGACTTG,  
CDT1-F 5'-GGAGGTCAGATTACCAGCTCAC,  
CDT1-R, 5'-TTGACGTGCTCCACCAGCTTCT,  
SOX2-F 5'-CTACAGCATGATGCAGGACCA,  
SOX2 -R 5'-TCTGCGAGCTGGTCATGGAGT,  
PAX6-F 5'-AATCAGAGAAGACAGGCCA,  
PAX6-R 5'-GTGTAGGTATCATAACTC,  
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ACTB-F 5'-CACCATTGGCAATGAGCGGTTC,  
ACTB-R 5'-AGGTCTTTGCGGATGTCCACGT. 
Generating ARPE-19-iPS cells 
 ARPE-19-iPS cells were derived from the human retinal pigment epithelial cell line 
ARPE-19 by reprogramming with CytoTune-iPS 2.0 Sendai reprogramming kit (Invitrogen) 
following the manufacturer's instructions.  
 Briefly, two days before Sendai virus transduction, 100,000 ARPE-19 cells were plated 
into one well of a 6-well plate with ATCC-formulated DMEM:F12 medium and were transduced 
with the CytoTune™ 2.0 Sendai reprogramming vectors at the MOI recommended by the 
manufacturer 48 hours later (d0). The medium was replaced with fresh medium every other day 
starting from one day after transduction (d1). At day 7, transduced cells were replated on 
Matrigel coated 6-well plates. Cells were fed with Essential 8 medium every day. Colonies 
started to form in 2-3 weeks and were ready for transfer after an additional week. 
Undifferentiated colonies were manually picked and transferred to Matrigel coated 6-well plates 
for expansion. After two rounds of subcloning and expansion (after passage 10), RT-PCR was 
used to verify whether iPS cells were vector-free with the primer sequences published in the 
manufacturer’s manual. 
 After iPS cells became virus-free, they were submitted to the University of Minnesota 
Cytogenomic Laboratory for karyotype analysis. This analysis indicated that the ARPE-19-iPS 
cells have normal karyotypes.  
Immunofluorescence characterization of ARPE-19-iPS cells 
 To examine pluripotency markers, iPS cells were fixed with 4% paraformaldehyde for 20 
minutes. If nuclear permeation was required, cells were treated with 0.2% triton-x-100 in 
phosphate-buffered saline (PBS) for 30 minutes, blocked in 3% bovine serum albumin in PBS 
for 2 hours, and incubated with the primary antibody overnight at 4˚C. Antibodies targeting the 
following antigens were used: TRA1-60 (MAB4360, 1:400), TRA1-81 (MAB4381, 1:400), stage-
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specific embryonic antigen-4 (MAB4304, 1:200), and stage- specific embryonic antigen-3 (MAB-
4303, 1:200), all from Millipore/Chemicon (Billerica, MA), OCT3/4 (AB27985, 1:200) from 
Abcam (Cambridge, MA), and NANOG (EB068601:100) from Everest (Upper Heyford, 
Oxfordshire, UK). Cells were incubated with secondary Alexa Fluor Series antibodies (all 1:500, 
Invitrogen) for 1 hour at room temperature and then with DAPI for 10 minutes. Images were 
examined using an Olympus FluoView 1000m IX81 inverted confocal microscope and analyzed 
with Adobe Photoshop CS6. Direct alkaline phosphatase (AP) activity was analyzed as per the 
manufacturer’s recommendations (Millipore).  
Bisulfite sequencing and methylation analysis 
Genomic DNA was isolated using the DNeasy Blood and Tissue kit (Qiagen) per 
manufacturer’s recommendations for isolation from mammalian cells. Bisulfite conversion was 
performed using the Epitect Bisulfite kit (Qiagen) according to the manufacturer’s protocol for 
low amounts of DNA. Single-step PCR amplification of the NANOG and OCT4 promoter regions 
were conducted using Accuprime Supermix II (Invitrogen). Amplification products were 
visualized by gel electrophoresis and bands were excised and purified using the QIAquick Gel 
Extraction kit (Qiagen). Purified PCR products were inserted into the PCR4-TOPO vector 
(Invitrogen) and individual clones were sequenced. Alignment and methylation analysis were 
performed using the online QUMA program (http://quma.cdb.riken.jp/). Sequenced clones with 
at least 90% non-CpG cytosine conversion and at least 90% sequence homology were retained 
for analysis. 
Quantitative reverse transcriptase PCR (Figure 3.3) 
 RNA was isolated using RNeasy Mini kit (Qiagen) and treated with TURBO DNA-free 
(Ambion, Austin, TX). First-strand cDNA was synthesized using a Superscript III First-Strand 
Synthesis SuperMix (Invitrogen). Reverse transcriptase-PCR was performed using TaqMan 
Gene Expression Assays and TaqMan Universal PCR Master Mix, No AmpErase UNG (Applied 
Biosystems, Carslbad, CA) as per the manufacturer’s protocol. 
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          TaqMan gene expression assays used were OCT4 (Hs04260367-gH), SOX2 
(Hs01053049-sl), NANOG (Hs04399610-g1), KLF4 (Hs00358836-m1), MYC (Hs00153408-m1), 
LIN28 (Hs00702808-s1), REXO1 (Hs00810654-m1), ABCG2 (Hs1053790-m1), DNMT3 
(Hs00171876-m1), with GAPDH (Hs99999905-m1) used as an endogenous control. Expression 
levels were measured in duplicate. For genes with expression below the fluorescence threshold, 
the cycle threshold (Ct) was set at 40 to calculate the relative expression. Analysis was 
performed using an ABI PRISM 7500 sequence detection system (Applied Biosystems).  
Teratoma analysis 
 ARPE-19-iPS cells contained in a mixture of DMEM/F12, Matrigel and collagen were 
implanted onto the hind flank of NSG mice (n=5) until a palpable mass formed. Teratoma tissue 
was excised for histological examination following embedding and staining by haematoxylin and 
eosin. Experiments were conducted with the approval of the Institutional Animal Care and 
Research Committee at the University of Minnesota. 
Ergodic Rate Analysis 
Ergodic Rate Analysis for cell cycle data was based on previously published work (Kafri 
et al., 2013). First, the raw data from flow cytometry files were extracted using FCSExtract Utility 
(Earl F Glynn) to comma separated value (.csv) files. The data in the .csv files were then gated 
in FCS Express 6 (De Novo Software) and the data for only G1-MCMDNA were exported. MCM 
negative cells were excluded based on the negative control sample (see Flow Cytometry). The 
mean MCM loading rate was calculated in MATLAB (MathWorks). To calculate the mean MCM 
loading rate, the G1-MCMDNA were subdivided into 10 equal sized bins, with rate calculated for 
each bin, and all 10 rates were averaged together for a mean MCM loading rate. The rate 




wn = MCM loading rate in bin n 
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α = ln(2) / doubling time (Figure 3.6) 
F = number of G1-MCMDNA cells / total number of cells in sample. F was calculated from FCS 
Express and entered into MATLAB manually (Figure 3.6). 
fn = number of cells in bin n / number of G1-MCMDNA cells 
The bins were created in MATLAB (Figure 3.6). To control for small day to day 
differences in raw data from staining intensities, the histogram edges were defined with the first 
bin starting at the lowest MCM value and the last bin ending at the highest MCM value, divided 
into 10 equal sized bins between the lowest and highest MCM value. The 10 wn were then 
averaged for a final mean w per sample.  
The mean MCM loading rate was calculated for 3 biological replicates for each cell line, 
and the replicates were averaged using GraphPad Prism for further statistical analysis. We 
cannot use ergodic rate analysis on actively differentiating cells (e.g. Figure 3.7) because they 
are not at steady state. 
Quantification and Statistical Analysis 
Statistical analysis was performed with GraphPad Prism 7 using unpaired, two-tailed t 
test (displayed as mean ±SD) or two-tailed Mann-Whitney test as indicated in figure legends. 
Significance levels were set at *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001, ****p≤ 0.0001. All experiments 
were performed a minimum of 2 times, and representative data are shown in figures. 
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CHAPTER 4: INTRINSIC CHECKPOINT DEFICIENCY DURING CELL CYCLE RE-ENTRY 
FROM QUIESCENCE3 
Introduction 
 Proliferating mammalian cells initiate DNA replication at thousands of DNA replication 
origins every cell cycle. Replication origins are chromosomal loci where DNA synthesis initiates 
in S phase. The Minichromosome Maintenance complex (MCM) is an essential component of 
the helicase that unwinds DNA to initiate replication. MCM loading dynamics are tightly 
regulated and coordinated with cell cycle progression for precise and complete genome 
duplication. Cells prepare for DNA replication in S phase by loading MCMs onto replication 
origins in the preceding G1 phase, a process called “origin licensing.” The amount of DNA-
loaded MCM increases as cells progress through G1 until reaching a maximum per cell at the 
G1/S transition (Siddiqui et al., 2013; Remus and Diffley, 2009). Once cells enter S phase, 
multiple overlapping mechanisms block any new origin licensing, thus restricting MCM loading 
to G1 phase (Truong and Wu, 2011; Arias and Walter, 2007). Cells block MCM loading outside 
of G1 phase to prevent genotoxic re-replication, which causes aneuploidy, double strand 
breaks, and genome instability (Neelsen et al., 2013; Truong and Wu, 2011; Arias and Walter, 
2007). MCMs unwind DNA in S phase, travel with replication forks, and MCMs are unloaded 
throughout S phase as replication forks terminate (Maric et al., 2014; Moreno et al., 2014).  
 Cells may encounter replication stress and replication fork stalling in S phase from a 
variety of endogenous and exogenous sources. A stalled replication fork can be rescued if a 
                                                            
3Modified from unpublished work submitted to the Journal of Cell Biology: Jacob Peter Matson, 
Amy M. House, Gavin D. Grant, Huaitong Wu, Joanna Perez, Jeanette Gowen Cook. Intrinsic 
checkpoint deficiency during cell cycle re-entry from quiescence. 2019. 
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nearby licensed origin initiates a new fork to replicate the intervening DNA (Alver et al., 2014; 
Yekezare et al., 2013). Since MCM loading is tightly restricted to G1 phase, cells typically load 
excess MCM to license 5-10 fold more origins than they would require to complete S phase if 
there were no replication stress at all. These excess licensed origins function as “dormant 
origins”, and are activated as needed to respond to local replication stress and rescue stalled 
forks (Woodward et al., 2006; Ge et al., 2007; Ibarra et al., 2008). Cells with considerably less 
loaded MCM can still complete a normal S phase (Ge et al., 2007).  Nonetheless, if cells enter S 
phase with less loaded MCM they are “underlicensed” with fewer dormant origins, and are 
hypersensitive to replication stress. In addition, animal models of underlicensing reveal its long-
term consequences. Mice heterozygous for MCM null alleles or homozygous for hypomorphic 
MCM alleles have less MCM loading , increased replication stress, and defects in highly 
proliferative tissues such as hematopoietic cells and intestinal crypts (Alvarez et al., 2015; Pruitt 
et al., 2007). In addition, these mice with underlicensed cells are prone to genomic instability 
and cancer (Kunnev et al., 2010; Shima et al., 2007; Pruitt et al., 2007). 
  If dormant origins are critical to protect cells from replication stress and its consequent 
genome instability, then cells should have a control mechanism to ensure sufficient origin 
licensing. An origin licensing checkpoint in G1 phase of untransformed mammalian cells 
ensures abundant licensing in G1 phase before S phase entry (Shreeram et al., 2002; Nevis et 
al., 2009; Liu et al., 2009; Gillespie et al., 2007). Artificially reducing MCM loading in checkpoint 
proficient cells delays the late G1 activation of Cyclin E/Cyclin Dependent Kinase 2 (CDK2) 
(Nevis et al., 2009; McIntosh and Blow, 2012). Delayed Cyclin E/CDK2 activation delays the 
phosphorylation of multiple substrates that drive S phase entry. Delaying CDK2 activity 
lengthens G1 phase and ensures that cells do not enter S phase with low levels of origin 
licensing. Moreover, this checkpoint is p53-dependent (Nevis et al., 2009; Liu et al., 2009; 
Shreeram et al., 2002), thus a common genetic perturbation in transformed cancer cells likely 
compromises the normal coordination of origin licensing and S phase onset.  
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 Given the importance of coordinating G1 length with the progress of origin licensing for 
robust S phase completion, we considered natural circumstances where G1 length changes. 
One example is the short G1 phase of pluripotent stem cells. We previously found that stem 
cells load MCM faster than differentiated cells with long G1 phases to achieve the same amount 
of loaded MCM at S phase entry (Matson et al., 2017). Another example is the long G1 after cell 
cycle re-entry from quiescence. Cell cycle quiescence, or “G0,” is a reversible cell cycle exit to a 
non-dividing state. G0 is distinct from a G1 arrest; it is an active state requiring upregulation of 
anti-apoptotic, anti-senescent and anti-differentiation genes as well as repression of cell cycle 
genes (Coller et al., 2006; Sang et al., 2008; Litovchick et al., 2007; Sagot and Laporte, 2019). 
Cells re-entering G1 phase from G0 have a longer G1 than cells entering G1 from mitosis 
(Coller, 2007). The longer G1 phase during re-entry likely reflects the need to reactivate and 
express genes repressed in G0 as well as fundamental differences in G1 regulation. 
 The increased G1 length after G0 and the restriction of origin licensing to G1 phase 
suggests that origin licensing may be distinctly regulated in the longer G1 upon cell cycle re-
entry. We entertained the notion that the increased G1 length may allow more time for MCM 
loading, causing a meaningful increase in DNA-loaded MCM when entering S phase compared 
to subsequent proliferating cell cycles. To test this idea, we used single cell flow cytometry to 
measure the amount of loaded MCM at S phase entry and live cell imaging to measure cell 
cycle timing to determine if the amount of loaded MCM differs between cell cycle re-entry and 
active proliferation. Surprisingly, we discovered instead that cells re-entering the cell cycle from 
G0 are underlicensed and hypersensitive to replication stress compared to proliferating cells. 
This finding is consistent with a recent report that the first S phase experiences higher 
spontaneous replication stress, though the source of that endogenous stress was not identified 
(Daigh et al., 2018). We report here that MCM loading is slow in the first G1 phase and that the 
first cell cycle has a severely compromised origin licensing checkpoint relative to the robust 
checkpoint in actively proliferating cells. This combination promotes premature S phase entry 
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and underlicensing. To our knowledge, these results demonstrate the first naturally 
underlicensed cell cycle and suggest that repeated cell cycle re-entry from G0 is particularly 
hazardous for long-term genome stability. 
Results 
G0 cells re-entering the cell cycle are underlicensed compared to actively proliferating 
cells. 
Cells re-entering the cell cycle from G0 have a long G1 before S phase entry relative to 
actively proliferating cells (Coller, 2007). We hypothesized that the difference in G1 length and 
unique aspects of the G0 to G1 transition could alter the timing or amount of loaded MCM at S 
phase entry in normal human cells. The amount of MCM loaded at the onset of S phase 
determines replication stress tolerance and thus overall replication success.  For this reason we 
focused on quantifying how much MCM is loaded at the onset of S phase (G1/S transition). 
Standard synchronization and immunoblotting is an inadequate approach however because G0 
cells re-enter G1 phase semi-synchronously, particularly untransformed cells. Even in the first 
cycle, there is no time point near the G1/S transition after cell cycle re-entry that is not a mix of 
different phases (e.g. G1 and S phase cells), and the following second cell cycle is nearly 
asynchronous (Wang et al., 2017; Kwon et al., 2017). We therefore used a previously published 
and validated single cell flow cytometry assay to measure DNA-loaded MCM at the G1/S 
transition (Matson et al., 2017; Håland et al., 2015; Moreno et al., 2016; Carroll et al., 2018; 
Hiraga et al., 2017). We examined proliferating Retinal Pigmented Epithelial cells (RPE1) whose 
only genetic alteration is the introduction of telomerase (RPE1-hTert). We extracted soluble 
proteins with nonionic detergent, DNA-bound proteins were retained, then fixed and stained with 
anti-Mcm2 antibody as a marker for the whole MCM2-7 complex, DAPI to measure DNA 
content, and for the nucleotide analog 5-Ethynyl-2´-deoxyuridine (EdU) to measure DNA 
synthesis (Fig. 4.1). We defined MCM-positive cells based on an antibody negative control; grey 




Figure 4.1. The first S phase after cell cycle re-entry from quiescence (G0) is 
underlicensed. 
a. Flow cytometry of proliferating RPE1-hTert cells extracted with nonionic detergent to measure 
DNA bound protein (analytical flow cytometry for chromatin-bound proteins). Cells were labeled 
with 10 uM EdU for 30 minutes before harvesting then stained with anti-Mcm2 antibody to 
measure DNA-loaded MCM, DAPI to measure DNA content, and EdU to measure DNA 
synthesis. Gates to define colors are provided in Fig. 4.2A: orange cells are S phase, EdU-
positive cells DNA-loaded MCM-positive, blue cells are G1 phase cells, EdU-negative with DNA-
loaded MCM-positive, grey cells are all MCM-negative cells. Arrow indicates the G1/S transition. 
b. Cartoon of MCM loading in the first and second cell cycles. The amount of MCM loaded at 
the point of S phase entry determines the likelihood of replication success (indicated by 
question marks). At the start of this study, MCM loading before the first S phase after the long 
G1 relative to MCM loading in second and subsequent cell cycles was unknown. 
c. DNA loaded MCM, DNA content (DAPI), and DNA Synthesis (EdU) as in Fig. 4.1A. RPE1 
cells were synchronized in G0 by contact inhibition with 10% fetal bovine serum and released 
from G0 into the cell cycle by replating. Cells were analyzed in G0, 24 hours after release (first 
cell cycle), and 48 hours after release (second cell cycle). 
d. Immunoblot of cells treated as in Fig. 4.1C, Samples were fractionated into DNA loaded 
chromatin fractions and whole cell lysates then probed for MCM2. 
e. Gating of early S cells from Fig. 4.1C, showing only the S phase-MCMDNA-positive cells. Black 
rectangles define early S phase cells as MCMDNA-positive with 2C DNA content. Inset: Displays 
only early S phase cells. Cells above the dashed line were normally licensed whereas cells 
below the line were underlicensed. 
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f. Histogram measuring DNA-loaded MCM in early S phase cells from Fig. 4.1E. The orange 
line is early S phase loaded MCM from first cell cycle, and the grey line is early S phase loaded 
MCM from second cell cycle. 
g. Fold change in early S phase loaded MCM between first and second cell cycles of RPE1 G0 
synchronized by contact inhibition from Fig. 4.1E, RPE1 G0 synchronized by mitogen starvation 
(Fig. 4.2I, J), and Wi38, and NHF1-hTert G0 synchronized by contact inhibition (Fig. 4.2E-H). Y 
axis is ratio of mean early S phase loaded MCM from first cell cycle divided by mean early S 
phase loaded MCM from second cell cycle, plotted center line is mean with standard deviation 
(SD) error bars, n=3 biological replicates.  
h. Percentage of underlicensed cells from first and second cell cycles of cells in Fig. 4.1G, 
plotted center line is mean with standard deviation (SD) error bars, n=3 biological replicates. 
First and second cell cycles compared by unpaired, two tailed t test. RPE1 contact p=0.0035** 





Figure 4.2. Flow cytometry gating and alternate cell lines 
a. Flow cytometry gating to isolate cells for analysis. Proliferating RPE1 cells (Fig. 4.1A) were 
processed for analytical flow cytometry for chromatin-bound proteins, labeling DNA Content 
(DAPI), Loaded MCM (anti-Mcm2) and DNA Synthesis (EdU). Cells were labeled with 10 uM 
EdU for 30 minutes before harvesting. Gating to isolate cells from debris is Forward Scatter 
Area vs Side Scatter Area, cells gate. Gating to isolate single cells from doublets is DAPI Area 
vs DAPI Height, singlets gate. Gating to determine cell cycle phase distributions is DNA Content 
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vs DNA Synthesis. Color gating for S-MCMDNA positive (orange), G1-MCMDNA positive (blue) and 
MCMDNA negative (grey) is on DNA Synthesis vs Loaded MCM using a negative control sample 
without Mcm2 primary antibody or EdU, but with Donkey anti Mouse-488 secondary antibody 
and 647-azide as a measure of background staining.  
b. Cell cycle phase of RPE1 cells G0 synchronized by contact inhibition, Fig. 4.1C, RPE1 cells 
G0 synchronized by mitogen starvation, Fig. 4.21I, Wi38 cells G0 synchronized by contact 
inhibition, Fig. 4.2G, and NHF1-htert cells G0 synchronized by contact inhibition, Fig. 4.2E. 
Horizontal bars indicate means, error bars mark standard deviation (SD), n=3 biological 
replicates. 
c. Immunoblot for Cyclin D1 or p27 on total protein lysate from RPE1 cells synchronized in G0 
or released into the first cell cycle (24 hours) as in Fig. 4.1C. 
d. Percentage of S phase cells defined by analytical flow cytometry. RPE1 cells were 
synchronized in G0 by contact inhibition were released into the cell cycle with 1 uM EdU at time 
of release, harvesting cells, 24, 28, and 32 hours after release from G0. S phase was 
determined by DAPI (DNA Content) and EdU (DNA Synthesis) cells as in Fig. 4.2A. Horizontal 
bars indicate means, error bars mark standard deviation (SD), n=3 biological replicates.  
e. Flow cytometry of chromatin-bound protein on Wi38 cells synchronized in G0 by contact 
inhibition in 0.1% FBS for 72 hours and released from G0 into the cell cycle, harvesting 24 
hours after release (first cell cycle) and 48 hours after release (second cell cycle). Flow 
cytometry measured DNA Content (DAPI), Loaded MCM (anti-Mcm2) and DNA Synthesis 
(EdU). Cells were labeled with 10 µM EdU for 30 minutes before harvesting. Orange cells are S 
phase MCMDNA positive, blue cells are G1 phase MCMDNA positive, grey cells are MCMDNA 
negative.  
f. Loaded MCM in early S phase determined by flow cytometric analysis of early S phase Wi38 
from Fig. 4.2E. Orange line is first cell cycle, grey line is second cell cycle. 
g. Flow cytometry of chromatin-bound protein on NHF1-htert cells synchronized in G0 by 
contact inhibition in 0.1% FBS for 72 hours and released from G0 into the cell cycle, harvesting 
24 hours after release (first cell cycle) and 48 hours after release (second cell cycle). Flow 
cytometry measured DNA Content (DAPI), Loaded MCM (anti-Mcm2) and DNA Synthesis 
(EdU). Orange cells are S phase MCMDNA positive, blue cells are G1 phase MCMDNA positive, 
grey cells are MCMDNA negative.  
h. Loaded MCM in early S phase determined by flow cytometric analysis of NHF1 from Fig. 
4.2G. Orange line is first cell cycle, grey line is second cell cycle. 
i. Flow cytometry of chromatin-bound protein on RPE1 cells synchronized in G0 by starvation in 
0% FBS for 72 hours and released from G0 into the cell cycle, harvesting 24 hours after release 
(first cell cycle) and 48 hours after release (second cell cycle). Flow cytometry measured DNA 
Content (DAPI), Loaded MCM (anti-Mcm2) and DNA Synthesis (EdU). Orange cells are S 
phase MCMDNA positive, blue cells are G1 phase MCMDNA positive, grey cells are MCMDNA 
negative.  
j. Loaded MCM in early S phase determined by flow cytometric analysis of RPE1 from Fig. 4.2I. 
Orange line is first cell cycle, grey line is second cell cycle. 
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Fig. 4.2A shows the flow cytometry gating scheme. We marked cells blue for 2C DNA content 
(G1) that are negative for DNA synthesis but positive for DNA-loaded MCM (G1- MCMDNA pos.). 
MCM loading is unidirectional in G1 phase, increasing in G1 until the maximum amount of 
loaded MCM at the G1/S transition (Kuipers et al., 2011). The column of blue cells with 2C DNA 
on the flow cytometry plot reflects cells at different G1 stages, cells in early G1 have less loaded 
MCM and cells in late G1 have more loaded MCM (Fig. 4.1). Loaded MCMs are very stable and 
are only unloaded in S phase as replication terminates (Moreno et al., 2014; Maric et al., 2014). 
We marked cells orange for S phase based on EdU incorporation and DNA-loaded MCM (S- 
MCMDNA pos.). In actively proliferating populations with robust licensing prior to S phase entry, 
we consistently observe that the majority of cells reach a similar maximum loaded MCM per cell 
in G1 (blue) before becoming EdU positive (orange) in very early S phase. In this way, we 
accurately measured loaded MCM in very early S phase even in fully asynchronous 
populations. (Fig. 4.1A “G1/S” marked by the arrow).  
 Our goal was to apply this method to measure how much MCM had been loaded by the 
time of the G1/S transition in the first cell cycle compared to the amount loaded at G1/S in the 
second cell cycle (Fig. 4.1B). We arrested RPE1-hTert cells in G0 by contact inhibition (in the 
presence of growth serum) for 48 hours. Contact-inhibited G0 cells showed a robust cell cycle 
exit to G0 with very little loaded MCM; 94% of cells were G0/G1 but only 1% were still in S 
phase (Fig. 4.1C and Fig. 4.2B).  We then released cells to re-enter the cell cycle by plating at 
sub-confluent cell density. G0 cells also expressed the expected high levels of p27 and low 
Cyclin D1 compared to cells in the first cycle (Fig. 4.2C). We pulse-labeled cells with EdU and 
harvested some cells in G0 and some at 24 hrs when they were a mix of first G1 and ~50-70% 
first S phase cells. In a separate continuous EdU labeling experiment in which EdU was added 
at the time of release, we determined that nearly 100% of cells had entered S phase by 28 
hours (Fig. 4.2D), and almost no cells remained in G0/G1. Thus, we concluded that additional 
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cells harvested 48 hours after release had completed their first S phase and were into their 
second cell cycle.   
Strikingly, the amount of loaded MCM at the G1/S transition was markedly different 
between the first and second cell cycles after G0. Cells in the first cell cycle progressed into S 
phase (orange cells) with substantially less MCM loaded than cells in the second cell cycle. By 
the second cell cycle, G1 cells progressed into S phase as a tight group with relatively high 
amounts of loaded MCM (transition from blue to orange).  In contrast, many cells in the first cell 
cycle entered S phase with low amounts of loaded MCM. This behavior creates the filled orange 
triangle on flow cytometry plots of the first S phase instead of the normally clear region under a 
high arc characteristic of the second S phase. We also observed decreased loaded MCM in the 
first cycle using biochemical chromatin fractionation and immunoblotting (Fig. 4.1D). 
To quantify the amount of loaded MCM at the G1/S transition, we analyzed the S phase 
cells from Fig. 4.1C, and defined very early S phase cells as EdU-positive with ~2C DNA 
content (Fig. 4.1E black rectangles). Early S phase cells in the first cycle had a broad range of 
loaded MCM levels that included many cells with low MCM, whereas early S phase cells in the 
second cycle primarily had high loaded MCM levels. The second cell cycle was nearly 
indistinguishable from asynchronously proliferating cells that had not been arrested. We thus 
used the second cell cycle to define the normal licensing levels, and classified cells with less 
MCM loaded in early S as “underlicensed cells” (Fig. 4.1E dashed line). To more readily 
visualize and compare the different populations, we generated histograms of loaded MCM 
levels in early S phase cells (Fig. 4.1F). On this plot the differences between the first and 
second S phases were readily apparent (compare orange and grey lines). We quantified the 
differences as fold change between the mean MCM loaded in the first and second S phases. 
Cells in the first cycle after re-entry from G0 loaded only half as much MCM as cells in the 
second cell cycle (Fig. 4.1G). We then used this same comparison to test if this underlicensed 
first cell cycle is common among different untransformed cell lines or methods of quiescence 
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induction. We observed similar underlicensing after quiescence induction in RPE1-hTert by 
serum starvation and re-stimulation and in two fibroblast cell lines arrested by contact inhibition 
and release (Fig. 4.1G and Fig. 4.2E-J). We observed that not only was the mean MCM loaded 
of the first S phase half that of subsequence S phases, but also that the majority of first S phase 
cells were underlicensed (Fig. 4.1H). Thus, re-entry from G0 is characterized by substantial 
underlicensing in the first cell cycle.  
Cells re-entering S phase from G0 are hypersensitive to replication stress. 
 Cells typically load extra MCM in G1 to license dormant origins that protect against 
replication stress in S phase (Woodward et al., 2006; Ge et al., 2007; Ibarra et al., 2008). Given 
our observations that the first S phase is underlicensed relative to the subsequent S phase, we 
hypothesized that cells re-entering the cell cycle from G0 would be hypersensitive to replication 
stress in the first S phase. To test that idea directly, we treated cells in the first or second cell 
cycle after G0 with low-dose gemcitabine, a drug that depletes nucleotides to cause replication 
stress (Ewald et al., 2007). We used flow cytometry to measure the expression of γH2AX, a 
common replication stress marker (Ewald et al., 2007)(Fig. 4.3A, B, and Fig. 4.4A). We 
specifically analyzed mid-S phase cells to control for differences in cell cycle distribution, and 
we counted the number of γH2AX-positive S phase cells with expression equal to or greater 
than the top 5% of untreated cells (Fig. 4.3C, dashed line). By this measurement, cells in the 
first S phase after G0 are significantly more sensitive to replication stress than cells in the 
second S phase (Fig. 4.3D). Moreover, gemcitabine-treated first S phase cells expressed 
double the amount of γH2AX per cell than cells in the second S phase, suggesting that not only 
were more total cells exhibiting a replication stress response but also that there was more 
replication stress per cell (Fig. 4.3E, F). This hypersensitivity to replication stress in the 
underlicensed first cell cycle suggests that cell cycle re-entry is an inherently risky cycle with 





Figure 4.3. The first S phase after G0 is hypersensitive to replication stress. 
a. Diagram of gemcitabine treatment. RPE1 cells synchronized in G0 by contact inhibition and 
released into the first (harvest 24 hrs later) or second cell cycle (harvest 48 hrs later) were 
treated with 50 nM gemcitabine for the last 2 hours before harvesting for flow cytometry.  
b. Chromatin flow cytometry of cells treated as Fig. 4.3A and stained for DNA content (DAPI), 
DNA Loaded MCM (anti-Mcm2, Fig. 4.4) and γH2AX (anti-H2AX phospho S139). Red cells are 
replication stress (gemcitabine) induced γH2AX positive, as indicated in Fig. 4.3C. 
c. Gating of cells from Fig. 4.3B isolate γH2AX induced by gemcitabine. Rectangle gate isolates 
Mid S phase cells, between 2C and 4C DNA Content. Inset: Shows only Mid S phase cells, 
replication stress (gemcitabine) induced γH2AX (red cells in gate) are defined as cells equal to 
or above the top 5% of untreated cells, also plotted red in Fig. 4.3B. 
d. Percentage of replication stress (gemcitabine) induced γH2AX in first and second cell cycles 
from cells in Fig. 4.3B. n=3 biological replicates, center line is mean with SD error bars. 
Untreated and gemcitabine treated compared by unpaired, two tailed t test. First cell 
p=0.0035**. Second cell cycle p=0.1174 (ns). 
e. Histograms of mid S phase γH2AX intensity from cells in Fig. 4.3B, upper panel is first cell 
cycle and lower panel is second cell cycle. Grey lines are untreated cells, red lines are 
gemcitabine treated cells. Y axis counts are normalized to peak value of untreated cells. 
f. Fold induced γH2AX. Y axis ratio is mean Mid S γH2AX intensity of gemcitabine treated cells 
divided by mean Mid S γH2AX intensity of untreated cells from cells in Fig. 4.3E, n=3 biological 
replicates. Plotted center line is mean, error bars are SD. Samples compared by unpaired, two 




Figure 4.4. Repeated transitions between G0 and proliferation trend towards an increased 
replication stress sensitivity 
a. Flow cytometry of chromatin-bound protein from cells in Fig. 4.3B, showing DNA loaded MCM 
(anti-MCM2). Red cells are gemcitabine (replication stress) induced γH2AX positive, as 
indicated in Fig. 4.3C. 
b. Diagram of experiment. For 1xG0: RPE1 cells were synchronized in G0 by contact inhibition 
for 48 hours, then released into the cell cycle with 5 nM gemcitabine, harvesting cells 24 hours 
after release. For 3xG0: RPE1 cells were synchronized in G0 by contact inhibition for 48 hours, 
released into the cell cycle without gemcitabine and grown to confluency to repeat the G0 by 
contact inhibition a second time, then repeating once again for a 3rd G0. Then cells were 
released into the cell cycle with 5 nM gemcitabine, harvesting cells 24 hours after release. 
c. Flow cytometry of chromatin-bound protein from cells treated as in Fig. 4.4B, measuring DNA 
Content (DAPI) and γH2AX (anti H2AX phospho S139). Histograms plot γH2AX of Mid-S phase 
cells as described in Fig 4.3C. Upper panel is 1xG0, lower panel is 3xG0. Grey lines are first cell 
cycle untreated, red lines are first cell cycle treated with 5 nM gemcitabine.  
d. Percentage of replication stress-induced γH2AX in 1xG0 and 3xG0 release into the first cycle 
from Fig. 4.4C. Horizontal bars indicate means, error bars mark standard deviation (SD), n=3 
biological replicates. 1xG0 and 3xG0 compared by unpaired, two tailed t test. p=0.153 (ns). 
e. Comparison of γH2AX intensity per cell presented as fold-change between gemcitabine-
treated and untreated cells from Fig. 4.4C. Horizontal bars indicate means, error bars mark 
standard deviation (SD), n=3 biological replicates. Samples compared by unpaired, two tailed t 




 Many cells in vivo switch between periods of active proliferation and periods of G0, 
repeatedly re-entering the cell cycle to proceed through this presumably underlicensed first cell 
cycle. We considered the possibility that repeated cell cycle exit and re-entry would lead to 
additional replication stress sensitivity over time. To measure accumulation of replication stress 
during repeated cell cycle re-entry, we synchronized RPE1 cells in G0 by contact inhibition for 
48 hours and released them into the cell cycle for about 48 hours (~2-3 cycles) and then they 
became contact inhibited again. We reiterated this procedure for a total of 3 rounds of G0 arrest 
and re-entry. In the third release, we treated with gemcitabine and measured the induction of 
γH2AX as before (Fig. 4.4B, C). Cells re-entering S phase from three repeated arrests in G0 
(“3xG0”) were more likely to induce γH2AX cells than cells that been arrested only once 
(“1xG0”), and these cells were also more intensely γH2AX positive per cell (Fig. 4.4D, E). The 
increased replication stress sensitivity after three rounds of G0 was variable due to inherent 
variations in the G0 synchronization over multiple rounds (Kwon et al., 2017; Wang et al., 2017). 
This variability was reflected by unpaired t test p values of ~p=0.15 for both the number of 
γH2AX positive cells and the γH2AX intensity Fig. 4.4D, E. Nevertheless, we observed a clear 
trend that repeated cell cycle re-entry from G0 increased sensitivity to replication stress.  
Proliferating epithelial cells have a robust p53-dependent origin licensing checkpoint. 
Our findings raised a larger question about the relationship between origin licensing and 
S phase entry. The consistently high amount of loaded MCM we observed prior to G1/S in the 
second and subsequent cell cycles is consistent with an active origin licensing checkpoint (e.g. 
Fig. 1A arrow).  The origin licensing checkpoint delays S phase entry when the amount of 
loaded MCM is still low in untransformed cells by delaying the activation of G1 Cyclin 
Dependent Kinases (CDK) (McIntosh and Blow, 2012). Evidence for this checkpoint is low CDK 
activity and lengthening of G1 in proliferating cells treated to reduce MCM loading by siRNA-
mediated depletion of MCM loading factors or by overproduction of the MCM loading inhibitor, 
Geminin (Shreeram et al., 2002; Liu et al., 2009; Nevis et al., 2009). The origin licensing 
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checkpoint ensures that S phase begins with abundant licensed dormant origins that protect 
against replication stress. Because we observed routinely underlicensed cells in the first S 
phase after G0 and consistently higher licensing in the second cell cycle, we hypothesized that 
the origin licensing checkpoint is mostly active in the second and subsequent cell cycles.  
Origin licensing checkpoint activity is cell type-dependent however (Shreeram et al., 
2002). We therefore sought first to assess checkpoint status in proliferating untransformed 
epithelial cells (RPE1-hTert). We decreased origin licensing with siRNA targeting Cdc10 
dependent transcript 1 (Cdt1), an essential MCM loading protein (Pozo and Cook, 2016). We 
used either a pool of four siCdt1 sequences (siCdt1 A) or a single independent siCdt1 (siCdt1 B) 
and analyzed Cdt1 protein by immunoblotting (Fig. 4.5B). We then tested both MCM loading 
and the length of G1 phase. Cdt1 depletion induced both a reduction in the rate of G1 phase 
MCM loading (Fig. 4.6A, B) and also a striking G1 lengthening. G1 length dramatically 
increased by several-fold (12 to 42 hrs for siCdt1B), and the more profound Cdt1 depletion by 
siCdt1 B caused a greater G1 delay (Fig. 4.5F). Importantly, Cdt1 depletion changed neither the 
amount of early S loaded MCM (compare black and grey lines in Fig. 4.5C, and fold change in 
Fig. 4.5D) nor the percentage of underlicensed early S phase cells (Fig. 4.5E). By the time cells 
finally entered S phase, they had achieved normal amounts of loaded MCM. These 
observations indicate that actively proliferating RPE1 cells wait for the normal amount of loaded 
MCM in G1 phase before entering S phase. 
A cell cycle checkpoint that delays progression to the next phase is distinct from a 
simple incapacity to proceed to the next phase because it is possible for genetic alterations to 
bypass a checkpoint and induce premature cell cycle progression (Hartwell and Weinert, 1989). 
The origin licensing checkpoint delays the activation of Cyclin E/CDK2 (Fig. 4.5A) (Nevis et al., 
2009). To test if the G1 phase delay can be bypassed in Cdt1-depleted RPE1-hTert cells, we 
overproduced Cyclin E1 to prematurely activate CDK2. We used flow cytometry to measure 




Figure 4.5. Cyclin E1 overproduction bypasses the licensing checkpoint-induced G1 
arrest in proliferating cells  
a. Left: Model. Robust licensing promotes CDK2 activation and S phase entry. Cdt1 depletion 
by RNAi prevents robust licensing, CDK2 activation, and S phase entry. Cyclin E1 
overproduction in Cdt1-depleted cells directly activates CDK2 independently of licensing and 
induces S phase entry. Right: Diagram of the experimental workflow. Proliferating RPE1-hTert 
cells containing integrated doxycycline inducible exogenous Cyclin E1 were treated with 
siControl, or independent siRNAs targeting Cdt1 (siCdt1 A, or siCdt1 B) for 72 hours. 100 ng/mL 
doxycycline to overproduce Cyclin E1 were added at 48 hours. 
b. Immunoblots of the indicated proteins in total protein lysates of cells treated as in Fig. 4.5A. 
↑Cyclin E1 indicates addition of 100 ng/mL doxycycline at 48 hours to overproduce Cyclin E1. 
c. Loaded MCM in early S phase determined by flow cytometric analysis of cells treated as in 
Fig. 4.5A, measuring DNA content (DAPI), DNA-Loaded MCM (anti-Mcm2) and DNA synthesis 
(EdU). Black lines are siControl treated cells, grey lines are siCdt1 A (upper) or siCdt1 B (lower), 
red lines are siControl plus overproduced Cyclin E1. Orange lines are siCdt1 A (upper) or siCdt1 
B (lower) plus overproduced Cyclin E1. See Fig. 4.6A for complete flow cytometry plots. 
d. Comparison of early S phase DNA-loaded MCM per cell from Fig. 4.5C. Values plotted are 
the ratio of mean loaded MCM in cells treated with siCdt1 and cells treated with siControl. 
Horizontal bars indicate means, error bars mark standard deviation (SD), n=3 biological 
replicates. Control and Cyclin E-overproducing cells were compared by unpaired, two tailed t 
test, siCdt1 A p<0.001****. siCdt1 B p=0.0096**. 
e. Percentage of underlicensed cells from cells treated as Fig. 4.5A. Horizontal bars indicate 
means, error bars mark standard deviation (SD), n=3 biological replicates. Control and Cyclin E-
overproducing cells were compared by unpaired, two tailed t test. SiControl p<0.001****, siCdt1 
A p=0.001***, siCdt1 B p=0.001***. 
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f. Mean lengths of G1 (green), S (purple), and G2/M (grey) phases in hours for cells treated as 
Fig. 4.5A. G1 lengths: siControl = 11.7 hrs, siControl + ↑Cyclin E1 = 4.1 hours, siCdt1 A = 25.1 
hrs, siCdt1 A + ↑Cyclin E1= 13.4 hrs, siCdt1 B = 42.3 hrs, siCdt1 B + ↑Cyclin E1 = 29.6 hours. 
Error bars are SD, n=minimum 3 biological replicates. Cell cycle phase percentages from DNA 
Content vs DNA synthesis plots (see Fig. 4.2) were multiplied by the doubling time in hours to 





Figure 4.6. Flow cytometry plots of siRNA in proliferating cells. 
a. Flow cytometry of chromatin-bound protein of cells shown in Fig. 4.5C, measuring DNA 
Content (DAPI), Loaded MCM (anti-Mcm2) and DNA Synthesis (EdU). Orange cells are S 
phase MCMDNA positive, blue cells are G1 phase MCMDNA positive, grey cells are MCMDNA 
negative.  
b. Loaded MCM in G1 cells from Fig 4.5C. Black lines are siControl treated cells. Green lines 
are siCdt1 A (left) or siCdt1 B (right). Blue lines are siCdt1 A, ↑Cyclin E1 (left) or siCdt1 B, 
↑Cyclin E1 (right).  
c. Flow cytometry of chromatin-bound protein of cells shown in Fig. 4.7C, measuring DNA 
Content (DAPI), Loaded MCM (anti-Mcm2) and DNA Synthesis (EdU). Orange cells are S 
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phase MCMDNA positive, blue cells are G1 phase MCMDNA positive, grey cells are MCMDNA 
negative. 
d. Loaded MCM in G1 cells from Fig. 4.7C. Left histogram: Black line is siControl, p53 WT, blue 
line is siControl p53 KO. Middle and right histograms: Black lines are siControl, p53 WT, green 
lines are siCdt1A, p53 WT (left) or siCdt1 B, p53 WT (right), blue lines are siCdt1 A p53 KO 





As expected from prior reports, Cyclin E1 overproduction in control cells shortened G1 phase 
nearly three-fold (siControl vs ↑Cyclin E1, Fig. 4.5F) (Matson et al., 2017; Resnitzky et al., 
1994). In addition Cyclin E1 overproduction alone induced underlicensing as measured by the 
amount of early S loaded MCM (compare black and red lines, Fig. 4.5C, and the percentage of 
underlicensed cells, Fig. 4.5E) (Ekholm-Reed et al., 2004; Matson et al., 2017). Strikingly, when 
we overproduced Cyclin E1 after Cdt1 depletion (Fig. 4.5A), early S phase cells became 
severely underlicensed, quantified by both MCM loaded per cell (compare grey and orange 
lines, Fig. 4.5C and fold change in Fig. 4.5D), and the percentage of underlicensed cells (Fig. 
4.5E).  Moreover, G1 length decreased even in the Cdt1-depleted cells (Fig. 4.5F). We 
previously determined that the apparent decease in Cdt1 protein upon Cyclin E1 overproduction 
is an indirect effect of cell cycle phase distribution because Cdt1 is stable in G1 and unstable in 
S phase (Matson et al., 2017). Since Cyclin E1 overproduction bypassed the strong G1 delay in 
control Cdt1-depleted cells and induced S phase entry with low amounts of loaded MCM, the 
G1 delay is caused by a bona fide origin licensing checkpoint.   
 Full origin licensing checkpoint activity in normal human fibroblasts requires the p53 
tumor suppressor (Fig. 4.7A)(Nevis et al., 2009). To test if p53-deficient epithelial cells are more 
likely to enter S phase underlicensed, we compared isogenic WT and p53 homozygous null 
RPE1-hTert cells (Rodriguez-Rodriguez et al., 2018). We analyzed the effects of reduced origin 
licensing from Cdt1 depletion on both G1 length and early S phase licensing status. We first 
noted by immunoblotting that Cdt1 depletion induced accumulation of both p53 and the CDK2 
inhibitor p21, the product of a p53-inducible gene, whereas p53 null cells lacked both p53 and 
detectable levels of p21 (Fig. 4.7B). The absence of p53 had little effect on either G1 phase 
MCM loading (Fig. 4.6C) or the amount of MCM loaded by early S phase in otherwise 
unperturbed cells (compare black and grey lines in Fig 4.7C, fold change in Fig. 4.7D, and 
percentage of underlicensed cells in Fig 4.7E). As before, Cdt1 depletion slowed MCM loading 




Figure 4.7 p53 knockout cripples the licensing checkpoint, causing underlicensing 
a. Model. Cdt1 depletion causes slow origin licensing leading to p53-dependent inhibition of 
CDK2 which delays S phase entry. 
b. Immunoblot of the indicated endogenous proteins in total protein lysates of RPE1-hTert p53 
WT or p53 null, (knockout “KO”) cells treated with siControl, siCdt1 A, or siCdt1 B for 72 hours. 
c. Loaded MCM in early S phase determined by flow cytometric analysis of cells treated as in 
Fig. 4.7B, measuring DNA Content (DAPI), loaded MCM (anti-Mcm2), and DNA synthesis 
(EdU). Histograms plot early S phase loaded MCM. Black lines are siControl + p53 WT, grey 
lines are siCdt1A + p53 WT (top) or siCdt1 B + p53 WT (bottom), red lines are siControl  + p53 
KO, orange lines are siCdt1 A + p53 KO (top) or siCdt1 B + p53 KO (bottom). The black 
siControl + p53 WT and red siControl + p53 KO are the same data on both histograms. Counts 
for all lines were normalized to siControl + p53 WT. 
d. Comparison of early S phase DNA-loaded MCM per cell from Fig. 4.7C. Values plotted are 
the ratio of mean loaded MCM in cells treated with siCdt1 and cells treated with siControl as 
indicated. Horizontal bars indicate means, error bars mark standard deviation (SD), n=3 
biological replicates. WT and p53 KO cells were compared by unpaired, two tailed t test. SiCdt1 
A p=0.0122*, siCdt1 B p=0.0011**. 
e. Percentage of underlicensed cells from Fig. 4.7C. Horizontal bars indicate means, error bars 
mark standard deviation (SD), n=3 biological replicates. WT and p53 KO cells were compared 
by unpaired, two tailed t test. SiControl p=0.0541 (ns), siCdt1 A p=0.0028**, siCdt1 B 
p=0.0011** 
f. Mean length of G1 (green), S (purple), and G2/M (grey) phases in hours for cells treated as 
Fig. 4.7C. G1 length: WT + siControl=10.9 hrs, WT + siCdt1 A = 25.7 hrs, WT + siCdt1 B= 35.5 
hrs, p53 KO + siControl=14.1 hrs, p53 KO + siCdt1 A=7.6 hrs, p53 KO + siCdt1 B=16 hrs. Error 
bars are SD, n= minimum 3 biological replicates. Cell cycle phase percentages from DNA 
Content vs DNA synthesis plots (see Fig. 4.2) were multiplied by the doubling time in hours to 
calculate hours for each phase. Doubling time is the mean of 3 biological replicates. 
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cells lacking p53 entered S phase with significantly less MCM loaded (compare red and orange 
lines in Fig. 4.7C, fold change in Fig. 4.7D, and percentage of underlicensed cells in Fig. 4.7E). 
Moreover, unlike p53 WT cells, Cdt1 depletion in p53 null cells did not cause G1 lengthening 
(Fig. 4.7F). Thus, loss of p53 cripples the origin licensing checkpoint in proliferating cells, 
allowing premature S phase entry of underlicensed cells. We note that even in control cells that 
had not been depleted of Cdt1, the p53 null cells entered S phase at a slightly lower amount of 
loaded MCM on average compared to p53 WT cells (compare black and red lines in Fig. 4.7C). 
We also detected a modest increase in the percentage of underlicensed p53 null siControl cells 
(Fig. 4.7E).  Overall we conclude that these untransformed epithelial cells utilize a p53-
dependent checkpoint to couple the timing of S phase entry to the status of origin licensing.  
The first G1 phase after G0 has an impaired origin licensing checkpoint. 
 We had established in Figures 1 and 2 that cells re-entering the first cell cycle after G0 
are routinely underlicensed relative to subsequent cycles. We hypothesized that the first cell 
cycle has an impaired origin licensing checkpoint that poorly couples the length of G1 phase to 
the status of MCM loading. To test that hypothesis, we compared actively proliferating cells 
treated with siCdt1 to G0 cells re-entering the first cycle also treated with siCdt1 (Fig. 4.8A). We 
measured cell cycle phase distribution by DNA Content (DAPI) and DNA Synthesis (EdU) (Fig. 
4.8B). The actively proliferating cells treated with siCdt1 increased the percentage of G1 cells as 
before, but there was little effect on G1 distribution in Cdt1-depleted cells re-entering the first 
cell cycle from G0 (Fig. 4.8B). These data indicated that cells re-entering the cell cycle from G0 
failed to extend G1 when licensing was reduced, consistent with a weak origin licensing 
checkpoint. We also tested if the loss of p53 enhanced this apparent checkpoint deficiency (Fig. 
4.8C). First cell cycle p53 null cells were no worse than first cell cycle WT cells with respect to 
cell cycle phase distribution (Fig. 4.8D). In contrast, p53 loss had affected the checkpoint 
behavior of actively proliferating cells. We note that siControl p53 null cells re-entering the first 




Figure 4.8. Cells re-entering the first G1 after G0 lack a checkpoint-induced G1 arrest 
a. Immunoblot of total protein lysates of cells released from G0 into the first cell cycle with 
siControl or siCdt1 (24 hours after release) and of proliferating cells treated with siControl or 
siCdt1 for 72 hours. 
b. Cell cycle phase distribution of cells treated as Fig. 4.8A defined by DNA synthesis (EdU) and 
DNA Content (DAPI) using flow cytometry. Data plotted are mean percentage of G1 (green), S 
(purple), and G2/M (grey) phases. G1 percentage: 1st cycle siControl = 33%, 1st cycle siCdt1 A 
= 32.2%, 1st cycle siCdt1 B = 28.7%, proliferating siControl = 56.7%, proliferating siCdt1 A = 
67.5%, proliferating siCdt1 B = 77.5%. Error bars are SD, n= minimum 3 biological replicates. 
Cell cycle phase percentages from DNA Content vs DNA Synthesis plots (see Fig. 4.2). 
c. Immunoblot of total protein lysate of RPE1-hTert WT and p53 KO cells synchronized in G0 or 
released into the first cell cycle with siControl or siCdt1 (24 hours after release) as indicated. 
d. Cell cycle phase distribution of cells treated as Fig. 4.8C defined by DNA synthesis (EdU) 
and DNA Content (DAPI) using flow cytometry. Data plotted are mean percentage of G1 
(green), S (purple), and G2/M (grey) phases. Error bars are SD, n= minimum 3 biological 
replicates. G1 percentage 16.6% (siControl) 17.0% (siCdt1 A) 16.4% (siCdt1B). Cell cycle 
phase percentages from DNA Content vs DNA Synthesis plots (see Fig. 4.2).  
108 
distributions at the same time after G0 release (Fig. 4.8B 33% G1  vs, 16.6% G1 in Fig. 4.8D). 
The faster S phase entry by the p53 null cells could be due to both the impaired licensing 
checkpoint and the general loss of basal p21 protein (Fig. 4.8C) (Overton et al., 2014), among 
other possible p53-dependent effects), and each could promote faster CDK2 activation in the 
first cell cycle. The ability of actively proliferating cells to activate the licensing checkpoint to 
extend G1 during siCdt1 treatment combined with the observation that G0 cells do not extend 
G1 during the same treatment and enter S phase underlicensed strongly suggests cells in the 
first cell cycle after G0 have an impaired origin licensing checkpoint.   
G0 cells re-entering the first cell cycle load MCM to license origins slowly. 
 We considered two explanations for underlicensing in the first S phase after G0: Cells 
may start loading MCM much later in the first G1 and, despite their longer G1, actually have less 
time to load than cells in the second cycle. Alternatively, cells in the first cycle may begin 
loading at the same time as in other cycles but they load MCM more slowly than cells in the 
second cycle. In both cases, the compromised origin licensing checkpoint is unable to extend 
G1 in response to the low MCM loading status resulting in an underlicensed first S phase. To 
distinguish between those explanations, we measured the nuclear accumulation of the Cell 
Division Cycle 6 (Cdc6) protein, an essential MCM loading protein. Cdc6 is degraded by the 
Anaphase promoting complex-Cdh1 (APCCdh1) in G1 phase, both in cells re-entering the cell 
cycle and in proliferating cells (Petersen et al., 2000; Mailand and Diffley, 2005). CDK2/Cyclin 
E1 phosphorylates Cdc6 in late G1 to protect it from APCCdh1, allowing Cdc6 protein to 
accumulate (Mailand and Diffley, 2005). Because Cdc6 is essential for MCM loading, Cdc6 
accumulation is one of the rate-limiting steps for MCM loading in G1. The time for MCM loading 
ends when S phase starts and Cdc6 is exported from the nucleus to the cytoplasm (Petersen et 
al., 1999b). Therefore, the time Cdc6 is detectable in nuclei is one proxy for the length of 
available MCM loading time in G1 phase and is a marker for the functional border between 
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G0/early G1 when MCM is not loaded (or loaded very slowly) and late G1 when MCM can be 
loaded. 
 We used live cell imaging of fluorescently tagged protein biosensors to compare the 
length of available MCM loading time between the first and second cell cycles after G0. We 
imaged an RPE1 cell line stably expressing three fluorescent fusion proteins: 1) full length Cdc6 
fused to mVenus (Segev et al., 2016), 2) Proliferating Cell Nuclear Antigen (PCNA) fused to 
mTurq2 to track cell nuclei and the borders of S phase (Burgess et al., 2012; Grant, Kedziora et 
al., 2018), and 3) a CDK kinase activity sensor fused to mCherry (Hahn et al., 2009). This 
kinase sensor was previously established to report CDK2 activity in G1 and early S phase and 
both CDK2 and Cdk1 activity in S and G2 phase; it is not a direct reporter of CDK4/6 activity 
(Spencer et al., 2013; Schwarz et al., 2018). CDK2 phosphorylates the reporter beginning in late 
G1 phase to induce export from the nucleus to the cytoplasm. The higher the ratio of 
cytoplasmic/nuclear signal, the higher the kinase activity. We imaged RPE1 cells expressing all 
three biosensors synchronized in G0 and released into the cell cycle for 72 hours, capturing an 
image every 10 minutes, starting 6.5 hours after release. PCNA-mTurq2 is present throughout 
the cell cycle and is punctate during S phase (Fig. 4.9A). Cdc6-mVenus is not present in G0 due 
to APCCdh1-mediated degradation. Nuclear Cdc6 first appeared in G1 and increased until S 
phase at which point it was lost from the nuclei and accumulated in the cytoplasm instead. After 
mitosis, Cdc6 was degraded in early G1 phase, then nuclear Cdc6 increased again later in G1 
(Fig. 4.9A). The CDK reporter (mCherry) was nuclear in G0 (low CDK activity) and gradually 
became cytoplasmic beginning in late G1 (high CDK activity)(Fig. 4.9A). We tracked 50 cells 
through the first and second cell cycles after G0 release. Fig. 4.9B shows an individual cell trace 
for nuclear Cdc6 in which the first full cell cycle took nearly 35 hrs whereas the second cycle 
took only 20 hrs mostly from the difference in G1 length. The time Cdc6 first appeared in G1 is 
marked rise, and the time of maximum nuclear Cdc6 in G1 is marked peak (Fig. 4.9B). Cells 




Figure 4.9. Live cell imaging of Cdc6 in first and second cycles after G0. 
a. Micrograph of RPE1 cells expressing Cdc6-mVenus, DHB-mCherry, and PCNA mTurq2 
synchronized in G0 by contact inhibition and released, imaging for 72 hours, images every 10 
minutes, with representative time points shown, rounded to whole hours. Images were 
background subtracted and brightness/contrast adjusted. Representative cell shown out of n=50 
cells, with two cell cycles for each cell. Scale bar is 10 um, applies to all images.  
b. An individual cell trace of mean nuclear Cdc6 intensity imaged from Fig 4.9A. Orange part is 
first cell cycle, grey line is a daughter cell second cell cycle. Hours on X axis indicate hours from 
G0 release, trace starts at 6.5 hours after release. Images were every 10 minutes. Circles 
indicate relevant features. Rise is first appearance of nuclear Cdc6. Peak is maximum nuclear 
Cdc6 before cytoplasmic translocation. Licensing window is difference between peak and rise. 
Division is last image before cytokinesis. 
c. Quantification of licensing window time (value of Cdc6 peak time minus Cdc6 rise time) for 
the 50 cells imaged in Fig. 4.9A, two cell cycles for each cell. 
d. Values of Cdc6 peak time for the 50 cells imaged in Fig. 4.9A, two cell cycles for each cell. 
e. Ratio of licensing window time divided by Cdc6 peak time for each cell imaged as in Fig. 
4.9A, 50 cells total with both first and second cell cycle 
f. Ratio of mean cytoplasmic DHB-mCherry divided by mean nuclear DHB-mCherry at the time 
of Cdc6 peak for the 50 cells imaged in Fig. 4.9A, two cell cycles for each cell. 
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peak (data not shown). The length of time Cdc6 was present in G1 is the time between nuclear 
Cdc6 rise and peak, and represents the licensing window for robust MCM loading in G1 (Fig. 
4.9B). Cells re-entering the first cell cycle after G0 had about twice as long licensing window 
than cells in the second cell cycle, and about twice as much time in G1 overall (Cdc6 peak time) 
than cells in the second cell cycle (Fig. 4.9C, D).  
We calculated the licensing window to the total G1 length by dividing the licensing 
window time by the Cdc6 peak time and found that the licensing window is the same proportion 
of G1 in both the first and second cell cycles (Fig. 4.9E). These data suggest that G1 during cell 
cycle re-entry is a stretched rather than delayed G1 compared to actively proliferating cells in 
the second cycle, and cells in the first cycle have a longer amount of available time with high 
Cdc6 than cells in the second cycle. Cells in the second G1 have more potential time to load 
MCM and yet enter S phase with less loaded MCM than cells in the second cycle. Taken 
together, these data suggest that cells in the first G1 after G0 load MCM slowly 
Cells in both the first and second cell cycles also reached a similar CDK activity 
(cytoplasmic/nuclear ratio greater than 1) at the time of peak nuclear Cdc6 and S phase entry 
(Fig. 4.9F) close to previously-reported values of 0.84-1.0 in other untransformed cell lines 
(Spencer et al., 2013; Schwarz et al., 2018). In other words, the underlicensed first G1 cells 
achieved the same level of CDK activity in late G1 as normally-licensed second G1 cells. These 
equivalent CDK activity indicators further supports the notion that the licensing checkpoint does 
not delay CDK2 activation in the first G1.  
Extending the first G1 after G0 substitutes for the impaired licensing checkpoint. 
 Cells re-entering the cell cycle from G0 license origins slowly and begin S phase before 
they are fully licensed. We hypothesized that artificially extending the first G1 phase could 
rescue the underlicensing of the first S phase by extending time for MCM loading. If successful, 
then cells would enter S phase with the high amount of loaded MCM typical of proliferating cells. 




Figure 4.10. G1 length of first and second cell cycle effects amount of loaded MCM at S 
phase entry. 
a. Model of experiment. RPE1 cells constitutively producing 5myc-Cdc6-mut (R56A, L59A, 
K81A, E82A, N83A, not targeted for degradation by APCCDH1) were synchronized in G0 by 
contact inhibition, then released back into the first cell cycle. Cells were treated with 10 uM 
nutlin-3a 10 hours after release and then nutlin was washed out at 18 hours after release, 
harvesting cells 26 hours after release from G0. Untreated cells were harvested at 24 hours 
(first cell cycle) and 48 hours (second cell cycle) after release from G0. 
b. Immunoblot of total protein lysate from cells treated as Fig. 4.10A. Untreated lane is cells at 
18 hours after G0 without nutlin-3a. Nutlin block lane is cells with 10 uM nutlin-3a added at 10 
hours and harvested at 18 hours after G0. Release lane is nutlin block, then washed to fresh 
media and harvested at 26 hours after G0. 
c. Loaded MCM in early S phase determined by flow cytometric analysis from cells treated as 
Fig. 4.10A, measuring DNA Content (DAPI), Loaded MCM (anti-Mcm2), and DNA Synthesis 
(EdU). Histograms show early S loaded MCM. Orange line is first cell cycle, green line is first 
cell cycle with nutlin block and release, grey line is second cell cycle. See Fig. 4.11A for 
complete flow cytometry plots. 
d. Comparison of early S phase DNA-loaded MCM from cells in Fig. 4.10C. Values plotted are 
the ratio of mean loaded MCM of first cell cycle with or without nutlin block and release divided 
by mean loaded MCM of second cell cycle. Horizontal bars indicate means, error bars mark 
standard deviation (SD), n=3 biological replicates. Samples were compared by unpaired, two 
tailed t test. p=0.0036**. 
e. Percentage of underlicensed cells from Fig. 4.10C. Horizontal bars indicate means, error bars 
mark standard deviation (SD), n=3 biological replicates. Untreated and nutlin treated cells were 
compared by unpaired, two tailed t test. First cell cycle and nutlin block p=0.0027**, Nutlin block 
and second cell cycle p=0.2447 (ns).  
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f. Diagram of experiment. RPE1 cells containing integrated doxycycline inducible exogenous 
Cyclin E1 were synchronized in G0 by contact inhibition, then released into the cell cycle, 
adding 100 ng/mL of doxycycline at 24 hours after release to overproduce Cyclin E1 and 
shorten G1 of the second cell cycle, harvesting cells at 40 hours after release from G0. 
Untreated cells were harvested at 24 hours (first cell cycle) and 40 hours (second cell cycle) 
after release from G0.  
g. Immunoblot for Cyclin E1 on total protein lysate from cells treated as Fig. 4.10F.  
h. Loaded MCM in early S phase determined by flow cytometric analysis of cells treated as Fig. 
4.10F, measuring DNA Content (DAPI), Loaded MCM (anti-Mcm2), and DNA Synthesis (EdU). 
Orange line is first cell cycle, green line is second cell cycle with ↑Cyclin E1 starting at 24 hours 
after G0 release, and grey line is second cell cycle. See Fig. 4.11G. 
i. Comparison of early S phase loaded MCM per cell from Fig. 4.10F. Values plotted are the 
ratio mean loaded MCM of second cell cycle divided by mean loaded MCM of first cell cycle. 
Horizontal bars indicate means, error bars mark standard deviation (SD), n=3 biological 
replicates. Samples were compared by unpaired, two tailed t test. p=0.0036** 
j. Percentage of underlicensed cells from Fig. 4.10F. Horizontal bars indicate means, error bars 
mark standard deviation (SD), n=3 biological replicates. Samples were compared by unpaired, 
two tailed t test. first cell cycle vs second cell cycle with ↑Cyclin E1 p=0.6593 (ns), second cell 
cycle with ↑Cyclin E1 vs second cell cycle untreated p<0.001****. 
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lengthen G1 (Tovar et al., 2006). We treated cells re-entering the first G1 phase with nutlin-3a 
beginning in mid-G1 for 8 hrs, then washed off the drug to permit passage into S phase and 
measured the amount of loaded MCM at S phase entry (Fig. 4.10A, B). Nutlin-3a stabilized p53, 
causing p21 protein accumulation. This effect is known to inhibit CDK2 kinase activity and delay 
S phase entry (Giono and Manfredi, 2007). An unwanted secondary effect of low CDK2 activity 
for our purposes is failure to protect Cdc6 in late G1 phase, which would prevent the 
accumulation of that essential MCM loading protein (Petersen et al., 2000; Mailand and Diffley, 
2005). To allow MCM loading during the nutlin-induced G1 arrest, we constitutively expressed a 
mutant form of Cdc6 that does not require CDK2 activity for stability (Matson et al., 2017). We 
then compared licensing in these treated cells to untreated cells from the first and second cell 
cycles (Fig. 4.10C, Fig. 4.11A). RPE1 released from G0 typically begin to enter S phase about 
16 hours after G0 release, while the nutlin 3a block and release cells begin to enter S phase 
about 24 hours after G0 release. Strikingly, transiently extending the first G1 phase by several 
hours almost fully rescued licensing in the first cell cycle to the same high level as in the second 
cell cycle (compare green and grey lines, Fig. 4.10C, and fold change Fig. 4.10D) and 
decreased the percentage of underlicensed cells to the same low level as the second cell cycle 
(Fig. 4.10E). Unlike the effects of stable Cdc6 on the rate of MCM loading in proliferating cells 
(Matson et al., 2017), neither stable Cdc6 alone or in combination with Cdt1 overproduction 
increased the rate of MCM loading in the first G1 phase (Fig. 4.11B and 4.11C). These genetic 
changes also had little-to-no effect on underlicensing in the first S phase (Fig. 4.11D-F). 
Therefore, the improved licensing by early S phase from nutlin-induced G1 extension is due to 
the increased time for MCM loading, rather than improving MCM loading itself. 
Finally, we predicted that since the second cell cycle has a robust origin licensing 
checkpoint, bypassing the checkpoint and artificially shortening the second G1 would induce a 
phenotype similar to the underlicensed first cell cycle. To test this prediction, we overproduced 




Figure 4.11 Overproduction of Cdt1 and a stable Cdc6 mutant do not rescue 
underlicensing in the first cell cycle after G0. 
a. Flow cytometry of chromatin-bound protein from cells shown in Fig. 7C, measuring DNA 
Content (DAPI), Loaded MCM (anti-Mcm2) and DNA Synthesis (EdU). 1st cell cycle is 24 hrs 
after G0 release, 1st cycle with nutlin block and release are cells treated with 10 μM nutlin-3a 
from 10-18 hours and released to 26 hours after G0. 2nd cell cycle is 48 hours release from G0. 
Orange cells are S phase MCMDNA positive, blue cells are G1 phase MCMDNA positive, grey cells 
are MCMDNA negative.  
b. Immunoblot for Cdc6 and Cdt1 on total protein lysate from RPE1 cells constitutively 
producing either 5myc-Cdc6 WT or 5myc-Cdc6-mut (a mutant of Cdc6 that is not targeted for 
degradation by APCCdh1: R56A, L59A, K81A, E82A, N83A) and a doxycycline inducible Cdt1-
HA. RPE1 cells were synchronized in G0 by contact inhibition, treated with 100 ng/mL 
doxycycline for 4 hours before re-plating cells to release into the first cell cycle, harvesting cells 
24 hours after release. 
c. Flow cytometry of chromatin-bound protein on cells treated as Fig. S4B, harvested 24 hours 
(first cell cycle) and 48 hours (second cell cycle) after G0 release, measuring DNA Content 
(DAPI), Loaded MCM (anti-Mcm2), and DNA Synthesis (EdU). Orange cells are S phase 
MCMDNA positive, blue cells are G1 phase MCMDNA positive, grey cells are MCMDNA negative.  
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d. Loaded MCM of early S phase from Fig. S4C. Orange lines are cells from first cell cycle, grey 
lines are cells from second cell cyclist. Top panel is RPE1 cells producing Cdt1-HA WT and 
5myc-Cdc6 WT, bottom panel is RPE1 cells producing Cdt1-HA WT, 5myc-Cdc6-mut.  
e. Comparison of early S phase DNA-loaded MCM per cell from Fig. S4D. Values plotted are 
the ratio of mean loaded MCM of first cell cycle divided by mean loaded MCM of second cell 
cycle. Horizontal bars indicate means, error bars mark standard deviation (SD), n=3 biological 
replicates. First and second cell cycles compared by unpaired, two tailed t test. p=0.8635 (ns). 
f. Percentage of underlicensed cells from early S phase cells in Fig. S4D. Horizontal bars 
indicate means, error bars mark standard deviation (SD), n=3 biological replicates. First and 
second cell cycles compared by unpaired, two tailed t test. Cdc6 WT p=0.0041** Cdc6 mut 
p=0.0001***. 
g. Flow cytometry of chromatin-bound protein from cells shown in Fig. 7H, measuring DNA 
Content (DAPI), Loaded MCM (anti-Mcm2) and DNA Synthesis (EdU). Orange cells are S 




bypass the checkpoint. We then compared licensing in the second S phase in these Cyclin E1-
overproducing cells to both control second S phase and first S phase cells (Fig. 4.10F, 4.10G, 
and Fig. 4.11G). The second cell cycle with a bypassed licensing checkpoint strongly resembled 
the first cell cycle (compare green and orange lines, Fig. 4.10H, fold change in Fig. 4.10I, and 
percentage of underlicensed cells in Fig. 4.10J). Taken together, we conclude that cells re-
entering the cell cycle from G0 are routinely underlicensed, but that the second and subsequent 
cell cycles are fully licensed because of a robust p53-dependent checkpoint that ultimately 
controls the timing of Cyclin E/CDK2-mediated S phase entry.  
Discussion 
The origin licensing checkpoint protects cells from premature S phase entry that could 
lead to genome instability (Fig. 4.12). This checkpoint couples the activity of CDK to the status 
of MCM loading such that the G1 CDKs are not activated while MCM loading is still low. Cyclin 
E1 overproduction can bypass the checkpoint-induced delay and induce premature S phase 
entry while cells are still underlicensed (Fig. 4.5) (Ekholm-Reed et al., 2004; Matson et al., 
2017). Moreover, p53 loss clearly impairs the normal coupling of MCM loading and S phase 
entry whereas p53 activation lengthens G1 to give enough time to complete licensing (Fig. 4.7, 
4.8, and 4.10). These observations fit Hartwell and Weinert’s classic definition for a cell cycle 
checkpoint (Hartwell and Weinert, 1989). A checkpoint enforces the dependence of one event 
on a previous event, but the dependency can be bypassed by mutation to occur out of order. 
The ability of mutations to induce inappropriate cell cycle progression indicates that in wild-type 
cells, progression could have occurred but was instead restrained by the checkpoint. This 
relationship is in contrast to a simple inability to progress. Of relevance to the origin licensing 
checkpoint, we induced S phase entry when the amount of loaded MCM was low, but not 
completely absent, since RNAi-mediated depletion of MCM loading factors does not prevent all 












have been no DNA synthesis even in p53 null or Cyclin E-overproducing cells because MCM is 
an essential component of the replicative helicase.  
Many questions remain about the origin licensing checkpoint itself. How do cells monitor 
the status of origin licensing, what conditions satisfy the checkpoint, and how is licensing status 
coupled to the activation of CDKs? The mere existence of the checkpoint was an unresolved 
question until relatively recently in large part because it appears to be restricted to  
untransformed metazoan cells. This restriction poses technical challenges for probing the 
molecular nature of the coupling because untransformed cells are more difficult to synchronize 
and manipulate than tumor-derived cells or yeast cells. Our results indicate that a 50% reduction 
in the amount of loaded MCM by the time of S phase entry sensitizes human cells to exogenous 
replication stress; this level is similar to that reported for checkpoint-deficient U2OS cells (Ge et 
al., 2007). Some stem cell types have a greater amount of loaded MCM at S phase entry than 
their differentiated counterparts, suggesting that the licensing threshold may vary by cell type 
(Ge et al., 2015; Carroll et al., 2018).  The fact that p53 status correlates with licensing 
checkpoint proficiency gives clues that a p53-dependent process, perhaps one or more p53-
regulated genes, are involved in efficient coupling. The discovery here that cell cycle re-entry 
induces natural underlicensing also suggests future screens for checkpoint mediators. Our 
analysis of origin licensing status at the G1/S transition using analytical flow cytometry provides 
a promising opportunity to dissect this pathway in the future. 
We note that licensing checkpoint activity is only readily detected in cells with particularly 
slow MCM loading. In previous studies, MCM loading was artificially slowed to test for 
checkpoint proficiency in various genetic backgrounds (Shreeram et al., 2002; Liu et al., 2009; 
Nevis et al., 2009). Under normal growth conditions however both checkpoint-proficient and 
checkpoint-impaired cell lines enter S phase with normal high levels of MCM loading. This 
behavior suggests that MCM loading is usually fast enough to achieve high levels of loaded 
MCM in advance of the other rate-limiting molecular events necessary to trigger CDK2 
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activation and S phase entry. It is only slow-loading cells that are visibly affected by the 
checkpoint. In that sense, the origin licensing checkpoint resembles other cell cycle checkpoints 
that operate in all cell cycles. For example, the contribution of the mitotic spindle assembly 
checkpoint is most obvious when attachments are severely compromised (Lara-Gonzalez et al., 
2012). The effect of the spindle assembly checkpoint on the rate of unperturbed mitotic 
progression is relatively minor except in individual cells that fail to form kinetochore-microtubule 
attachments on time (Lara-Gonzalez et al., 2012). Similarly, we did detect a modest increase in 
the number of underlicensed S phase cells in otherwise unperturbed proliferating p53 null cells 
compared to p53 WT cells (Fig. 4.7). We infer that these individual cells loaded MCM slowly, but 
could not effectively delay S phase entry.  
We were surprised to find that the first G1 phase after cell cycle re-entry from 
quiescence (G0) is routinely followed by an underlicensed S phase in multiple cell lines. To our 
knowledge, cell cycle re-entry from G0 is the first known naturally-occurring normal 
underlicensed cell cycle; previous investigations required siRNA or mutations to artificially force 
underlicensing (McIntosh and Blow, 2012). Clearly the extra time in G1 after G0 was not enough 
to lead to full licensing. Our investigation leads us to conclude that the routine underlicensing in 
cells re-entering the cycle is the consequence of a combination of slow MCM loading plus an 
ineffective licensing checkpoint. If MCM loading were fast enough in the first cell cycle, then 
their checkpoint deficiency wouldn’t matter and they would not be underlicensed in the first S 
phase. Although it is not yet technically possible to monitor MCM loading in real time in 
individual cells, we used the transition from Cdc6-negative to Cdc6-positive as a proxy for the 
maximum amount of time available for MCM loading (Fig. 4.9). Since cells in the first G1 phase 
had more time with abundant nuclear Cdc6 than cells in the second G1 phase, yet began S 
phase with less MCM loaded, we are confident in our assertion that MCM loading is particularly 
slow in the first G1 phase. If we presume that the nuclear Cdc6 levels correlate with Cdc6 
activity, then some other aspect of the MCM loading process must be slower in the first G1. 
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It is unclear why cells re-entering G0 load MCM slowly. The difference may be caused 
by one or more of the fundamental differences in G1 regulation between cell cycle re-entry and 
active proliferation. These differences include the status of Rb phosphorylation which is 
monophosphorylated in proliferating G1 cells, but unphosphorylated in G0 (Narasimha, Kaulich, 
Shapiro et al., 2014). Rb-dependent genes include those whose products are directly involved in 
MCM loading, and these genes are subject to unique transcriptional repression by the DREAM 
complex in G0 that must be reversed at cell cycle re-entry (Litovchick et al., 2007). Proliferating 
cells also load MCM both before and after Rb is removed from chromatin, but cells re-entering 
G1 from G0 only load MCM after Rb is removed from chromatin (Håland et al., 2015). CDK2 is 
constitutively nuclear in proliferating cells, but is cytoplasmic in G0 (Brown et al., 2004; Dietrich 
et al., 1997; Nevis et al., 2009). Of additional particular relevance is the indication of a kinase-
independent function of Cyclin E1 to promote loading that is only required in cells re-entering 
the cycle form G0 (Geng et al., 2003, 2007). These differences illustrate that cell cycle re-entry 
into G1 from G0 poses additional challenges and requirements not encountered during G1 in 
actively proliferating cells. It is striking however that both the checkpoint defect and slow MCM 
loading are normal just one cell cycle later after mitosis. 
Previous analysis by Daigh et al. indicated that cells released from G0 had increased 
endogenous replication stress in the first S phase compared to actively proliferating cells. This 
stress was detected as mid-S phase fluctuations in CDK activity and γH2AX staining that 
depended on the status of the replication stress response signaling pathway (Daigh et al., 
2018). Our findings here suggests a molecular mechanism by which that replication stress was 
generated. We propose that the underlicensed S phase after the first G1 has higher 
endogenous replication stress because fewer dormant origins are available. While we did not 
detect frank DNA damage markers in the absence of exogenous replication stress by our 
methods, we presume that endogenous stress was generated because these cells were 
uniquely sensitive to low dose gemcitabine. This hypersensitivity is a hallmark of cells that enter 
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S phase while underlicensed (Woodward et al., 2006; Zimmerman et al., 2013). The increased 
endogenous replication stress from too few licensed origins promotes genome instability from a 
higher frequency of stalled and un-rescued replication forks  
How frequently do cells experience this naturally-underlicensed cell cycle in vivo? Cell 
cycle re-entry from quiescence is common in tissues that naturally turn over cell populations 
(Sosa et al., 2014; Sagot and Laporte, 2019; Wells et al., 2013). One might imagine however, 
that one risky cell cycle is a small contributor to overall genome instability. On the other hand, 
even in actively proliferating cultures, recent studies have detected populations of cells that 
appear to spontaneously and transiently exit to a quiescence-like state (Spencer et al., 2013; 
Overton et al., 2014; Arora et al., 2017; Barr et al., 2017). Such transient cell cycle exit may be 
even more common in tissues compared than in cell culture conditions that have been 
optimized for maximal uninterrupted growth. Whether or not that transient quiescence also 
causes underlicensing is not yet known.  
Quiescent hematopoietic stem cells re-enter the cell cycle in response to stresses such 
as viral infection and then return to quiescence (Cheung and Rando, 2013). Interestingly, 
hematopoietic stem cells acquire DNA damage in the first cycle after G0, accumulate DNA 
damage over time in older stem cells, and become depleted as they age from repeated cell 
cycle re-entry (Beerman et al., 2014; Walter et al., 2015). Additionally, quiescent human T cells 
re-enter the first S phase even when treated with siRNA to substantially reduce the amount of 
loaded MCM to ~5-10% of their normal loaded amount (Orr et al., 2010). Taken together, these 
data suggest that at least some quiescent cells in vivo lack a licensing checkpoint in the first 
cycle, although it is unknown if the first cell cycle is naturally underlicensed compared to the 
second cycle in vivo. Old hematopoietic stem cells experience more replication stress in the first 
S phase after G0 compared to young stem cells, possibly because they express less MCM 
protein. In that regard, a defective licensing checkpoint would be particularly toxic to old 
quiescent cells re-entering G1 because they may enter S phase with even less loaded MCM 
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than young cells (Flach et al., 2014). These in vivo studies are consistent with our observation 
that artificially inducing repeated rounds of quiescence and cell cycle re-entry enhanced 
replication stress sensitivity (Fig. 4.4). We suggest that over many rounds of quiescence and re-
entry, incremental DNA damage accrues from unresolved replication stress or incomplete 
replication that may pass through mitosis into the next cell generation. The ability of unresolved 
replication stress to carry forward into subsequent cell cycles was recently established both by 
artificially inducing underlicensing and by monitoring spontaneous replication stress passing 
from mother to daughter cells (Moreno et al., 2016; Yang et al., 2017; Arora et al., 2017; Ahuja 
et al., 2016). Repeated rounds of underlicensed cell cycle re-entry could contribute to the 
genome damage that drives both aging and oncogenesis. Thus, the most important 
consequences of entering a high-risk underlicensed cell cycle may primarily appear over an 
organism’s lifetime.  
Materials and Methods 
Cell culture and synchronization 
RPE1-hTERT cells, 293T and NHF1-hTERT cells (ATCC) were grown in Dulbecco's 
modified Eagle’s medium (DMEM) (Sigma Aldrich) with 10% Fetal Bovine Serum (FBS) 
(Seradigm) and 2 mM L-glutamine (Gibco) at 37°C with 5% CO2. Wi38 cells (ATCC) were grown 
in Minimum Essential Medium (MEM) with 10% FBS (Seradigm), 2 mM L-glutamine (Gibco) and 
Minimum Essential Medium non-essential amino acids (NEAA) (Gibco) at 37°C with 5% CO2. 
Cells were passaged every three days with trypsin (Sigma Aldrich) and not allowed to reach 
confluency.  
To synchronize RPE1 cells in G0 by contact inhibition, cells were grown to 100% 
confluency, washed with PBS, and incubated in DMEM with 10% FBS and 2 mM L-glutamine 
for 48 hours. To release cells into the first or second cell cycles, G0 cells were re-stimulated by 
passaging 1:10 for the first cycle, harvesting 24 hours later or 1:20 for the second cycle, 
harvesting 48 hours later, in DMEM with 10% FBS and 2 mM L-glutamine. To synchronize 
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RPE1 cells in G0 by serum starvation, cells were plated sub-confluent, washed 3 times with 
PBS, and starved in DMEM with 0% FBS and 2 mM L-glutamine for 72 hours. To release cells 
into the first or second cell cycles, cells were washed with PBS and re-stimulated by washing 
once with PBS and adding DMEM with 10% FBS and 2mM L-glutamine for 24 hours (first cycle) 
or 48 hours (second cycle). To synchronize NHF1-hTERT cells in G0, cells were grown to 100% 
confluency, washed with PBS, and incubated in DMEM with 0.1% FBS and 2 mM L-glutamine 
for 72 hours. To release cells into the first or second cell cycles, G0 cells were re-stimulated by 
passaging 1:4 for first cycle, harvesting 24 hours later or 1:8 for second cycle, harvesting 48 
hours later, in DMEM with 10% FBS and 2 mM L-glutamine. To synchronize Wi38 cells in G0, 
cells were grown to 100% confluency, washed with PBS, and incubated in MEM with 0.1% FBS, 
2 mM L-glutamine, and NEAA for 72 hours. To release cells into the first or second cell cycles, 
G0 cells were re-stimulated by passaging 1:4 for first cycle, harvesting 24 hours later or 1:8 for 
second cycle, harvesting 48 hours later, in in MEM with 10% FBS, 2 mM L-glutamine, and 
NEAA. 
To synchronize RPE1 in 3 repeated G0s, cells were synchronized in G0 by contact 
inhibition (above), re-stimulated into the cell cycle by passaging 1:6 in DMEM with 10% FBS 
and 2 mM L-glutamine, and grown to 100% confluency within 48-72 hours to start the second 
G0 by contact inhibition for 48 hours. Cells were re-stimulated as before and grown to 100% 
confluency to start the 3rd G0 for 48 hours. To release cells for the experiment, G0 cells were re-
stimulated by passaging 1:10 in DMEM with 10% FBS and 2 mM L-glutamine, harvesting the 
first cell cycle at 24 hours after re-stimulation. 
DNA Cloning and cell lines 
The RPE1 CRISPR p53 KO was a gift of Dr. Prasad Jallepalli and described previously 
(Rodriguez-Rodriguez et al., 2018). The RPE1 cells with doxycycline inducible Cyclin E1 and 
the RPE1 cells with doxycycline inducible Cdt1 and stable Cdc6 WT or Cdc6-mut were 
described previously (Matson et al., 2017). The pLenti-PGK hygro PCNA-mTurq2 was 
125 
described previously (Grant et al., 2018). The CSII-EF zeo DHB-mCherry CDK activity reporter 
was a gift Dr. Sabrina Spencer. The CSII-EF zeo Cdc6-mVenus was a gift from Dr. Michael 
Brandeis. Each reporter is under control of a constitutive heterologous promoter.  
To make the RPE1 line containing PCNA-mTurq2, Cdc6-mVenus, and DHB-mCherry, 
the plasmids were transfected into 293T with pCI-GPZ or ∆NRF and VSVG virus packaging 
plasmids with 50 ug/mL Polyethylenimine (Aldrich Chemistry). Viral supernatants were 
transduced onto RPE1 cells with 8 ug/mL Polybrene (Millipore). 
A clonal cell line was picked based on fluorescence of all 3 biosensors. 
siRNA transfections and drug treatment 
siRNA concentration and sequences: 
siControl, (siLuciferase) 100 nM (synthesized by Life Technologies) 
5′-CUUACGCUGAGUACUUCGA-3′ 





siCdt1 B, 50 nM (synthesized by Life Technologies) 
5'-CCUACGUCAAGCUGGACAATT-3'  
For siRNA transfections, siRNA was spotted into plates with DharmaFECT 4 transfection 
reagent (Dharmacon) and Opti-MEM (Gibco), incubating for 20 minutes before adding cells in 
DMEM with 10% FBS and 2 mM L-glutamine (final concentrations), harvesting cells 72 hours 
later for proliferating experiments, and 24 hours later for G0 release, as described above. To 
overproduce Cyclin E1 or Cdt1-HA, 100 ng/mL of doxycycline (CalBiochem) was added at times 
indicated in the figure legend. To block and release cells with nutlin-3a (Sigma Aldrich), RPE1 
were synchronized in G0 by contact inhibition, released into the first cell cycle, adding 10 uM 
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nutlin-3a 10 hours after release, washing off nutlin-3a 18 hours after release by washing 3 times 
with PBS and adding back DMEM with 10% FBS and 2 mM L-glutamine. To treat cells with 
gemcitabine (Sigma Aldrich) in Fig. 4.3, cells were synchronized in G0 by contact inhibition, 
released into the first cycle and treated with 50 nM gemcitabine from 22-24 hours or released 
into the second cycle and treated with 50 nM gemcitabine from 44-46 hours. To treat cells with 
gemcitabine in Fig. 4.4, cells were synchronized in one or three G0 (above), adding 5 nM 
gemcitabine at time of re-stimulation from 0-24 hours. 
Total protein lysate and chromatin fractionation 
 To prepare total protein lysate for immunoblot, cells were harvested with trypsin and 
frozen in dry ice, then lysed in cold cytoskeletal buffer (CSK) (10 mM Pipes pH 7.0, 300 mM 
sucrose, 100 mM NaCl, 3 mM MgCl2 hexahydrate) with 0.5% triton x-100 (Sigma Aldrich) and 
protease and phosphatase inhibitors (0.1 mM Pefabloc, 1 µg/mL pepstatin A, 1 µg/mL leupeptin, 
1 µg/mL aprotinin, 10 µg/mL phosvitin, 1 mM β-glycerol phosphate, 1 mM sodium 
orthovanadate) on ice for 15 minutes. Lysate was centrifuged at 13,000 x g at 4°C for 10 
minutes, and a Bradford Assay (Biorad) was done on the supernatant to load equal amounts of 
protein per sample. 
 To prepare chromatin fractions for immunoblot, cells were harvested with trypsin and 
frozen in dry ice, then lysed in cold CSK with 0.5% triton x-100, 1 mM ATP, 5 mM CaCl2 and 
protease and phosphatase inhibitors (complete CSK) on ice for 20 minutes. Then a Bradford 
assay for equal loading was done on the lysate, a small aliquot removed from each sample as 
total lysate, and complete CSK was added to each sample, mixed, and centrifuged for 5 min, 
1,000 x g. The supernatant was removed, pellet was washed again with complete CSK, 
incubated for 10 minutes on ice, and then centrifuged for 5 min, 1,000 x g. The supernatant was 
removed, and DNA loaded proteins were released by incubation with S7 nuclease (Sigma 
Aldrich) in complete CSK at room temperature (RT) for 10 minutes. Samples were centrifuged 
again, keeping the supernatant as the chromatin fraction. 
127 
Immunoblotting 
Samples were diluted with loading buffer to final concentration: 1% SDS, 2.5% 2-
mercaptoethanol, 0.1% bromophenol blue, 50 mM Tris pH 6.8, 10% glycerol then boiled. 
Samples were run on SDS-PAGE gels, then transferred to nitrocellulose (GE Healthcare) or 
polyvinylidene difluoride membranes (Thermo Fisher). After transferring, samples were blocked 
in 5% milk in tris buffered saline with 0.1% tween 20 (TBST), then incubated overnight at 4°C in 
primary antibody with 2.5% milk in TBST. Then membranes were washed with TBST, incubated 
in horseradish peroxidase conjugated (HRP) secondary antibody for 1 hour at RT, washed with 
TBST, and imaged with ECL Prime (Amersham) on autoradiography film (Denville). Antibodies 
were: Mcm2 (BD Biosciences Cat#610700, 1:10,000), Cyclin E1 (Cell Signaling Technology 
#4129S, 1:2,000), p53 (Santa Cruz Biotechnology, sc-126, 1:2,000), p21 (Cell Signaling 
Technology, #2947S, 1:6,000) Cdc6 (Santa Cruz Biotechnology, sc-9964, 1:2,000), Cdt1 (Santa 
Cruz Biotechnology, sc-365305, 1:3,000), Donkey-anti-Mouse-HRP (Jackson ImmunoResearch, 
1:10,000) Donkey-anti-Rabbit-HRP (Jackson ImmunoResearch, 1:10,000). Membranes were 
stained with Ponceau S (Sigma Aldrich) to determine equal protein loading. 
Flow cytometry 
Cells stained with EdU were incubated with 10 uM EdU for 30 minutes before 
harvesting, except in Fig 4.2D, when cells were incubated with 1 uM EdU from re-stimulation to 
harvesting. Cells were harvested with trypsin to measure DNA loaded proteins by flow 
cytometry. Cells were washed once with PBS, centrifuged at 2,000 x g for 3 minutes, then 
supernatant was aspirated and pellets lysed on ice in cold CSK with 0.5% triton X-100 and 
protease and phosphatase inhibitors for 5 minutes. After incubation, 1% Bovine serum albumin 
(Fisher) in PBS (B-PBS) was added to each sample, mixed, and centrifuged at 2,000 x g for 3 
minutes. Supernatant was aspirated, pellets were fixed with 4% paraformaldehyde (Electron 
Microscopy Sciences) in PBS for 15 minutes at RT. Then B-PBS was added, mixed, and 
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samples centrifuged (2,000 x g for 7 minutes, all following steps). Supernatant was aspirated, B-
PBS was added, and samples stored at 4°C before labeling.  
 EdU labeling was done before antibody staining. Cells were centrifuged, supernatant 
aspirated, and incubated in PBS with 1 mM CuSO4, 100 mM ascorbic acid (fresh), 1 uM Alexa 
Flour-647-azide (Life Technologies) for 30 minutes, RT in the dark. Then B-PBS with 0.5% NP-
40 (United States Biochemical) was added, mixed, and centrifuged. For antibody staining, 
supernatant was aspirated, cells incubated in primary antibody: anti-Mcm2 (1:200, BD 
Biosciences, Cat#610700), anti-γH2AX (1:200, Cell Signaling Technologies, #9718S) in B-PBS 
with 0.5% NP-40 for 1 hour at 37°C in the dark. Next, B-PBS with 0.5% NP-40 was added, 
mixed, and samples centrifuged. Supernatant was aspirated, cells incubated in secondary 
antibody: Donkey-anti-Mouse-Alexa Flour 488 (1:1,000, Jackson ImmunoResearch, for Mcm2), 
Donkey-anti-Rabbit-Alexa Flour 647 (1:1,000, Jackson ImmunoResearch, for γH2AX) in B-PBS 
with 0.5% NP-40 for 1 hour at 37°C in the dark. Then B-PBS with 0.5% NP-40 was added, 
mixed, and samples centrifuged. Finally, supernatant was aspirated, cells were incubated in 1 
ug/mL DAPI (Sigma Aldrich) and 100 ng/mL RNAse A (Sigma Aldrich) in B-PBS with 0.5% NP-
40 overnight at 4°C in the dark. For negative control samples used to draw positive/negative 
gates, cells were not incubated with EdU but were labeled with Alexa Flour-647-azide, and were 
not incubated with primary antibody but were labeled with secondary antibody and DAPI. 
Data were acquired primarily on an Attune NxT flow cytometer (Thermo Fisher), with 
some data acquired on a CyAn ADP flow cytometer (Beckman Coulter). Data was analyzed 
using FCS Express 6 (De Novo Software). Gates are shown in Fig. 4.2. Gate to isolate cells 
from debris was from Forward Scatter-Area vs Side Scatter Area. Gate to isolate singlets from 
doublets was from DAPI Area vs DAPI height (Parent gate: cells). Gate to isolate cell cycle 
phases was from DAPI Area (DNA Content) vs 647-Area (DNA Synthesis, EdU) (Parent gate: 
singlets). Color gates to isolate S-MCMDNA positive, G1-MCMDNA positive and MCMDNA negative 
were on 647 Area (DNA Synthesis, EdU) vs 488 Area (Loaded MCM), using a negative control 
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sample to mark positive cells (Parent gate: singlets). Early S phase gate was on DAPI Area 
(DNA Content) vs 488-Area (Loaded MCM), gating cells with 2C DNA content, S-MCMDNA 
positive in early S phase (Parent gate: S-MCMDNA positive). Mid S phase gate was on DAPI 
Area (DNA Content) vs 647-Area (γH2AX), cells between 2C and 4C DNA Content (Parent 
gate: singlets). Replication stress induced γH2AX was gated as cells equal to or greater than 
the top 5%-6% of γH2AX signal from untreated cells (Parent gate: Mid S). Each flow cytometry 
plot typically has 9,000-11,000 total single cells. 
Y axis is cell counts, normalized to peak value of second cell cycle. 
Doubling time 
 Cells were plated with siRNA and counted 48 hours or 72 hours later after dissociating 
with trypsin using a Luna II automated cell counter (Logos Biosystems). Each treatment was 
done with 3 biological replicates and each dish in the replicate was counted twice as technical 
replicates. Doubling time was calculated using Prism 8 (GraphPad) regression analysis: 
exponential growth equation. Doubling times from the 3 biological replicates were averaged, 
and then the average doubling time was multiplied by the cell cycle phase percentages to obtain 
cell cycle phase hours. 
Live cell imaging 
Cells were plated for live cell imaging with G0 by contact inhibition and re-stimulation in 
Flourobrite DMEM (Gibco) with 10% FBS and 2 mM L-glutamine in #1.5 glass bottom plates 
(Cellvis) in a humidified enclosure at 37° C with 5% CO2. Movie started 6.5 hours after plating, 
cells were imaged for 72 hours with images every 10 minutes. Cells were imaged on a Nikon Ti 
Eclipse inverted microscope with a 20x (NA 0.75) Apochromat dry objective lens with the Nikon 
Perfect Focus System. The camera was an Ando Zyla 4.2 sCMOS detector with 12 bit 
resolution, filters were from Chroma: (excitation; beam splitter; emission filter) CFP - 436/20 nm; 
455 nm; 480/40 nm, YFP - 500/20 nm; 515 nm; 535/30 nm; and mCherry - 560/40 nm; 585 nm; 
630/75 nm. Images were collected with Nikon NIS-Elements AR software. 
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 Images were analyzed with Fiji version 1.51n, ImageJ. Briefly, images were background 
subtracted and tracked with custom ImageJ scrips based on the PCNA signal, and nuclear 
signal quantified in a region of interest as described previously (Grant, Kedziora et al., 2018). 
Cdc6 traces of mean nuclear intensity were scored as follows: Cdc6 peak time: frame with 
highest nuclear Cdc6 intensity before the sharp drop in intensity indicating export to the 
cytoplasm. Cdc6 rise time: frame with Cdc6 nuclear intensity 2 standard deviations greater than 
the lowest Cdc6 nuclear intensity before Cdc6 peak time. Licensing window time: Cdc6 peak 
time minus Cdc6 rise time. Relative licensing window time: Licensing window time divided by 
Cdc6 peak time. 
For DHB cytoplasmic measurement, fluorescence signal of the cytoplasm was 
approximated by measuring signal within a ring-shaped region (5 px wide) around the nucleus. 
The ratio between the cytoplasm and the nucleus was calculated using mean signals of the ring-
shaped cytoplasmic region and the full nuclear region.  
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
 In this work, we demonstrated the significance of both the rate of MCM loading and the 
amount of loaded MCM at S phase entry. Pluripotent stem cells use a fast MCM loading rate 
during their short G1 phase, while differentiated cells use a slow MCM loading rate during their 
long G1 phase. A higher amount of Cdt1 protein contributes to the fast loading of the MCM 
complex in stem cells. Both Cdt1 protein levels and MCM loading rate decrease during early 
stem cell differentiation to all lineages. The fast MCM loading rate maintains the pluripotency of 
stem cells, as prematurely decreasing the MCM loading rate in stem cells promotes their 
differentiation. The stem cells and differentiated cells have different loading rates but reach the 
same amount of loaded MCM at S phase entry. We showed that the origin licensing checkpoint 
enforces the amount of loaded MCM at S phase entry in actively proliferating cells.  The 
licensing checkpoint is a true cell cycle checkpoint and not a requirement for S phase entry, 
because it can be bypassed by Cyclin E1 overproduction or p53 knockout to force premature S 
phase entry with underlicensing. Surprisingly, cells re-entering the cell cycle from G0 are 
underlicensed due to a defective origin licensing checkpoint. The underlicensing causes 
hypersensitivity to replication stress during the 1st S phase after re-entry. The hypersensitivity 
accumulates over multiple rounds of quiescence and re-entry, demonstrating that repeated cell 
cycle re-entry is toxic over long periods. Thus, controlling both the amount of loaded MCM and 
the rate of MCM loading is important for proper cell cycle progression, genome stability and cell 
fate outcomes. 
 While we made significant progress in understanding MCM loading in diverse cellular 
contexts, many questions remain unanswered for future work. The remainder of this chapter will 
address two questions for future directions of study. 
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Does chromatin influence the rapid MCM loading in stem cells? 
 We demonstrated that stem cells have higher amounts of the MCM loading protein Cdt1 
than differentiated cells. The increased Cdt1 promotes faster MCM loading, but it may not be 
the only rate limiting factor in the fast loading stem cells. There is only a twofold difference in the 
amount of Cdt1 but a six fold difference in the rate of MCM loading between stem cells and 
differentiated cells. It is not clear if the amount of Cdt1 is sufficient to produce the larger 
increase in MCM loading rate. Other factors may also be rate limiting for MCM loading in stem 
cells. 
 One interesting factor that might contribute to MCM loading rate is the epigenetic 
chromatin structure of the cell. Stem cells have more euchromatin across their genome and less 
heterochromatin than differentiated cells. DNA in euchromatin is called “open chromatin” 
because it is accessible to other factors such as RNA polymerases or transcription factors. DNA 
in heterochromatin is called “closed chromatin” because it is compacted and less accessible to 
external factors. The open chromatin in stem cells may facilitate rapid MCM loading. MCM 
loading onto DNA replication origins in metazoans is not sequence specific. Instead, origins 
seem to be located in regions of open chromatin that are more accessible to MCM and its 
loading proteins. Closed heterochromatin may require additional chromatin remodeling factors 
to allow MCM loading, such as the origin recognition complex-associated protein ORCA. 
Therefore, it may be easier and faster to load MCM into regions of open euchromatin than 
closed heterochromatin. The greater amounts of open euchromatin in stem cells may facilitate 
rapid MCM loading, while differentiated cells may require extensive heterochromatin remodeling 
before MCM loading takes place. 
 Our lab is actively investigating the role of epigenetic marks in regulating MCM loading 
rate. I have worked with two rotating graduate students, Rachel Cherney and Jackson Peterson, 
to measure how epigenetic markers for euchromatin and heterochromatin change during 
133 
differentiation. Their goal was to correlate changes in histone marks that control open or closed 
chromatin with changes in MCM loading during differentiation. They both measured specific 
histone modifications at the same time points that the MCM loading rate decreased during early 
differentiation.  Rachel found that H3K4me3, a marker of open chromatin, was higher in 
pluripotent cells than their isogenic differentiated counterparts. She also found that differentiated 
cells have more H3K27me3, a marker of repressed heterochromatin, than pluripotent cells. 
Jackson found that pluripotent stem cells have high levels of H4 acetylation, a marker of open 
chromatin, and that the acetylation rapidly decreases at the same time as the MCM loading rate 
decreases during differentiation towards mesoderm. He also found that the transcription factor 
Myc decreases during differentiation towards mesoderm. Myc promotes global open chromatin 
and is also one of the four genes used to reprogram differentiated cells into induced pluripotent 
stem cells. Taken together, these data suggest that changes in epigenetics and chromatin 
structure correlate with changes in MCM loading rate. Future work should artificially manipulate 
chromatin structure to determine if changing chromatin structure can also change loading rate. 
How does the origin licensing checkpoint measure the amount of loaded MCM?  
 We demonstrated that actively proliferating cells have a functional origin licensing 
checkpoint. The checkpoint ensures cells have a threshold amount of loaded MCM before 
entering S phase. If a cell lacks the threshold amount of loaded MCM, the origin licensing 
checkpoint decreases CDK2 activity to prevent S phase entry. However, the molecular sensor 
for the amount of loaded MCM or the exact number of MCM to pass the threshold is unknown. 
Cells load about 100,000 to 250,000 MCM double hexamers onto replication origins every cell 
cycle (Rodriguez-Martinez and Mechali, 2014). It seems unlikely a sensor protein could monitor 
MCM and tell the difference between 100,000 MCM and 99,999 MCM to activate the origin 
licensing checkpoint or that the threshold for S phase is a precise number of loaded MCM. 
Instead a more generalized signal might activate the checkpoint. 
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 One option could be that the lack of loaded MCM at some genomic region generates a 
signal. This signal would be analogous to how the spindle assembly checkpoint works, which 
occurs not by counting the number of attached kinetochores, but by the detection of just one 
unattached kinetochore to activate the spindle assembly checkpoint (Lara-Gonzalez et al., 
2012). Perhaps a certain histone modification is sensed by the checkpoint. MCM loading 
involves some changes in histone modification by Cdt1 that recruits HBO1 to genomic loci. 
Additionally, ORC also participates in nucleosome remodeling (Miotto and Struhl, 2008, 2010; 
Azmi et al., 2017). MCM loading onto regions of DNA that actively generate a signal could 
remodel the nucleosomes and turn off the signal. Alternatively, loaded MCM double hexamers 
themselves could recruit or activate an inhibitor of the licensing checkpoint, similar to how 
double hexamers specifically recruit Dbf4-dependent kinase  (Abid Ali et al., 2017). As the 
amount of loaded MCM double hexamers increases, the amount of activated/recruited licensing 
checkpoint inhibitor would increase, eventually saturating the checkpoint to allow Cdk2 activity 
and S phase entry. A model of gradual inhibition would fit with the observation that the amount 
of loaded MCM dictates the strength of the licensing checkpoint response, i.e. the less loaded 
MCM, the stronger the checkpoint response. Discovering more pieces of the pathway from the 
sensor to the effector will facilitate greater understanding of the licensing checkpoint. 
 Future work to discover the molecular players in the origin licensing checkpoint could 
take a candidate gene approach. We know the pathway is p53-dependent. Therefore, we could 
screen genes upstream or downstream of p53 as candidates for additional components of the 
licensing checkpoint. First, we could identify if the checkpoint depends on p53-dependent 
transcription by adding back WT p53 or mutants that are defective for DNA binding to RPE1 
CRISPR p53 null cells, and measuring underlicensing by flow cytometry. Knowing whether the 
licensing checkpoint requires p53-dependent transcription will guide selection of candidate 
genes to screen. Then, a medium throughput approach would use previously established 
CRISPR knockout lines from published screens, treat cells with siCdt1, and measure 
135 
underlicensing by flow cytometry (Zimmermann et al., 2018; McKinley and Cheeseman, 2017). 
The readout would be an underlicensing phenotype that matches the RPE1 p53 KO cells. 
Candidates could be furthered tested for epistasis with the p53 KO to determine if they function 
in the same pathway. An alternative approach is an unbiased mass spectrometry screen to 
identify potential licensing checkpoint proteins. We could compare cells re-entering the cell 
cycle from G0 (a defective licensing checkpoint) with cells synchronized in the following G1 (a 
functional licensing checkpoint), measuring total protein and phosphorylation levels under the 
two conditions. Alternatively, we could perform MCM chromatin immunoprecipitation and total 
chromatin fraction with the idea that a sensor for the licensing checkpoint either senses 
something with MCM directly on DNA, or the lack of MCM on DNA. Potential candidates would 
be proteins that are regulated differently between the two G1 phases. Potential candidates 
could be screened further for underlicensing by the same flow cytometry assay. In summary, we 
can use p53, to search for related proteins in the checkpoint, or we can use two unique cell 
cycles with and without the checkpoint to screen for potential checkpoint proteins. 
 Future work on origin licensing clearly has more impact than just allowing cells to 
replicate their DNA in S phase. Discovering how MCM loading rate changes during stem cell 
differentiation by epigenetics or otherwise would improve therapies to build new tissues from 
induced pluripotent stem cells. Understanding the origin licensing checkpoint would improve 
understanding of how quiescence contributes to aging by repeated cell cycle re-entry without a 
functional licensing checkpoint. Discoveries for both MCM loading rate in stem cells and the 
licensing checkpoint may converge in cancer. Cancer cells often revert to a stem cell like state 
with rapid cell cycles and rapid MCM loading rate, in addition to loss of p53 and the origin 
licensing checkpoint. Understanding what contributes to MCM loading rate and the origin 
licensing checkpoint could provide new avenues for cancer therapy by decreasing origin 
licensing in cancer cells without the licensing checkpoint. In conclusion, uncovering regulation of 
MCM loading rate and the licensing checkpoint would be new advances for the cell cycle field. 
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